[{"Bold":false,"Classes":"['WordSection1']","Element":"<div class=\"WordSection1\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX I<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/b><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:green'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><img height=\"18\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAABUAAAASCAYAAAC0EpUuAAAAAXNSR0IArs4c6QAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAFDSURBVDhPrZSxTsJQFIYr6eBK4uoL8AjuuqGjq4k7LCaNLNeyYFxxMw41+gDgE5g0PgFxB3ccYUH9\/uaWlHCBwuUkP\/eW85+v57a9NwyCoIfO0R\/yjQPxQn4a6Awd+hKpn6BmGMfx0BjzyMXNHqBd8dSpooMu0bEHeETtveozKPQx3d4xffaAGjg\/c6gFJYzX6GQHcErNS16XL1\/dzug2IvGBKluAf\/FG1GvMYg61jyEFrDtebQFNAH4W\/QtQmzCMF6haAjzGI\/9CLEG564hu9TU8lIB28H9vhFqDvls9gtoa8ICcfEvhWr5e2oRub3FrC6+KFr5paaiMFPQBvzOtOwr75JVzhrPTgrPF\/BQVzwXtb61iZayF0s3AcS5of3\/tDLWFxXNhyH\/Z\/vaC2nOhDeQJtfP97QW1xa+MR+htU5fK\/wN70lz+TMoSywAAAABJRU5ErkJggg==\" width=\"21\"\/><span lang=\"EN-GB\">This medicinal\r product is subject to additional monitoring. This will allow quick\r identification of new safety information. Healthcare professionals are asked to\r report any suspected adverse reactions. See section 4.8 for how to report\r adverse reactions.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.       NAME OF <\/span><\/b><b><span lang=\"EN-GB\">THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo\r 10 mg\/ml concentrate for solution for infusion<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each ml of\r concentrate for solution for infusion contains 10 mg crizanlizumab.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">One vial of\r 10 ml contains 100 mg crizanlizumab.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Crizanlizumab is\r a monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by\r recombinant DNA technology.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For the full\r list of excipients, see section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.       PHARMACEUTICAL <\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif'>FORM<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"_Toc259706902\"><\/a><a name=\"_Toc259707071\"><\/a><a name=\"_Toc259707134\"><\/a><a name=\"_Toc259713075\"><span lang=\"EN-GB\">Concentrate for solution for infusion<\/span><\/a><span lang=\"EN-GB\">\r (sterile concentrate)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Colourless to\r slightly brownish\u2011yellow liquid at pH 6 and with an osmolality of\r 300 mOsm\/kg.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><\/b><b><span lang=\"EN-GB\">CLINICAL<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif'>\r PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.1     Therapeutic\r indications<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"Standard\"><span lang=\"EN-GB\">Adakveo<\/span><span lang=\"EN-GB\"> is indicated\r for the prevention of recurrent vaso\u2011occlusive crises (VOCs) in sickle\r cell disease patients aged 16 years and older. It can be given as an add\u2011on\r therapy to hydroxyurea\/hydroxycarbamide (HU\/HC) or as monotherapy in patients\r for whom HU\/HC is inappropriate or inadequate.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.2     Posology and method of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Treatment should\r be initiated by physicians experienced in the management of <\/span><span lang=\"EN-GB\">sickle cell disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><a name=\"_nth_Adults_and_patients_ag4131\"><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The recommended\r dose of crizanlizumab is 5 mg\/kg administered over a period of\r 30 minutes by intravenous infusion at week 0, week 2, and every\r 4 weeks thereafter.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Crizanlizumab <\/span><span lang=\"EN-GB\">c<\/span><span lang=\"EN-GB\">an be given alone or with HU\/HC.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"Standard\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">If a dose is missed, the treatment should be administered as soon as\r possible.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">If crizanlizumab is administered\r within 2 weeks after the missed dose, dosing should be continued according\r to the patient\u2019s original schedule.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">If crizanlizumab is administered\r more than 2 weeks after the missed dose, dosing should be continued every\r 4 weeks thereafter.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Crizanlizumab\r has not been studied in elderly patients. No dose adjustment is required as the\r pharmacokinetics of crizanlizumab in adults are not affected by age.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Based on the\r population pharmacokinetic (PK) results, no dose adjustment is required in\r patients with mild or moderate renal impairment (see section 5.2). Data\r from patients with severe renal impairment are too limited to draw conclusions\r on this population.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety and\r efficacy of crizanlizumab in patients with hepatic impairment have not been\r established. Crizanlizumab is a monoclonal antibody and is cleared via\r catabolism (i.e. breakdown into peptides and amino acids), and a change in dose\r is not expected to be required for patients with hepatic impairment (see\r section<\/span><span lang=\"EN-GB\">5.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p> <p class=\"Standard\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety and\r efficacy of <\/span><span lang=\"EN-GB\">crizanlizumab<\/span><span lang=\"EN-GB\"> in\r paediatric patients from 6 months to 16 years have not been\r established. No data are available.<\/span><\/p> <p class=\"Standard\" style=\"line-height:normal\"><\/p> <p class=\"Standard\" style=\"line-height:normal\"><span lang=\"EN-GB\">There is no\r relevant use of crizanlizumab in infants aged less than 6 months for the\r indication of prevention of recurrent vaso\u2011occlusive crises.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of administration<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo <\/span><span lang=\"EN-GB\">should be diluted with sodium chloride 9 mg\/ml (0.9%) solution\r for injection or dextrose 5% before administration.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The diluted solution<\/span><span lang=\"EN-GB\"> must be administered through a sterile, non\u2011pyrogenic 0.2 micron\r in\u2011line filter by intravenous infusion over a period of 30 minutes. It\r must not be administered by intravenous push or bolus.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For instructions\r on dilution of the medicinal product before administration, see section 6.6.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hypersensitivity\r to Chinese Hamster Ovary (CHO) cell products.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.4     Special warnings and\r precautions for use<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Traceability<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\u2011related reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r studies, infusion\u2011related reactions (defined as occurring within\r 24 hours) were observed in 2 patients (1.8%) treated with crizanlizumab\r 5 mg\/kg<\/span><span lang=\"EN-GB\">. Patients should be monitored for signs\r and symptoms of infusion\u2011related reactions, which may include fever,\r chills, nausea, vomiting, fatigue, dizziness, pruritus, urticaria, sweating,\r shortness of breath or wheezing. <\/span><span lang=\"EN-GB\">In the event of a\r severe reaction, crizanlizumab should be discontinued and appropriate therapy\r should be instituted.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Laboratory test interference: automated platelet counts<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Interference\r with automated platelet counts (platelet clumping) has been observed in\r patients treated with crizanlizumab in clinical studies, in particular when\r tubes containing EDTA (ethylenediaminetetraacetic acid) were used. This may\r lead to unevaluable or falsely decreased platelet counts. There is no evidence\r that crizanlizumab causes a reduction in circulating platelets or has a pro\u2011aggregant\r effect <i>in vivo<\/i>.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">To mitigate the\r potential for laboratory test interference, it is recommended to run the test as\r soon as possible (within 4 hours of blood collection) or use citrate\r tubes. When needed, <\/span><span lang=\"EN-GB\">platelet counts can be estimated via\r a peripheral blood smear<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Excipients with known effect<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicine\r contains less than 1 mmol sodium (23 mg) per vial, that is to say\r essentially \u201csodium\u2011free\u201d.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.5     Interaction with\r other medicinal products and other forms of interaction<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Interactions\r between crizanlizumab and other medicinal products have not been investigated\r in dedicated studies.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Monoclonal\r antibodies are not metabolised by cytochrome P450 (CYP450) enzymes. Therefore,\r medicinal products that are substrates, inhibitors or inducers of CYP450 are\r not expected to affect the pharmacokinetics of crizanlizumab. In clinical\r studies, HU\/HC had no effect on crizanlizumab pharmacokinetics in patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No effect on\r exposure of co\u2011administered medicinal products is expected based on the\r metabolic pathways of monoclonal antibodies.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6     <\/span><\/b><b><span lang=\"EN-GB\">Fertility, p<\/span><\/b><b><span lang=\"EN-GB\">regnancy and lactation<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"Standard\"><span lang=\"EN-GB\">There is a limited amount of data from the\r use of Adakveo in pregnant women. Based on data from animal studies, crizanlizumab\r has the potential to cause foetal losses when administered to a pregnant woman\r (see section 5.3). As a precautionary measure, it is preferable to avoid\r the use of Adakveo during pregnancy and in woman of childbearing potential not\r using contraception.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"Standard\" style=\"line-height:normal\">To help determine the effects in\r pregnant women, healthcare professionals are encouraged to report all pregnancy\r cases and complications during pregnancy (from 105 days prior to the last\r menstrual period onward) to <span lang=\"EN-GB\">the local representative of the<\/span>\r marketing authorisation holder (see package leaflet), in order to allow\r monitoring of these patients through the PRegnancy outcomes Intensive\r Monitoring programme (PRIM). In addition, all adverse pregnancy events should\r be reported <span lang=\"EN-GB\">via <span style=\"color:black;background:#D9D9D9\">the\r national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V<\/span><\/a><\/span>.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is unknown whether\r crizanlizumab is excreted in human milk after administration of Adakveo. There\r are no data on the effects of crizanlizumab on the breast\u2011fed newborn\/infant\r or on milk production.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Because many\r medicinal products, including antibodies, can be excreted in human milk, a risk\r to the newborn\/infant cannot be excluded.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A decision must\r be made whether to discontinue breast\u2011feeding or to discontinue Adakveo\r therapy, taking into account the benefit of breast\u2011feeding for the child\r and the benefit of therapy for the woman.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">There are no\r data on the effect of Adakveo on human fertility. Available non\u2011clinical\r data do not suggest an effect on fertility under crizanlizumab treatment (see\r section 5.3).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7     Effects on ability\r to drive and use machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo may have\r a minor influence on the ability to drive and use machines. Dizziness, fatigue\r and somnolence may occur following administration of crizanlizumab.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Summary of the safety profile<\/span><\/u><a name=\"_nth_Summary_of_the_safety_6118\"><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The most frequently reported adverse drug reactions (\u226510% of\r patients) in the Adakveo 5 mg\/kg group were arthralgia, nausea, back pain,\r pyrexia and abdominal pain. Severe events were observed for pyrexia and\r arthralgia (each 0.9%).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Tabulated list of adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Table 1 lists adverse reactions based on pooled data from two\r studies: the pivotal study, SUSTAIN, and a single\u2011arm, open\u2011label\r pharmacokinetics\/pharmacodynamics and safety study. Use of crizanlizumab in\r combination with HU\/HC did not result in any meaningful differences in the\r safety profile.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Within each system organ class, the adverse reactions are ranked by\r frequency, with the most frequent reactions first. Within each frequency\r grouping, adverse reactions are presented in order of decreasing seriousness.\r In addition, the corresponding frequency category for each adverse reaction is\r based on the following convention: very common (\u22651\/10); common\r (\u22651\/100 to &lt;1\/10); uncommon (\u22651\/1,000 to &lt;1\/100); rare\r (\u22651\/10,000 to &lt;1\/1,000); very rare (&lt;1\/10,000).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><a name=\"_Toc272145403\"><\/a><a name=\"_Toc272145564\"><\/a><a name=\"_Toc266768477\"><\/a><a name=\"_Toc260903679\"><\/a><a name=\"_Toc266264818\"><\/a><a name=\"_Toc499550967\"><\/a><a name=\"_Toc517716325\"><b><span lang=\"EN-GB\">Table 1       Adverse\r reactions in clinical studies<\/span><\/b><\/a><a name=\"_hd6_Table_7_1_Percentage_o7395\"><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:459.0pt;border-collapse:collapse;border:none\" width=\"612\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">System organ class<\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Frequency<\/span><\/b><\/p> <\/td> <td style=\"width:202.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Adverse reaction<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Respiratory, thoracic and\r   mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Oropharyngeal pain<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Gastrointestinal disorders<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Very common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Nausea, abdominal pain*<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.45pt\"> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">D<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">iarrhoea, vomiting<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Skin and subcutaneous tissue\r   disorders<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pruritus*<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Musculoskeletal and\r   connective tissue disorders<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Very common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Arthralgia, back pain<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Myalgia, musculoskeletal\r   chest pain<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">General disorders and\r   administration site conditions<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Very common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pyrexia<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Infusion site reaction*<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Injury, poisoning and\r   procedural complications<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Infusion\u2011related\r   reaction<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:459.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"612\"> <p class=\"Table\" style=\"margin:0in\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>*The\r   following groupings contain the following MedDRA preferred terms:<\/span><\/p> <p class=\"Table\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r   margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>-<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Abdominal\r   pain: abdominal pain, abdominal pain upper, abdominal pain lower, abdominal\r   discomfort, and abdominal tenderness<\/span><\/p> <p class=\"Table\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r   margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"FR-CH\" style='font-family:\r   \"Times New Roman\",serif'>-<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Pruritus:\r   pruritus and vulvovaginal pruritus<\/span><\/p> <p class=\"Table\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r   margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-size:\r   11.0pt;font-family:\"Times New Roman\",serif'>-<\/span><span lang=\"FR-CH\" style='font-family:\"Times New Roman\",serif'>Infusion\r   site reaction: infusion site extravasation, infusion site pain, and infusion\r   site swelling<\/span><\/p> <\/td> <\/tr> <\/table> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r avoid\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r avoid\"><i><u><span style=\"font-size:11.0pt\">Immunogenicity<\/span><\/u><\/i><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">In clinical studies, treatment\u2011induced anti\u2011crizanlizumab\r antibodies were transiently detected in 1 patient (0.9%) among the 111 patients\r who received Adakveo 5 mg\/kg.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">There was no evidence of altered pharmacokinetics or of\r an altered safety profile with anti\u2011crizanlizumab antibody development.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"Standard\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"Standard\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Frequency, type and severity of adverse reactions in\r patients aged 16 and 17 years are expected to be the same as in adults.\r The safety of crizanlizumab was evaluated in 3 patients aged &lt;18 years.<\/span><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via <span style=\"color:black;\r background:#D9D9D9\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.9     Overdose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">No cases of overdose have been reported in clinical studies.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">General supportive\r measures and symptomatic treatment should be initiated in cases of suspected\r overdose.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.       PHARMACOLOGICAL\r PROPERTIES<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1     Pharmacodynamic\r properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Other haematological agents, ATC code: B06AX01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Crizanlizumab is a selective IgG2 kappa humanised monoclonal\r antibody (mAb) that binds to P\u2011selectin with high affinity and blocks the\r interaction with its ligands, including P\u2011selectin glycoprotein ligand 1.\r <\/span><span lang=\"EN-GB\">Crizanlizumab can also dissociate preformed P\u2011selectin\/PSGL\u20111\r complex. <\/span><span lang=\"EN-GB\">P\u2011selectin is an adhesion molecule\r expressed on activated endothelial cells and platelets. It plays an essential\r role in the initial recruitment of leukocytes and the aggregation of platelets\r to the site of vascular injury during inflammation. In the chronic pro\u2011inflammatory\r state associated with sickle cell disease, P\u2011selectin is over\u2011expressed\r and circulating blood cells and the endothelium are activated and become\r hyperadhesive. P\u2011selectin\u2011mediated multi\u2011cellular adhesion is\r a key factor in the pathogenesis of vaso\u2011occlusion and vaso\u2011occlusive\r crises (VOC). Elevated levels of P\u2011selectin are found in patients with\r sickle cell disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Binding P\u2011selectin on the surface of the activated endothelium\r and platelets has been shown to effectively block interactions between\r endothelial cells, platelets, red blood cells and leukocytes, thereby\r preventing vaso\u2011occlusion.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Pharmacodynamic effects<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Throughout\r clinical studies, treatment with crizanlizumab 5 mg\/kg resulted in dose\u2011dependent,\r immediate and sustained P\u2011selectin inhibition <\/span><span lang=\"EN-GB\">(as\r measured <i>ex vivo<\/i>) <\/span><span lang=\"EN-GB\">in patients with sickle cell disease.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Clinical efficacy and safety<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The efficacy of crizanlizumab, with or without HU\/HC, was evaluated\r in the pivotal study SUSTAIN, a 52\u2011week, randomised, placebo\u2011controlled,\r double\u2011blind, multicentre clinical study in sickle cell disease patients\r with a history of vaso\u2011occlusive crises (VOCs).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In this study, VOCs were defined as those leading to a healthcare\r visit, which captured all acute episodes of pain with no other cause than a\r vaso\u2011occlusive event that required a healthcare visit and treatment with\r oral or parenteral opioids or parenteral non\u2011steroidal anti\u2011inflammatory\r drugs (NSAIDs). Acute chest syndrome, hepatic sequestration, splenic\r sequestration and priapism (requiring a healthcare visit), by definition, were\r also considered VOCs.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A total of 198 sickle cell disease patients aged 16 to 63 years\r (inclusive; mean age 30.1\u00b110.3 years), with any sickle cell disease genotype\r (including HbSS [71.2%], HbSC [16.2%], HbSbeta0\u2011thalassaemia [6.1%],\r HbSbeta+\u2011thalassaemia [5.1%], and others [1.5%]) and a history of between\r 2 and 10 VOCs in the previous 12 months (62.6% and 37.4% of the\r patients had 2\u20114 or 5\u201110 VOCs, respectively), were randomised\r 1:1:1 to Adakveo 5 mg\/kg, Adakveo 2.5 mg\/kg or placebo. The majority\r of patients were Black or African American (91.9%). Patients received Adakveo with\r (62.1%) or without (37.9%) HU\/HC. Randomisation was stratified by patients\r already receiving HU\/HC (Y\/N) and by number of VOCs in the previous 12 months\r (2 to 4, 5 to 10). Patients were allowed to take medicinal products to\r relieve pain (i.e. paracetamol, NSAIDs and opioids) and to receive occasional\r transfusions on an \u201cas needed\u201d basis. Patients participating in a chronic\r transfusion programme (pre-planned series of transfusions for prophylactic\r purposes) were excluded from the study.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Treatment with Adakveo 5 mg\/kg resulted in a 45.3% lower median\r annual rate of VOCs compared to placebo (Hodges\u2011Lehmann, median absolute\r difference of \u20111.01 compared with placebo, 95% CI [\u20112.00, 0.00]),\r which was statistically significant (p=0.010). The median annual rates of uncomplicated\r VOCs (any VOCs as defined above, excluding acute chest syndrome, hepatic\r sequestration, splenic sequestration or priapism) and days hospitalised were\r 62.9% and 41.8% lower in the Adakveo 5 mg\/kg than in the placebo group,\r respectively. The VOCs occurring during the study were assessed by an\r independent review committee.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Main efficacy outcomes of the pivotal SUSTAIN study are summarised\r in Tables 2 and 3.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><a name=\"_Toc499550968\"><\/a><a name=\"_Toc517716326\"><b><span lang=\"EN-GB\">Table <\/span><\/b><\/a><b><span lang=\"EN-GB\">2       Results from SUSTAIN clinical study in <\/span><\/b><a name=\"_hd6_Table_12_1_Results_fro16811\"><\/a><b><span lang=\"EN-GB\">sickle cell\r disease<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.84%;border-collapse:collapse;border:none\" width=\"98%\"> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td style=\"width:20.16%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Event<\/span><\/b><\/p> <\/td> <td style=\"width:23.82%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Adakveo 5 mg\/kg<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">(N=67)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(standard median)<\/span><\/p> <\/td> <td style=\"width:11.54%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">(N=65)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(standard median)<\/span><\/p> <\/td> <td style=\"width:10.46%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Change vs placebo<\/span><\/b><\/p> <\/td> <td style=\"width:21.1%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Hodges\u2011Lehmann median\r   difference<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(95% CI)<\/span><\/p> <\/td> <td style=\"width:12.9%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">p-value<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(Wilcoxon rank sum)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td style=\"width:20.18%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Primary endpoint<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Annual rate of VOCs<\/span><\/p> <\/td> <td style=\"width:23.82%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.63<\/span><\/p> <\/td> <td style=\"width:11.54%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.98<\/span><\/p> <\/td> <td style=\"width:10.46%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201145.3%<\/span><\/p> <\/td> <td style=\"width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.00, 0.00)<\/span><\/p> <\/td> <td style=\"width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">0.010<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"5\" style=\"width:87.1%;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Secondary endpoints<\/span><\/b><\/p> <\/td> <td style=\"width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td style=\"width:20.18%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Annual rate of days hospitalised<\/span><\/p> <\/td> <td style=\"width:23.82%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">4.00<\/span><\/p> <\/td> <td style=\"width:11.54%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">6.87<\/span><\/p> <\/td> <td style=\"width:10.46%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201141.8%<\/span><\/p> <\/td> <td style=\"width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">0.00<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20114.36, 0.00)<\/span><\/p> <\/td> <td style=\"width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">0.450<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td style=\"width:20.18%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Annual rate of uncomplicated VOCs<\/span><\/p> <\/td> <td style=\"width:23.82%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.08<\/span><\/p> <\/td> <td style=\"width:11.54%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.91<\/span><\/p> <\/td> <td style=\"width:10.46%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201162.9%<\/span><\/p> <\/td> <td style=\"width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.00<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20111.98, 0.00)<\/span><\/p> <\/td> <td style=\"width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">-<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td colspan=\"6\" style=\"width:.02%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"0%\"> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">The primary (annual rate of VOC leading\r   to healthcare visit) and key secondary (annual rate of days hospitalised)\r   endpoints were the only ones formally tested for statistical significance\r   according to protocol.<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The clinical effect demonstrated in the\r primary efficacy analysis was supported by multiple supplementary analyses\r including a negative binomial regression on investigator assessments with a\r conservative method to handle missing data due to early discontinuation of\r treatment based on outcomes in the placebo group (RR=0.74, 95% CI=0.52, 1.06).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In the Adakveo 5 mg\/kg group, clinically significant reductions\r in the annual rate of VOCs were observed across important subgroups (<\/span><span lang=\"EN-GB\">HU\/HC use, 2\u20114 or 5\u201110 VOCs in the previous 12 months,\r and HbSS or non\u2011HbSS genotypes; <\/span><span lang=\"EN-GB\">see Table 3).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><b><span lang=\"EN-GB\">Table 3       Annual rate of VOCs in patients \u2011\r subgroup analyses<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"612\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:90.45pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"121\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Subgroup <\/span><\/b><\/p> <\/td> <td style=\"width:63.8pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><\/p> <\/td> <td style=\"width:70.85pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Adakveo 5 mg\/kg (N=67)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(standard median)<\/span><\/p> <\/td> <td style=\"width:63.8pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Placebo (N=65)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(standard median)<\/span><\/p> <\/td> <td style=\"width:63.8pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Change vs placebo<\/span><\/b><\/p> <\/td> <td style=\"width:106.3pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Hodges\u2011Lehmann median\r   difference<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"121\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">HU\/HC use<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Yes<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=42<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.43<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n= 40<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">3.58<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201132.1%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.44, 0.00)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">No<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=25<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.00<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=25<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.00<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201150.0%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.02<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.00, 0.00)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:20.2pt\"> <td rowspan=\"2\" style=\"width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:20.2pt\" width=\"121\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Number of VOCs in previous\r   12 months<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2\u20114 VOCs<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=42<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.14<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=41<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.00<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201143.0%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20110.05<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20111.56, 0.01)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">5\u201110 VOCs<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=25<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.97<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=24<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">5.32<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201163.0%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20112.74<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20115.00, \u20110.83)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"121\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Sickle cell disease genotypes,\r   including HbSC<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">HbSS<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=47<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.97<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=47<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">3.01<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201134.6%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.18, 0.00)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Non\u2011HbSS<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=20<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">0.99<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=18<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.00<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201150.5%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.01, 0.00)<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A greater than two\u2011fold increase in the proportion of patients\r with no VOC and who completed the study was observed in the Adakveo 5 mg\/kg\r group compared to placebo (22% vs 8%; odds ratio [95% CI]: 3.57 [1.20, 10.63]).\r A similar difference was also observed across important subgroups (HU\/HC use,\r genotype).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Treatment with Adakveo 5 mg\/kg was also associated with a three\u2011fold\r longer Kaplan\u2011Meier estimated median time to first VOC compared with\r placebo (4.07 vs 1.38 months; HR=0.495, 95% CI: 0.331, 0.741) (Figure 1)\r and a two\u2011fold longer median time from randomisation to second VOC\r compared to placebo (10.32 vs 5.09 months; HR=0.534, 95% CI: 0.329, 0.866).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 1      Kaplan\u2011Meier curve of time to first VOC<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><span style=\"position:absolute;z-index:251748352;left:0px;margin-left:61px;\r margin-top:211px;width:13px;height:9px\"><img alt=\"0\" height=\"9\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA0AAAAJCAYAAADpeqZqAAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAABRSURBVCjPY2hsbGQgFTPQRFN9noehiYnJTGNjj+7Y+npJojRFGxvXgxSDNBu75aWQpqk+VtLNLS+MdjbVR3rYGRtH13sYG3d75NUb0i70sGEAGHyta9OJwycAAAAASUVORK5CYII=\" width=\"13\"\/><\/span><span style=\"position:absolute;z-index:251746304;left:0px;margin-left:63px;\r margin-top:190px;width:10px;height:10px\"><img alt=\"10\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACHSURBVCjPY2hsbGQgBsMZ0aYehbH19ZIdHWk80R6mhbKyJtsj8+pV4QpBEu7GcrNAEiCFeW7GKcbRDT4gcTdjt9q0jg4euEIQJ9rYuB6kMMpYttcjr94QbAtUDNVqqCCyJF6FIKtBJoJs8jA27sapsD4vUtVE1mQFyN3GbnkpGL4mOniophAA2LuQewVJW9oAAAAASUVORK5CYII=\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251744256;left:0px;margin-left:64px;\r margin-top:169px;width:10px;height:10px\"><img alt=\"20\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACsSURBVCjPrZCxDYNADEUZgAUoTJcB0HfalOaKLEAQHaKKTopSI4fuJMQAYQIyQdaLjMQp6ShSuLDvPev7kmEYkj2VhNClJfKZmBdX6cn62h1vRPyuvB4ieBW6O6\/FKuSYRdCjfpytF0jfhZCu4GaoNhnycrbtJtqsBrRRzSJotiN6GfD9+APaJiZetjxe0G5RHDBG8AKa7BBmfgJu9L4qTLQIEN\/GY3Z\/z9\/BDzIIjqpQaDPwAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251742208;left:0px;margin-left:64px;\r margin-top:149px;width:10px;height:10px\"><img alt=\"30\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACoSURBVCjPrZDBCcMwDEUzQBbIwbllgPDdFWxRuoBrcgs5CjpAUX0zhA7QTJANul5RwYbecuhBgi89fb7dpJSaI9XkvLQErD38FlgG1ZFON2PsW3UF2WEmllFk6tD7TSHEx0UPHNx9ybn9gtqKCxzPV5inHuo8AjKJdBXUYg4jQKvGKMsfkCOdi1A3a+1LHUv2CgrTaI3dPfrNUBThMBStUepjDn\/P38EPZ1mO4Ar4bTAAAAAASUVORK5CYII=\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251740160;left:0px;margin-left:65px;\r margin-top:130px;width:10px;height:10px\"><img alt=\"40\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACjSURBVCjPY2hsbGQgBsMZOW6yxcbRDT4dHWk80R6mhbKyJtsj8+pVURTW53kYmsjKbgcpzHMzToFpcDN2q03r6OABK4QJ5EWbRoAURBnL9nrk1RuCJKONjetj6+slwQpBJoAkGqKNfUAKkSVRFILcY2JiMhNktaysx0oQH6QRZJOHsXE3XCHMsTAT6\/MiVU1kTVa4G8vNMnbLS8HwNdHBQzWFAHAmjuhoo9TWAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251738112;left:0px;margin-left:64px;\r margin-top:110px;width:10px;height:10px\"><img alt=\"50\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACrSURBVCjPrZCxDcJADEVvgAwAhekyQGRnhcNFakSw6KKUljIActKdhBgAJmCDrIeMOBS6FBRX3P3n568L0zSFNSek1BeMeCWie80y6Kgb4XoAoLlVK7+gKVcYtcsPGrFDGRsXRIyXPqXiDY6CjU8TwFyLHk8IN1arPBREO5ttP8a2zFMeeIUc\/oAa4yF3cZuDbszdF0aufPUedw9gMd9AQE+\/L7uH1d\/zd\/AF4j2OYb789v4AAAAASUVORK5CYII=\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251736064;left:0px;margin-left:64px;\r margin-top:90px;width:10px;height:10px\"><img alt=\"60\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACkSURBVCjPY2hsbGQgBoOJaA\/TQllZk+0ekfV2HR1pPDB+ZF69KlxhnptxinF0gw9IgZubWz5IEZxv7Fab1tHBA1YYbWxc7+ZmXAs2Ma\/eMMpYthdEg20CysXW10uCFUYZMyyEmeAuZzzLxMRkJkwSTSGqCSDTQXyQRg9j4264wvo8D0MTWZMVIEFZ46je+rxIVRDf3VhulrFbXgqKr4kOHqoqBABGdo3GbfQMNwAAAABJRU5ErkJggg==\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251734016;left:0px;margin-left:64px;\r margin-top:70px;width:10px;height:10px\"><img alt=\"70\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACdSURBVCjPY2hsbGQgBjPkuRmnmJiYzARhY2OP7si8PMNoD9NCWVmT7ZF59apwhTBGfZ6HobFxdD1Io3F0g09HRxqPm7FbbVpHBw9cIUjQw9i4O7a+XjLKWLbXI6\/eECQebWxcDxKDK2yINvYxdstLQZfEUIhsCshqEBvZFrBCkIC7nPEsmEB9XqSqiazJCndjuVkwW1A8QzB4qK4QAMhsj66qiUfoAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251731968;left:0px;margin-left:63px;\r margin-top:48px;width:10px;height:10px\"><img alt=\"80\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACmSURBVCjPY2hsbGQgBjN0dKTxRBnL9sqamKzwyKs3BPGjPUwLZWVNtkfm1avCFea4yRYbRzf4gBS4GbvVghQh89M6OnjACuvzPAyNjT26wQrc8lJApoNMBklGGxvXx9bXS4IV5rkZp4AU5OVFgjV4GBt3wyRRFCJzQKaZmJjMhLkVWRPYahNZkxVubsa1ssZRvfV5kaogvrux3CyQTXDPEB08VFcIAGfxjehIKaxZAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251729920;left:0px;margin-left:65px;\r margin-top:28px;width:10px;height:10px\"><img alt=\"90\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACjSURBVCjPY2hsbGQgBjN0dKTxuBvLzZIzdp8VmVevCuJHe5gWysqabAfx4Qpz3GSLPfLqDUEK3IzdakGKjKMbfGD8tI4OHrDCKGPZXpBCECfa2LjexER2BTI\/tr5eEqywPs\/DEGSNiYnJTBgNk0RR2JCXJwEyHmSVh7Fxt5ubcS3MKSA+ionGxh7dIA8Zu+Wl1OdFqprImqyA8eGeITp4qK4QAJ5TjiisGzNqAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251727872;left:0px;margin-left:60px;\r margin-top:9px;width:15px;height:10px\"><img alt=\"100\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA8AAAAKCAYAAABrGwT5AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAClSURBVCjPY2hsbGQgF8MZ0aYehbH19ZIgdkdHGk+0h2mhrKzJ9si8elV0PlwzSMLdWG4WSAKmOc\/NOMU4usEHJOdm7FYL0ojMT+vo4IFrBnGijY3rYZqjjGV7PfLqDcEuAoqbmMiuQObD1CGcjSSIzjYxMZmJTQ6rZpCzQTaBXOVhbNzt5mZci8zHq7k+L1LVRNZkBSgsjN3yUtD5GKFNUVTRXTMA8B3XufAXr20AAAAASUVORK5CYII=\" width=\"15\"\/><\/span><span style=\"position:absolute;z-index:251781120;left:0px;margin-left:459px;\r margin-top:8px;width:125px;height:38px\"><img height=\"38\" src=\"data:image\/png;base64,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\" width=\"125\"\/><\/span><span style=\"position:\r absolute;z-index:251779072;left:0px;margin-left:494px;margin-top:7px;\r width:92px;height:26px\"><img height=\"26\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFwAAAAaCAMAAAANMMsbAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJUExURf\/\/\/\/\/\/\/\/\/\/\/45K5f4AAAACdFJOU9vzMOtySgAAAAlwSFlzAAAOwwAADsMBx2+oZAAAADVJREFUSEvtzCECADAIw0Dg\/4\/eBDKSusS06qomVtL++m4kcUwcE8fEMXFMHBPHsnjvuW\/6ASpfEqvzA8MRAAAAAElFTkSuQmCC\" width=\"92\"\/><\/span><span style=\"position:\r absolute;z-index:251666432;left:0px;margin-left:22px;margin-top:28px;\r width:32px;height:178px\"><img alt=\"Probability of being free from first VOC (%)\" height=\"178\" src=\"data:image\/png;base64,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\" width=\"32\"\/><\/span><span style=\"position:absolute;z-index:251725824;left:0px;margin-left:320px;\r margin-top:242px;width:56px;height:10px\"><img alt=\"Time (months)\u00ac\u00ac\u00ac\u00ac\" height=\"10\" src=\"data:image\/png;base64,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\" width=\"56\"\/><\/span><sub><span style=\"font-size:11.0pt\">                                <img border=\"0\" height=\"223\" id=\"Picture 1243\" src=\"data:image\/jpg;base64,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\" width=\"518\"\/><\/span><\/sub><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"> <table align=\"left\" cellpadding=\"0\" cellspacing=\"0\"> <tr> <td height=\"1\" width=\"3\"><\/td> <td width=\"36\"><\/td> <td width=\"33\"><\/td> <td width=\"2\"><\/td> <td width=\"2\"><\/td> <td width=\"5\"><\/td> <td width=\"10\"><\/td> <td width=\"3\"><\/td> <td width=\"23\"><\/td> <td width=\"10\"><\/td> <td width=\"27\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"3\"><\/td> <td width=\"7\"><\/td> <td width=\"28\"><\/td> <td width=\"10\"><\/td> <td width=\"28\"><\/td> <td width=\"10\"><\/td> <td width=\"25\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"13\"><\/td> <td width=\"26\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"10\"><\/td> <td width=\"30\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"10\"><\/td> <td width=\"27\"><\/td> <td width=\"10\"><\/td> <td width=\"18\"><\/td> <\/tr> <tr> <td height=\"10\"><\/td> <td colspan=\"5\"><\/td> <td align=\"left\" valign=\"top\"><img alt=\"0\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB0SURBVCjPY2hsbGQgBsMZHR1pPNEepoWysibbI\/PqVXEqzHMzTjGObvABaXAzdqtN6+jgwaowyli21yOv3hDEjjY2ro+tr5fEqhBZEq9CkNUgE0FWexgbd+NUWJ8XqWoia7LC3VhulrFbXgpOzxAdPFRTCAAolJLNIdXXkAAAAABJRU5ErkJggg==\" width=\"10\"\/><\/td> <td colspan=\"2\"><\/td> <td align=\"left\" valign=\"top\"><img alt=\"1\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAA9SURBVCjPY2hsbGQgBmMIRJt6FMbW10viVNjRkcbjbiw3S1bWZDtBhWkdHTzRxsb1eBXCrR44hUQHD8UKAQJJlNuO03ePAAAAAElFTkSuQmCC\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"2\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB0SURBVCjPY2hsbGQgBsMZHR1pPO7GcrNkTUxWeETW2+FUmOMmW+yRV28I1iBnPCu2vl4Sq0IYrq+PlTSWc5+V1tHBg1MhyDQPWdmVIJNxWg0yyUTWZEVkXr0qXs9EGcv2gjxiYmIy09jYoxuv1UQFD9UUAgBwNJMS8y8R2wAAAABJRU5ErkJggg==\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" colspan=\"2\" valign=\"top\"><img alt=\"3\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB7SURBVCjPY2hsbGQgBsMZHR1pPB7Gxt1yxu6zIvPqVXEqzHMzTvHIqzesr4+VNJZzn5XW0cGDVSHM1GgP00Jjt7wUnCbCTc6LNDQ29ujGaWJetIdXbH29JIgdZSzbC3IGVoX1eR6GJrImK9yN5WbJekTXE7SaYPBQTSEAnxOTQJNoygYAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"4\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAABgSURBVCjPY2hsbGQgBmMI5LjJFhtHN\/jgVVif52FoIiu7Ha\/Cjo40Hjdjt9q8aNMIvArz3IxTPPLqDRuijX1wKgSZFu1hWmhiYjITZLWsrMfKtI4OHryewWsiWcFDsUIApiiTSLHBUzIAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"5\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB6SURBVCjPY2hsbGQgBsMZHR1pPB7Gxt0mJiYzTT2iC9M6OniwKqzP8zA0dstLIWhiQ7Sxj6ysyXYTWdntptF5ETgV1udFqsKsizY2ro+tr5fEqjDPzS0sMq9eFcSOMpbt9cirN8TpRpDV7sZys2Q9outxWk108FBNIQAlxZLDHicfXQAAAABJRU5ErkJggg==\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"6\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB2SURBVCjPY2hsbGQgBqNwoj1MC2VlTbZ7RNbb4VSY52acYhzd4NPRkcbj5uaWn9bRwYNVYbSxcb2bm3Et2MS8ekOcJkYZMyyEmeguZzwrtr5eEodC2V6YSSDTcSqsz\/MwNJE1WeFhbNwtaxzVi9fXRAcPVRQCAINekiNWacDGAAAAAElFTkSuQmCC\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"7\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA0AAAAKCAYAAABv7tTEAAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB7SURBVCjPY2hsbGQgFaNwysvLBYKDg2NBODw8PDgrK0uHoKb6+npRBweHeicnp0oFBYW9fn5+iQQ1IdnIC9TcwMDAwEi0Jltb29b4+HhnovwEtUXIwMBg4apVq5iI1hQbG+tuamo6hejQA+G8vDy5tLQ0LZI0kRxPxGIAnwu\/7JsP81AAAAAASUVORK5CYII=\" width=\"13\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"8\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB7SURBVCjPY2hsbGQgBsMZHR1pPFHGsr2yJiYrPPLqDXEqzHGTLTaObvABaXAzdqtN6+jgwaqwPs\/D0NjYozvaw7TQ2C0vBaeJeW7GKSAFeXmRYA04TYw2Nq6Pra+XBLFBbkV3J4rVJrImK9zcjGtljaN6cVpNdPBQTSEAp2uSSOWzepoAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"9\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB6SURBVCjPY2hsbGQgBsMZHR1pPO7GcrPkjN1nRebVq+JUmOMmW+yRV28I0uBm7Fab1tHBg1VhlLFsL0ghiB1tbFwfW18viVVhfZ6HoaysyXYTE5OZIBqnwoa8PAmQdSCrPYyNu\/GaaGzs0Q3ykLFbXgpOzxAdPFRTCADTGpKAXsOmnQAAAABJRU5ErkJggg==\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"10\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACHSURBVCjPY2hsbGQgBsMZ0aYehbH19ZIdHWk80R6mhbKyJtsj8+pV4QpBEu7GcrNAEiCFeW7GKcbRDT4gcTdjt9q0jg4euEIQJ9rYuB6kMMpYttcjr94QbAtUDNVqqCCyJF6FIKtBJoJs8jA27sapsD4vUtVE1mQFyN3GbnkpGL4mOniophAA2LuQewVJW9oAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"11\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAABFSURBVCjPY2hsbGQgBsMZ0aYehbH19ZK4+AwdHWk87sZys2RlTbaDJND5KArTOjp4oo2N62EKkfmYVqNJ0FEh0cFDNYUAogCSidVvHywAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"12\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACNSURBVCjPY2hsbGQgBsMZ0aYehbH19ZIdHWk87sZys2RNTFZ4RNbbwRXCJWRNtoMU5rjJFnvk1RuCxeWMZ4HE4ArTOjp4oo2N62GCIFxfHytpLOc+CySHajWSQpBmD1nZlSCTMd0IVQgyyUTWZEVkXr0qds9AFUYZy\/aCPGJiYjLT2NijG8NqooOHagoBHkKQwNKEDRYAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"13\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACWSURBVCjPY2hsbGQgBsMZ0aYehbH19ZIdHWk8HsbG3XLG7rMi8+pV4QpBEu7GcrNkZU22gxTmuRmneOTVG9bXx0oay7nPSuvo4IErBHGijY3rQQpBgiCxaA\/TQmO3vBRMq5EUgnBeXqShsbFHN9xEdIV50R5eMA1RxrK9IGdgVVif52FoImuyAuxuj+h6DKuJDh6qKQQAS7GQ7lbNrkIAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <\/tr> <tr> <td height=\"14\"><\/td> <\/tr> <tr> <td height=\"9\"><\/td> <td colspan=\"7\"><\/td> <td align=\"left\" colspan=\"6\" valign=\"top\"><img alt=\"Number of patients at risk\" height=\"9\" src=\"data:image\/png;base64,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\" width=\"99\"\/><\/td> <\/tr> <tr> <td height=\"7\"><\/td> <\/tr> <tr> <td height=\"7\"><\/td> <td colspan=\"4\"><\/td> <td align=\"left\" colspan=\"31\" rowspan=\"5\" valign=\"top\"><img alt=\"67,49,41,35,30,26,24,20,18,17,16,15,7,65,37,23,21,17,13,12,9,8,6,5,4,1,0,0\" height=\"43\" src=\"data:image\/png;base64,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\" width=\"513\"\/><\/td> <\/tr> <tr> <td height=\"10\"><\/td> <td align=\"left\" colspan=\"3\" valign=\"top\"><img alt=\"Adakveo 5 mg\/kg \" height=\"10\" src=\"data:image\/png;base64,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\" width=\"71\"\/><\/td> <\/tr> <tr> <td height=\"14\"><\/td> <\/tr> <tr> <td height=\"10\"><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"Placebo\" height=\"10\" src=\"data:image\/png;base64,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\" width=\"33\"\/><\/td> <\/tr> <tr> <td height=\"2\"><\/td> <\/tr> <\/table> <\/p> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><\/p> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <br clear=\"ALL\"\/> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><a name=\"_hd6_Table_2_1_Patients_wit18544\"><\/a><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The efficacy of\r crizanlizumab in patients aged 16 and 17 years is expected to be the same\r as in adults. Three patients (2.7%) aged less than 18 years were treated\r with crizanlizumab 5 mg\/kg in clinical studies.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European\r Medicines Agency has deferred the obligation to submit the results of studies\r with Adakveo in one or more subsets of the paediatric population in the\r treatment of sickle cell disease (see section 4.2 for information on\r paediatric use).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Conditional approval<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicinal\r product has been authorised under a so\u2011called \u201cconditional approval\u201d\r scheme. This means that further evidence on this medicinal product is awaited.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European\r Medicines Agency will review new information on this medicinal product at least\r every year and this SmPC will be updated as necessary.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic\r properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The median time\r to reach maximum serum concentration of crizanlizumab (T<sub>max<\/sub>) was 1.92 hours\r at steady state following intravenous administration of 5 mg\/kg over a\r period of 30 minutes in sickle cell disease patients.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Crizanlizumab\r distribution is typical of endogenous human antibodies within the vascular and\r extracellular spaces. The volume of distribution (V<sub>z<\/sub>) was 4.26 litres\r after a single 5 mg\/kg intravenous infusion of crizanlizumab in healthy\r volunteers.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Antibodies are\r primarily eliminated via proteolysis by lysosomal enzymes in the liver to small\r peptides and amino acids.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In healthy\r volunteers, the mean terminal elimination half\u2011life (T<sub>\u00bd<\/sub>) was\r 10.6 days and the mean clearance was 11.7 ml\/h at crizanlizumab dose\r level 5 mg\/kg. In patients with sickle cell disease, the mean elimination T<sub>\u00bd<\/sub>\r during the dosing interval was 7.5 days.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Linearity\/non\u2011linearity<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The exposure to\r crizanlizumab (mean C<sub>max<\/sub>, AUC<sub>last<\/sub>, or AUC<sub>inf<\/sub>)\r increased in non\u2011linear manner over the dose range of 0.2 to 8 mg\/kg\r in healthy volunteers.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a population\r PK analysis in patients with eGFR ranging from 35 to 202 ml\/min\/1.73 m<sup>2<\/sup>,\r no clinically important differences in the pharmacokinetics of crizanlizumab\r were found between patients with mild or moderate renal impairment and patients\r with normal renal function. Data from patients with severe renal impairment are\r too limited to draw conclusions on this population (see section<\/span><span lang=\"EN-GB\">4.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety and\r efficacy of crizanlizumab in patients with hepatic impairment have not been\r established. Crizanlizumab is a monoclonal antibody and is cleared via\r catabolism (i.e. breakdown into peptides and amino acids), and a change in dose\r is not expected to be required for patients with hepatic impairment.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Paediatric <a name=\"_nth_Pediatric_patients__be14752\"><\/a>population<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharmacokinetics\r in paediatric patients below the age of 16 years have not been\r investigated.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.3     Preclinical safety\r data<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">N<\/span><span lang=\"EN-GB\">on\u2011clinical data revealed no special hazard for humans based\r on conventional studies of safety pharmacology, tissue cross\u2011reactivity\r and repeated dose toxicity.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the 26\u2011week\r repeated dose toxicity study, administration of crizanlizumab in cynomolgus\r monkeys at dose levels up to 50 mg\/kg\/dose once every 4 weeks (at\r least 13.5 times the human clinical exposure based on AUC in patients with\r sickle cell disease at 5 mg\/kg once every four weeks) was generally well tolerated.\r There were no primary crizanlizumab\u2011related findings on any endpoint\r evaluated. At 50 mg\/kg, minimal to moderate inflammation of the vessels in\r multiple tissues considered to be an antigen\u2011antibody complex reaction\r (primate antihuman antibody) was observed in 2 of 10 animals. There was one\r death attributed to aspiration of gastric contents following a peri\u2011infusional\r reaction mediated by anti\u2011drug\u2011antibody\u2011dependent\r hypersensitivity.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Pharmacological effects of\r crizanlizumab on haemodynamic and electrocardiographic parameters in the\r cynomolgus monkey were evaluated in the 26\u2011week repeated dose toxicology\r study. Respiratory rate and neurological parameters were also assessed. There\r were no crizanlizumab\u2011related effects on arterial blood pressure or on\r heart rate, PR, RR, QRS, QT, and heart rate corrected QT (QTc) intervals on the\r electrocardiograms (ECG). No rhythm abnormalities or qualitative changes were\r observed during the qualitative ECG assessment. There were no crizanlizumab\u2011related\r effects on respiration rate or any neurological parameter evaluated.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Formal\r carcinogenicity, genotoxicity and juvenile toxicity studies have not been\r conducted with crizanlizumab.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a 26\u2011week\r repeated dose toxicity study, cynomolgus monkeys were administered\r crizanlizumab once every 4 weeks at doses up to 50 mg\/kg (at least\r 13.5 times the human clinical exposure based on AUC in patients with\r sickle cell disease at 5 mg\/kg once every four weeks). <\/span><span lang=\"EN-GB\">There were no adverse effects of crizanlizumab on male and female\r reproductive organs<\/span>.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In an enhanced\r pre\u2011 and postnatal development study in cynomolgus monkeys, pregnant\r animals received intravenous crizanlizumab once every two weeks during the\r period of organogenesis, at doses of 10 and 50 mg\/kg (approximately 2.8\r and 16 times <\/span><span lang=\"EN-GB\">the human clinical exposure based on\r AUC in patients with sickle cell disease at 5 mg\/kg\/dose once every four\r weeks, respectively)<\/span><span lang=\"EN-GB\">. No maternal toxicity was\r observed. <\/span><span lang=\"EN-GB\">There was an increase in foetal loss\r (abortions or stillbirths) at both doses and this was higher in the third\r trimester. The cause of the foetal losses in monkeys is unknown but may be due\r to the development of anti\u2011drug antibodies against crizanlizumab<\/span><span lang=\"EN-GB\">. There were no effects on infant growth and development during the 6 months\r postpartum that were attributable to crizanlizumab.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Measurable\r crizanlizumab serum concentrations were observed in the infant monkeys at\r postnatal day 28, confirming that crizanlizumab, like other IgG\r antibodies, crosses the placental barrier.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.       PHARMACEUTICAL\r PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Sucrose<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Sodium citrate (E331)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Citric acid (E330)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Polysorbate 80 (E433)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Water for\r injections<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicinal\r product<\/span><span lang=\"EN-GB\"> must not be mixed with other medicinal products\r except those mentioned in section 6.6.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Unopened vial<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">18 months<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Diluted solution<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Chemical and\r physical in\u2011use stability, from the start of preparation of the diluted\r solution for infusion until end of infusion, has been demonstrated for up to 8 hours\r at room temperature (up to 25\u00b0C) and at 2\u00b0C to 8\u00b0C for up to 24 hours\r overall.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">From a microbiological point of view, the diluted\r solution for infusion should be used immediately. If not used immediately, in\u2011use\r storage times and conditions prior to use are the responsibility of the user\r and would normally not be longer than 24 hours at 2\u00b0C to 8\u00b0C, including\r 4.5 hours at room temperature (up to 25\u00b0C) from the start of preparation\r to completion of the infusion, unless dilution has taken place in controlled\r and validated aseptic conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.4     Special precautions\r for storage<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Store in a refrigerator\r (2\u00b0C \u2013 8\u00b0C).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep the vial in\r the outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For storage conditions\r after dilution of the medicinal product, see section 6.3.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.5     Nature and contents\r of container<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">10 ml concentrate\r for solution for infusion in a type I glass vial with a coated chlorobutyl\r rubber stopper sealed with an aluminium cap with a plastic flip\u2011off disk containing\r 100 mg crizanlizumab.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pack of 1 vial.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6     Special\r precautions for disposal and other handling<\/span><\/b><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo vials\r are for single use only.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Preparing the infusion<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The diluted\r solution for infusion should be prepared by a healthcare professional using\r aseptic techniques.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The total dose\r and required volume of Adakveo depend on the patient\u2019s body weight; 5 mg\r of crizanlizumab is administered per kg body weight.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The volume to be used for the preparation of the infusion is\r calculated according to the following equation:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:12.5pt;border-collapse:collapse\" width=\"567\"> <tr> <td rowspan=\"2\" style=\"width:85.05pt;padding:0in 5.4pt 0in 5.4pt\" width=\"113\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Volume (ml) =<\/span><\/p> <\/td> <td style=\"width:269.35pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"359\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r   text-indent:-28.35pt;line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Patient\u2019s body weight (kg) x prescribed dose<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"94\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r   text-indent:-28.35pt;line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">[5 mg\/kg]<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:269.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"359\"> <p align=\"center\" class=\"Text\" style=\"margin-top:0in;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Concentration\r   of Adakveo<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"94\"> <p align=\"center\" class=\"Text\" style=\"margin-top:0in;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">[10 mg\/ml]<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"_hd6_Table_3_1_Example_of_d12477\"><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">1.       Obtain the number of\r vials required to deliver the prescribed dose and bring them to room\r temperature (for a maximum of 4 hours). One vial is needed for every\r 10 ml of Adakveo (see below table).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:28.35pt;border-collapse:collapse;border:none\" width=\"568\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Body weight (kg)<\/span><\/b><\/p> <\/td> <td style=\"width:92.15pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Dose (mg)<\/span><\/b><\/p> <\/td> <td style=\"width:114.75pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Volume (ml)<\/span><\/b><\/p> <\/td> <td style=\"width:114.75pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Vials (n)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">200<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">20<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">2<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">60<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">300<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">30<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">3<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">80<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">400<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">4<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">100<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">500<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">50<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">5<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">120<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">600<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">60<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">6<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">2.       Visually inspect the vials.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The solution in the vials should be clear to\r opalescent. Do not use if particles are present in the solution.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The solution should be colourless or may have a\r slight brownish\u2011yellow tint.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">3.       Withdraw a volume\r equal to the required volume of Adakveo from a 100 ml infusion bag containing\r either sodium chloride 9 mg\/ml (0.9%) solution for injection or dextrose\r 5% and discard.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">No incompatibilities between the diluted Adakveo\r solution and infusion bags composed of polyvinylchloride (PVC), polyethylene\r (PE) and polypropylene (PP) have been observed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">4.       Withdraw the necessary\r volume of Adakveo from the vials and inject slowly into the previously prepared\r infusion bag.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The <\/span><span lang=\"EN-GB\">solution<\/span><span lang=\"EN-GB\"> must not be mixed or co\u2011administered with other medicinal\r products through the same intravenous line.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep the volume of Adakveo added to the infusion\r bag in the range of 10 ml to 96 ml to obtain a final\r concentration in the infusion bag within 1 mg\/ml to 9.6 mg\/ml.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">5.       Mix the\r diluted solution by gently inverting the infusion bag. DO NOT SHAKE.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Administration<\/span><\/u><a name=\"_nth_Administration25012\"><\/a><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Adakveo diluted solution must be administered through\r a sterile, non\u2011pyrogenic 0.2 micron in\u2011line filter by\r intravenous infusion over a period of 30 minutes.<\/span><span style=\"font-size:11.0pt\"> <span lang=\"EN-GB\">No incompatibilities have been\r observed between Adakveo and infusion sets composed of PVC, PE\u2011lined PVC,\r polyurethane, and in\u2011line filter membranes composed of polyethersulfone\r (PES), polyamide (PA) or polysulphone (PSU).<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">After\r administration of Adakveo, flush the line with at least 25 ml sodium\r chloride 9 mg\/ml (0.9%) solution for injection or dextrose 5%.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Disposal<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Any unused medicinal\r product or waste material should be disposed of in accordance with local\r requirements.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Novartis Europharm Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Vista Building<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Elm Park, Merrion Road<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Dublin 4<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">8.       MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/20\/1476\/001<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE\r AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed\r information on this medicinal product is available on the website of the\r European Medicines <\/span><span lang=\"EN-GB\">Agency <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a><\/span><span lang=\"EN-GB\">.<br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX II<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">A.      MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE\r SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY\r AND USE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">C.      OTHER CONDITIONS AND REQUIREMENTS OF THE\r MARKETING AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:77.9pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">D.      <span style=\"text-transform:uppercase\">conditions\r or restrictions with regard to the safe and effective use of the medicinal\r PRODUCT<\/span><\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:70.8pt;margin-bottom:\r 0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">E.      SPECIFIC OBLIGATION TO COMPLETE\r POST-AUTHORISATION MEASURES FOR THE <\/span><\/b><b><span lang=\"EN-GB\">CONDITIONAL<\/span><span lang=\"EN-GB\"> MARKETING AUTHORISATION<\/span><\/b><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">A.      MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE\r SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Name and address of the manufacturer(s) of the biological active\r substance(s)<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-right:70.8pt;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"Standard\" style=\"line-height:normal\"><span lang=\"DE-CH\">Novartis Pharma\r AG<\/span><\/p> <p class=\"Standard\" style=\"line-height:normal\"><span lang=\"DE-CH\">Lichtstrasse 35<\/span><\/p> <p class=\"Standard\" style=\"line-height:normal\"><span lang=\"DE-CH\">4056 Basel<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DE-CH\">Switzerland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Name and address of the manufacturer(s) responsible for batch\r release<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"Standard\" style=\"line-height:normal\">Novartis Pharma GmbH<\/p> <p class=\"Standard\" style=\"line-height:normal\">Roonstrasse 25<\/p> <p class=\"Standard\" style=\"line-height:normal\">90429 Nuremberg<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Germany<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><a name=\"OLE_LINK2\"><b><span lang=\"EN-GB\">B.<\/span><\/b><\/a><b><span lang=\"EN-GB\">      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Medicinal\r product subject to restricted medical prescription (see Annex I: Summary of\r Product Characteristics, section 4.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">C.      OTHER CONDITIONS AND\r REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">Periodic safety update reports (PSURs)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The requirements for submission of PSURs for this medicinal product\r are set out in the list of Union reference dates (EURD list) <\/span><span lang=\"EN-GB\">provided for under Article 107c(7) of Directive 2001\/83<\/span><span lang=\"EN-GB\">\/EC<\/span><span lang=\"EN-GB\"> and <\/span><span lang=\"EN-GB\">any\r subsequent updates published on the European medicines web\u2011portal.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The marketing\r authorisation holder (MAH) shall submit the first PSUR for this product within\r 6 months following authorisation.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">D.      CONDITIONS OR\r RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">Risk management plan (RMP)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:28.35pt;line-height:normal\"><span lang=\"EN-GB\">The <\/span><span lang=\"EN-GB\">marketing<\/span><span lang=\"EN-GB\">\r authorisation holder (<\/span><span lang=\"EN-GB\">MAH) shall perform the required\r pharmacovigilance activities and interventions detailed in the agreed RMP\r presented in Module 1.8.2 of the marketing authorisation and any agreed\r subsequent updates of the RMP.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">An updated RMP should be submitted:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"EN-GB\">At the request of the European Medicines Agency;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.05pt;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"EN-GB\">Whenever the risk management system is modified,\r especially as the result of new information being received that may lead to a\r significant change to the benefit\/risk profile or as the result of an important\r (pharmacovigilance or risk minimisation) milestone being reached.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.05pt;line-height:normal\"><\/p> <p class=\"Standard\" style=\"margin-right:-.05pt;line-height:normal\"><\/p> <p class=\"Standard\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">E.      SPECIFIC OBLIGATION\r TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING\r AUTHORISATION<\/span><\/b><\/p> <p class=\"Standard\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"Standard\" style=\"margin-right:-.05pt;line-height:normal;page-break-after:\r avoid\"><span lang=\"EN-GB\">This being a conditional marketing authorisation and\r pursuant to Article 14a(4) of Regulation (EC) No 726\/2004, the MAH shall\r complete, within the stated timeframe, the following measures:<\/span><\/p> <p class=\"Standard\" style=\"margin-right:-.05pt;line-height:normal;page-break-after:\r avoid\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"NormaleTabelle\" style=\"border-collapse:collapse;border:none\" width=\"100%\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:82.18%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"82%\"> <p class=\"Standard\" style=\"margin-right:-.05pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Description<\/span><\/b><\/p> <\/td> <td style=\"width:17.82%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"17%\"> <p class=\"Standard\" style=\"margin-right:-.05pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Due date<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:82.18%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"82%\"> <p class=\"TabletextrowsAgency\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>In\r   order to confirm the efficacy and safety of crizanlizumab, the MAH should\r   submit the results of the primary analysis of a phase III CSEG101A2301 study\r   of crizanlizumab with or without hydroxyurea\/hydroxycarbamide in adolescent\r   and adult sickle cell disease patients with vaso-occlusive crises<\/span><\/p> <\/td> <td style=\"width:17.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"17%\"> <p class=\"TabletextrowsAgency\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Clinical\r   study report primary analysis:<\/span><\/p> <p class=\"TabletextrowsAgency\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>December\r   2025<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:82.18%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"82%\"> <p class=\"TabletextrowsAgency\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>In\r   order to confirm the efficacy and safety of crizanlizumab, the MAH should\r   submit the final results of the phase II CSEG101A2202 study of\r   crizanlizumab with or without hydroxyurea\/hydroxycarbamide in sickle cell\r   disease patients with vaso\u2011occlusive crisis.<\/span><\/p> <\/td> <td style=\"width:17.82%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"17%\"> <p class=\"TabletextrowsAgency\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Clinical\r   study report:<\/span><\/p> <p class=\"TabletextrowsAgency\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>December\r   2025<\/span><\/p> <\/td> <\/tr> <\/table> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX III<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET<\/span><\/b><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">A. LABELLING<\/span><\/b><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal;background:white\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTON<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo\r 10 mg\/ml concentrate for solution for infusion<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">crizanlizumab<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each 10 ml\r vial contains 100 mg crizanlizumab.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Also contains:\r sucrose, sodium citrate (E331), citric acid (E330), polysorbate 80 (E433),\r water for injections.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Concentrate for solution for infusion<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">1 vial<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">100 mg\/10 ml<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For intravenous\r use after dilution.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Single use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\r sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL\r STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Store in a refrigerator.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep the vial in\r the outer carton in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS\r FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH\r MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Novartis Europharm Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Vista Building<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Elm Park, Merrion Road<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Dublin 4<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/20\/1476\/001<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">Justification for not including Braille\r accepted.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black;background:#D9D9D9\">2D barcode carrying the unique\r identifier included.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE IDENTIFIER - HUMAN\r READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">NN<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">VIAL LABEL<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Adakveo\r 10 mg\/ml sterile concentrate<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">crizanlizumab<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">IV<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       METHOD OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">100 mg\/10 ml<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       OTHER<\/span><\/b><\/p> <\/div> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">B. PACKAGE LEAFLET<\/span><\/b><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Package leaflet: Information for the patient<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r background:white\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Adakveo 10 mg\/ml concentrate for solution for infusion<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">crizanlizumab<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><img alt=\"BT_1000x858px\" border=\"0\" height=\"18\" id=\"Picture 1\" src=\"data:image\/png;base64,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\" width=\"21\"\/><span lang=\"EN-GB\">This medicine is subject to additional\r monitoring. This will allow quick identification of new safety information. You\r can help by reporting any side effects you may get. See the end of\r section 4 for how to report side effects.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Read all of\r this leaflet carefully before you are given this medicine because it contains\r important information for you.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\r again.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor\r or nurse.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor\r or nurse.<\/span><span lang=\"EN-GB\"> This includes any possible side effects not\r listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What is in this leaflet<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">1.       What Adakveo\r is and what it is used for<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">2.       What\r you need to know before you are given Adakveo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">3.       How Adakveo\r is given<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">4.       Possible\r side effects<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">5.       How to\r store Adakveo<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">6.       Contents\r of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.       What Adakveo is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Adakveo is<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo <\/span>contains\r the active substance crizanlizumab, which belongs to a group of medicines\r called monoclonal antibodies (mAbs).<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b>What Adakveo<\/b><b>is used for<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Adakveo is used to prevent recurrent\r painful crises occurring in patients aged 16 years and over with sickle\r cell disease. Adakveo can be given in combination with\r hydroxyurea\/hydroxycarbamide, although it may also be used alone.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Sickle cell disease is an\r inherited blood disorder. It causes affected red blood cells to become sickle\u2011shaped\r and have difficulty passing through small blood vessels. Additionally in sickle\r cell disease the blood vessels are damaged and sticky due to ongoing chronic\r inflammation. This leads to blood cells sticking to the blood vessels, causing\r acute episodes of pain and organ damage.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b>How Adakveo\r works<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Patients with sickle cell disease\r have higher levels of a protein called P\u2011selectin. Adakveo binds P\u2011selectin.\r This should stop blood cells sticking to the vessel walls and help prevent\r painful crises.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">If you have any questions about\r how Adakveo works or why this medicine has been prescribed for you, ask your <a name=\"_Toc312231909\"><\/a><span lang=\"EN-GB\">doctor or nurse<\/span>.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.       What you need to know before you are given Adakveo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">You must not be given Adakveo:<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-        if you are allergic to crizanlizumab or any\r of the other ingredients of this medicine (listed in section 6).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Warnings and precautions<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Infusion reactions<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Medicines of this type (called monoclonal antibodies) are\r administered into a vein (intravenously) as an infusion. They can cause\r unwanted reactions (side effects) when they are infused into your body. Such\r reactions may happen within 24 hours of receiving an infusion.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Tell your doctor or nurse immediately<\/span><\/b><span lang=\"EN-GB\"> if\r you experience any of the following, which may be signs of an infusion reaction:<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Fever, chills, shivering, nausea, vomiting,\r tiredness, dizziness, pain where the infusion needle is inserted, blisters,\r itching, shortness of breath or wheezing. See also section 4, \u201cPossible\r side effects\u201d.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Your doctor or\r nurse may monitor you for signs and symptoms of such infusion reactions.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Blood tests during Adakveo treatment<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you need to\r have any blood tests, tell the doctor or nurse that you are on treatment with Adakveo.\r This is important because this treatment may interfere with a laboratory test\r used to measure the number of platelets in your blood.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Children and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo <\/span>should\r not be used in children or adolescents below 16 years of age.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><b>Other medicines and Adakveo<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\">Tell your doctor\r or nurse if you are taking, have recently taken or might take any other\r medicines.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Pregnancy and breast\u2011feeding<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\">Adakveo has\r not been tested in pregnant women therefore there is limited information about its\r safety in pregnant women.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\">If you are\r pregnant, or are a woman who could become pregnant and is not using\r contraception, it is not recommended to use Adakveo.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\">It is not\r known whether <span lang=\"EN-GB\">Adakveo <\/span>or its individual ingredients\r pass into breast milk.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\">If you are\r pregnant or breast\u2011feeding, think you may be pregnant or are planning to\r have a baby, ask your doctor for advice before receiving this medicine. Your doctor\r will discuss with you the potential risk(s) of <span lang=\"EN-GB\">Adakveo <\/span>during\r pregnancy or breast\u2011feeding.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Adakveo could have a minor effect on your ability to drive and use\r machines. If you experience tiredness, drowsiness or dizziness, do not drive or\r use machines until you feel better.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Adakveo contains sodium<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">This medicine contains less than\r 1 mmol sodium (23 mg) per vial, that is to say essentially \u201csodium\u2011free\u201d.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.       How Adakveo is given<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Adakveo will be given to you by a doctor or nurse.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have any\r questions about how Adakveo is given, ask the doctor or nurse who is giving you\r the infusion.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Your doctor will\r tell you when you will have your infusions and follow\u2011up appointments.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">How much Adakveo you will be given<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The recommended\r dose is 5 mg per kilogram of body weight. You will be given the first infusion\r at Week 0 and the second infusion two weeks later (Week 2). After\r that you will be given an infusion every 4 weeks.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">How the infusion is given<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo is\r administered into a vein (intravenously) as an infusion lasting\r 30 minutes.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo can be given\r alone or with hydroxyurea\/hydroxycarbamide.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">How long Adakveo treatment lasts<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">You should\r discuss with your doctor how long you will need to receive treatment. Your doctor\r will regularly monitor your condition to check that the treatment is having the\r desired effect.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you forget a Adakveo infusion<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is very\r important that you receive all your infusions. If you miss an appointment for\r an infusion, contact your doctor as soon as possible to reschedule.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">If you stop Adakveo treatment<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not stop Adakveo\r treatment unless your doctor tells you that you can.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">If you have any\r further questions on the use of this medicine, ask your doctor or nurse.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.       Possible side\r effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Like all\r medicines, this medicine can cause side effects, although not everybody gets\r them.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:1.5in;text-indent:-1.5in;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Some side effects could be\r serious<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Tell the doctor or nurse giving you the infusion immediately<\/span><\/b><span lang=\"EN-GB\"> if you develop any of the following:<\/span><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Fever, chills, shivering, nausea, vomiting,\r tiredness, dizziness, pain where the infusion needle is inserted, blisters,\r itching, shortness of breath or wheezing.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">These symptoms\r can be signs of infusion reaction, which is a common side effect (this means it\r may affect up to 1 in every 10 people).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:1.5in;text-indent:-1.5in;line-height:\r normal;page-break-after:avoid\"><b>Other possible side effects<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Other\r possible side effects include those listed below. If these side effects become\r severe, tell your doctor or nurse.<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b>Very\r common (may affect more than 1 in 10 people)<\/b><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-pain in the joints (arthralgia)<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-nausea<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-back pain<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-fever<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-pain in the lower or upper abdomen, feeling of tenderness in the abdomen\r and abdominal discomfort<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b>Common\r (may affect up to 1 in every 10 people)<\/b><\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-diarrhoea<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-itching (including vulvovaginal itching)<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-vomiting<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-muscle pain (myalgia)<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-pain in the muscles or bones of the chest (musculoskeletal chest pain)<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-sore throat (oropharyngeal pain)<\/p> <p class=\"MsoListParagraph\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\">-redness or swelling and pain at the site of the infusion<\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"EN-GB\">Reporting\r of side effects<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor or nurse. This includes any possible side effects not listed in this\r leaflet.<\/span><span lang=\"EN-GB\">You can also report side effects directly via <span style=\"color:black;background:#D9D9D9\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><span lang=\"EN-GB\"> By reporting side effects you can help provide more information on\r the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.       How to store Adakveo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep this\r medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"BodytextAgency\" style=\"margin-bottom:0in;line-height:normal\"><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>Do not\r use this medicine after the expiry date which is stated on the outer carton and\r the label after \u201cEXP\u201d. The expiry date refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep the vial in\r the outer carton in order to protect from light. Store in a refrigerator\r (2\u00b0C \u2013 8\u00b0C). Do not freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Infusion\r solutions should be used immediately after dilution.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Adakveo contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The active substance is crizanlizumab. Each\r 10 ml vial contains 100 mg of crizanlizumab.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The other ingredients are sucrose, sodium\r citrate <\/span>(E331)<span lang=\"EN-GB\">, citric acid (E330), polysorbate 80\r (E433) and water for injections.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">What Adakveo looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo\r concentrate for solution for infusion is a colourless to slightly brownish\u2011yellow\r liquid.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo is\r available in packs containing 1 vial.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Novartis Europharm Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Vista Building<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Elm Park, Merrion Road<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Dublin 4<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Ireland<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Novartis\r Pharma GmbH<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">Roonstrasse\r 25<\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\">90429\r Nuremberg<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Germany<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local representative\r of the Marketing Authorisation Holder:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"0\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"FR-BE\">Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR-BE\">Novartis\r   Pharma N.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR-BE\">T\u00e9l\/Tel: +32 2\r   246 16 11<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"LT\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES\">SIA Novartis\r   Baltics Lietuvos filialas<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"LT\">Tel: +370 5 269\r   16 50<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"BG\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\">Novartis Pharma\r   Services Inc.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"BG\">\u0422\u0435\u043b:<\/span>\r   +359 2 489 98 28<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"DE-CH\">Luxembourg\/Luxemburg<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DE-CH\">Novartis\r   Pharma N.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR-BE\">T\u00e9l\/Tel: +32 2\r   246 16 11<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"SV\">\u010cesk\u00e1\r   republika<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">Novartis s.r.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DE-CH\">Tel: +420 225\r   775 111<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"HU\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"HU\">Novartis Hung\u00e1ria\r   Kft. Pharma<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"HU\">Tel.: +36 1 457\r   65 00<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b>Danmark<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Novartis Healthcare A\/S<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Tlf: +45 39 16 84 00<\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"MT\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"MT\">Novartis Pharma\r   Services Inc.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"MT\">Tel: +<\/span>356 <span lang=\"FR-CH\">2122 2872<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"DE\">Deutschland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DE\">Novartis Pharma\r   GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DE\">Tel: +49 911 273\r   0<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"NL\">Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"NL\">Novartis Pharma\r   B.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"NL\">Tel: +31 88 04 52\r   555<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"ET\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">SIA Novartis\r   Baltics Eesti filiaal<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ET\">Tel: +372 <\/span><span lang=\"EN-GB\">66 30 810<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"NO-BOK\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"NO-BOK\">Novartis\r   Norge AS<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"NO-BOK\">Tlf: +47 23\r   05 20 00<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ET\">Novartis (Hellas)\r   A.E.B.E.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EL\">\u03a4\u03b7\u03bb<\/span><span lang=\"ET\">: +30 210 281 17 12<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"DE-AT\">\u00d6sterreich<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DE-AT\">Novartis\r   Pharma GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"DE-AT\">Tel: +43 1 86\r   6570<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"ES\">Espa\u00f1a<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES\">Novartis\r   Farmac\u00e9utica, S.A.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES\">Tel: +34 93 306\r   42 00<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"PL\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"PL\">Novartis Poland\r   Sp. z o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"PL\">Tel.: +48 22 375\r   4888<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"FR\">France<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\">Novartis Pharma\r   S.A.S.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\">T\u00e9l: +33 1 55 47\r   66 00<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"PT\">Portugal<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"PT\">Novartis Farma \u2011\r   Produtos Farmac\u00eauticos, S.A.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"PT\">Tel: +351 21 000\r   8600<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"SV\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">Novartis Hrvatska\r   d.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel. +385 1\r   6274 220<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"FR-CH\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"FR-CH\">Novartis Pharma Services Romania SRL<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\">Tel: +40 21 31299 01<\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Novartis\r   Ireland Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +353 1\r   260 12 55<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"SL\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SL\">Novartis Pharma\r   Services Inc.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SL\">Tel: +386 1 300\r   75 50<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"IS\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IS\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">S\u00edmi<\/span><span lang=\"IS\">: +354 535 7000<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"SK\">Slovensk\u00e1\r   republika<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SK\">Novartis Slovakia\r   s.r.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SK\">Tel: +421 2 5542\r   5439<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"PT\">Italia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"PT\">Novartis Farma\r   S.p.A.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Tel: +39 02 96 54\r   1<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"SV\">Suomi\/Finland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">Novartis Finland\r   Oy<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">Puh\/Tel: +358 <\/span><span lang=\"SV\">(0)10 6133 200<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR-CH\">Novartis\r   Pharma Services Inc.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EL\">\u03a4\u03b7\u03bb:\r   +357 22 690 690<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"SV\">Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">Novartis Sverige\r   AB<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">Tel: +46 8 732 32\r   00<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"LV\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">SIA Novartis\r   Baltics<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"LV\">Tel: +371 67 887\r   070<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"IT\">United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"IT\">Novartis\r   Pharmaceuticals UK Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Tel: +44 1276\r   698370<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">This leaflet\r was last revised in<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicine\r has been given \u201cconditional approval\u201d. This means that there is more evidence\r to come about this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European\r Medicines Agency will review new information on this medicine at least every\r year and this leaflet will be updated as necessary.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed\r information on this medicine is available on the European Medicines Agency web\r site: <\/span><span lang=\"EN-GB\"><span class=\"MsoHyperlink\">http:\/\/www.ema.europa.eu<\/span><\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">The following\r information is intended for healthcare professionals only:<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo vials\r are for single use only.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Preparing the infusion<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The diluted\r solution for infusion  should be prepared by a healthcare professional using\r aseptic techniques.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The total dose\r and required volume of Adakveo depend on the patient\u2019s body weight; 5 mg\r of crizanlizumab is administered per kg body weight.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The volume to be used for the preparation of the infusion is\r calculated according to the following equation:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:12.5pt;border-collapse:collapse\" width=\"567\"> <tr> <td rowspan=\"2\" style=\"width:85.05pt;padding:0in 5.4pt 0in 5.4pt\" width=\"113\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Volume (ml) =<\/span><\/p> <\/td> <td style=\"width:269.35pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"359\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r   text-indent:-28.35pt;line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Patient\u2019s body weight (kg) x prescribed dose<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"94\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r   text-indent:-28.35pt;line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">[5 mg\/kg]<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:269.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"359\"> <p align=\"center\" class=\"Text\" style=\"margin-top:0in;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Concentration\r   of Adakveo<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"94\"> <p align=\"center\" class=\"Text\" style=\"margin-top:0in;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">[10 mg\/ml]<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">1.       Obtain the number of\r vials required to deliver the prescribed dose and bring them to room\r temperature (for a maximum of 4 hours). One vial is needed for every\r 10 ml of Adakveo (see below table).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:28.35pt;border-collapse:collapse;border:none\" width=\"568\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Body weight (kg)<\/span><\/b><\/p> <\/td> <td style=\"width:92.15pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Dose (mg)<\/span><\/b><\/p> <\/td> <td style=\"width:114.75pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Volume (ml)<\/span><\/b><\/p> <\/td> <td style=\"width:114.75pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Vials (n)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">200<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">20<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">2<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">60<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">300<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">30<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">3<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">80<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">400<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">4<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">100<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">500<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">50<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">5<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">120<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">600<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">60<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">6<\/span><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">2.       Visually inspect the vials.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The solution in the vials should be clear to\r opalescent. Do not use if particles are present in the solution.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The solution should be colourless or may have a\r slight brownish\u2011yellow tint.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">3.       Withdraw a volume\r equal to the required volume of Adakveo from a 100 ml infusion bag\r containing either sodium chloride <\/span><span lang=\"EN-GB\">9 mg\/ml (<\/span><span lang=\"EN-GB\">0.9%) solution for injection or dextrose 5% and discard.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">No incompatibilities between the diluted Adakveo\r solution and infusion bags composed of polyvinylchloride (PVC), polyethylene\r (PE) and polypropylene (PP) have been observed.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">4.       Withdraw the necessary\r volume of Adakveo from the vials and inject slowly into the previously prepared\r infusion bag.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The <\/span><span lang=\"EN-GB\">solution<\/span><span lang=\"EN-GB\"> must not be mixed or co\u2011administered with other medicinal\r products through the same intravenous line.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep the volume of Adakveo added to the infusion\r bag in the range of 10 ml to 96 ml to obtain a final\r concentration in the infusion bag within 1 mg\/ml to 9.6 mg\/ml.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">5.       Mix the\r diluted solution by gently inverting the infusion bag. DO NOT SHAKE.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Storage of the diluted solution<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Chemical and\r physical in\u2011use stability, from the start of preparation of the diluted\r solution for infusion until end of infusion, has been demonstrated for up to\r 8 hours at room temperature (up to 25\u00b0C) and at 2\u00b0C to 8\u00b0C for up to 24 hours\r overall.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">From a\r microbiological point of view, the diluted solution for infusion should be used\r immediately. If not used immediately, in\u2011use storage times and conditions\r prior to use are the responsibility of the user and would normally not be\r longer than 24 hours at 2\u00b0C to 8\u00b0C, including 4.5 hours at room\r temperature (up to 25\u00b0C) from the start of preparation to completion of the\r infusion, unless dilution has taken place in controlled and validated aseptic\r conditions.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Administration<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo diluted <\/span><span lang=\"EN-GB\">solution must be administered through a sterile, non\u2011pyrogenic\r 0.2 micron in\u2011line filter<\/span><span lang=\"EN-GB\"> by intravenous\r infusion over a period of 30 minutes.<\/span><span lang=\"EN-GB\"> No\r incompatibilities have been observed between Adakveo and infusion sets composed\r of PVC, PE\u2011lined PVC, polyurethane, and in\u2011line filter membranes\r composed of polyethersulfone (PES), polyamide (PA) or polysulphone (PSU).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">After\r administration of Adakveo, flush the line with at least 25 ml sodium\r chloride 9 mg\/ml (0.9%) solution for injection or dextrose 5%.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Disposal<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Any unused\r product or waste material should be disposed of in accordance with local\r requirements.<\/span><\/p> <\/div>","HasBorder":false,"ID":"c4aa3582-b12f-4af8-9392-0d721a01d452","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"a1e9cfdc-8053-4ab1-8433-304a218e84b4","Styles":"None","Text":"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"0b5f5623-d303-4390-81b1-37efa79e60e4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"659b5582-917f-4210-b009-28928060e991","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"bff780f6-48a2-4bd0-b4cd-9e1137c0957f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"74ddccf2-3ef4-4981-862e-4706bf905d7a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"93f9a74f-042d-4d3e-99ff-2cce4d5ae85d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"32f38f8b-ad90-4525-91f0-88581a267069","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"df45131e-3c15-40ca-b779-fccea1e26d5d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"256fe346-4377-43b0-a8b6-ad4887521887","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b7a11c15-b33e-4608-bc4e-f93e3f2f1eb0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"69668bcc-5045-408d-9aa3-0eac11476552","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3648e65c-dd5c-4854-b830-b257269687ae","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"9d17e3f3-4dda-40b1-aec2-55e23726f77b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"d7a1c421-2125-4444-87da-fb9181920550","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b5ff8a76-22b8-407d-a80f-b7457f1423f4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3e033226-cb52-4d0a-9ed8-cdeca42dad7b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b1235c08-3024-46c0-92d6-72c4d94a9e4b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"979cce21-a3ed-4ed8-acdf-5f69cc1f70e8","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"2975b3dc-476c-4663-bdb1-7ee7c63167a1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"a1337c3b-e952-4e7f-a3ac-8d05be4fd83e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"f9b30342-b45d-434e-b5ac-978fa977cfd9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"5f2a3671-ea07-4910-938b-408f5e03d0a7","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"d690ec99-786c-466e-bdee-5f8a637c8650","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b68c4b87-96a6-43d8-8faa-b899454c092c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX I<\/span><\/b><\/p>","HasBorder":false,"ID":"cc094e7c-3cb8-4d2e-82a6-4c498860ce83","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"text-align:center;line-height:normal","Text":"ANNEX I","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p>","HasBorder":false,"ID":"1348708c-f9cb-4e44-8403-258b7dcbf095","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"text-align:center;line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/b><\/p>","HasBorder":false,"ID":"33b9bef3-df78-491b-883a-178b2d6a3ebc","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"text-align:center;line-height:normal","Text":"SUMMARY OF PRODUCT CHARACTERISTICS","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"None","Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:green'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","HasBorder":false,"ID":"b4e25439-33be-4f8f-be87-4cbac5370563","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ncolor:green","Text":" ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"None","Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","HasBorder":false,"ID":"42874fe8-ea6e-4e7d-915a-4ef75a4c7c41","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"b4e25439-33be-4f8f-be87-4cbac5370563","Styles":"page-break-before:always","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><img height=\"18\" src=\"data:image\/png;base64,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\" width=\"21\"\/><span lang=\"EN-GB\">This medicinal\r product is subject to additional monitoring. This will allow quick\r identification of new safety information. Healthcare professionals are asked to\r report any suspected adverse reactions. See section 4.8 for how to report\r adverse reactions.<\/span><\/p>","HasBorder":false,"ID":"83cd08f6-fd90-4ea2-bcc1-0b70e1b0b316","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"This medicinal\r product is subject to additional monitoring. This will allow quick\r identification of new safety information. Healthcare professionals are asked to\r report any suspected adverse reactions. See section 4.8 for how to report\r adverse reactions.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"033bdaef-155a-44a4-84c9-8505f6def45e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"a4facfe3-abe8-47f2-b431-0025979c177a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">1.       NAME OF <\/span><\/b><b><span lang=\"EN-GB\">THE MEDICINAL PRODUCT<\/span><\/b><\/p>","HasBorder":false,"ID":"df61c055-e98f-48a9-aa40-684b6b673cc3","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"1.       NAME OF THE MEDICINAL PRODUCT","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"83a1b080-3b70-469e-93a6-b4744079b093","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo\r 10 mg\/ml concentrate for solution for infusion<\/span><\/p>","HasBorder":false,"ID":"4d8d70a2-017d-405c-bc86-57cba3606d52","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Adakveo\r 10 mg\/ml concentrate for solution for infusion","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"098325c8-ffb1-44e5-99c5-ea3375cdef8e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"29d17432-2d5a-4bb9-8440-7e5372ef162c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION<\/span><\/b><\/p>","HasBorder":false,"ID":"0ea96eda-893d-4d0d-a50c-856efb138199","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"2.       QUALITATIVE AND\r QUANTITATIVE COMPOSITION","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"57d6687e-c465-4cc9-8791-6a872e0fcf07","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each ml of\r concentrate for solution for infusion contains 10 mg crizanlizumab.<\/span><\/p>","HasBorder":false,"ID":"17f68344-584a-4440-8cd4-881fb1a9128c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Each ml of\r concentrate for solution for infusion contains 10 mg crizanlizumab.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"05e06a62-7f96-4b85-8684-15cb84bd2f95","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">One vial of\r 10 ml contains 100 mg crizanlizumab.<\/span><\/p>","HasBorder":false,"ID":"989d383e-daeb-4a77-a179-6fc606b6f4f1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"One vial of\r 10 ml contains 100 mg crizanlizumab.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"40723e29-050f-4685-a83c-1e7c2859e0bf","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Crizanlizumab is\r a monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by\r recombinant DNA technology.<\/span><\/p>","HasBorder":false,"ID":"d5842694-aac6-4f6a-98a0-30d88d2ca0e9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Crizanlizumab is\r a monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells by\r recombinant DNA technology.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3d0698b6-886f-4901-a3f7-a192df8e2273","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For the full\r list of excipients, see section 6.1.<\/span><\/p>","HasBorder":false,"ID":"b8c3699e-d58a-4260-a8d8-9ec6f95f16b2","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"For the full\r list of excipients, see section 6.1.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"d269dfe7-d56b-421f-b009-0f0002dab3ad","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"2409f643-16ea-45ac-a25d-6582f1810aeb","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">3.       PHARMACEUTICAL <\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif'>FORM<\/span><\/b><\/p>","HasBorder":false,"ID":"b5722358-aa72-4922-a03e-5f3fffe6ad70","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"3.       PHARMACEUTICAL FORM","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"65f32523-0ba9-4602-aaa6-d4fe8144e7a4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"_Toc259706902\"><\/a><a name=\"_Toc259707071\"><\/a><a name=\"_Toc259707134\"><\/a><a name=\"_Toc259713075\"><span lang=\"EN-GB\">Concentrate for solution for infusion<\/span><\/a><span lang=\"EN-GB\">\r (sterile concentrate)<\/span><\/p>","HasBorder":false,"ID":"6a6285e4-b4b6-4ed9-bc3d-12f84ce1962a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Concentrate for solution for infusion\r (sterile concentrate)","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"60926123-3805-4b0e-844a-623fa62477df","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Colourless to\r slightly brownish\u2011yellow liquid at pH 6 and with an osmolality of\r 300 mOsm\/kg.<\/span><\/p>","HasBorder":false,"ID":"8b34b33b-1e05-4ee6-b99b-f8a8653bbb2c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Colourless to\r slightly brownish\u2011yellow liquid at pH 6 and with an osmolality of\r 300 mOsm\/kg.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"7814391a-0e03-4dd1-828f-ed4077d556b5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"1336dbfd-bca2-42c5-9f6f-b8eba9012f09","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><\/b><b><span lang=\"EN-GB\">CLINICAL<\/span><\/b><b><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif'>\r PARTICULARS<\/span><\/b><\/p>","HasBorder":false,"ID":"19ce10d8-2c94-4183-a7e1-c785f0431ccc","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.       CLINICAL\r PARTICULARS","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"3c57b58d-3585-4cdc-9838-c6e1f2a6ef76","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.1     Therapeutic\r indications<\/span><\/b><\/p>","HasBorder":false,"ID":"9a947544-827e-46c2-a600-0a1c1f24a460","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.1     Therapeutic\r indications","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"b57ae6f4-5492-4c13-917e-bfc6c00f73b4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\"><span lang=\"EN-GB\">Adakveo<\/span><span lang=\"EN-GB\"> is indicated\r for the prevention of recurrent vaso\u2011occlusive crises (VOCs) in sickle\r cell disease patients aged 16 years and older. It can be given as an add\u2011on\r therapy to hydroxyurea\/hydroxycarbamide (HU\/HC) or as monotherapy in patients\r for whom HU\/HC is inappropriate or inadequate.<\/span><\/p>","HasBorder":false,"ID":"5d6323e0-5475-4cfa-9d30-f6e0e28db814","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"None","Text":"Adakveo is indicated\r for the prevention of recurrent vaso\u2011occlusive crises (VOCs) in sickle\r cell disease patients aged 16 years and older. It can be given as an add\u2011on\r therapy to hydroxyurea\/hydroxycarbamide (HU\/HC) or as monotherapy in patients\r for whom HU\/HC is inappropriate or inadequate.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"29eb1540-1146-44be-a2fa-4e7f0af0e641","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.2     Posology and method of administration<\/span><\/b><\/p>","HasBorder":false,"ID":"12c22128-bedc-4959-949c-49d2f368790d","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"4.2     Posology and method of administration","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"fbd7bd50-8b3f-4f0e-88f7-4082ef12e512","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Treatment should\r be initiated by physicians experienced in the management of <\/span><span lang=\"EN-GB\">sickle cell disease.<\/span><\/p>","HasBorder":false,"ID":"3c188396-137f-4a69-a4d5-037f2d20df50","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Treatment should\r be initiated by physicians experienced in the management of sickle cell disease.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"01e3cb48-b165-418b-a779-7f0649ea8873","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><a name=\"_nth_Adults_and_patients_ag4131\"><\/a><\/p>","HasBorder":false,"ID":"5cb35f1d-80c0-4ab0-a017-a24191a40add","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Posology","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"d066f137-0efb-430d-9491-e2792e6e08df","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The recommended\r dose of crizanlizumab is 5 mg\/kg administered over a period of\r 30 minutes by intravenous infusion at week 0, week 2, and every\r 4 weeks thereafter.<\/span><\/p>","HasBorder":false,"ID":"d37b676a-2dd3-415e-9868-b14dceae5815","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The recommended\r dose of crizanlizumab is 5 mg\/kg administered over a period of\r 30 minutes by intravenous infusion at week 0, week 2, and every\r 4 weeks thereafter.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"01dbbeba-807a-49cf-ba8c-08b9a228d934","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Crizanlizumab <\/span><span lang=\"EN-GB\">c<\/span><span lang=\"EN-GB\">an be given alone or with HU\/HC.<\/span><\/p>","HasBorder":false,"ID":"099fc2fb-4ff6-4f31-a891-223ef92fdcd0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Crizanlizumab can be given alone or with HU\/HC.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"08c90b28-832a-4267-94ac-05e58f59a01b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">If a dose is missed, the treatment should be administered as soon as\r possible.<\/span><\/p>","HasBorder":false,"ID":"83990ba2-c533-46bf-a945-efc856a34707","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"If a dose is missed, the treatment should be administered as soon as\r possible.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">If crizanlizumab is administered\r within 2 weeks after the missed dose, dosing should be continued according\r to the patient\u2019s original schedule.<\/span><\/p>","HasBorder":false,"ID":"f759658f-7729-41f2-9709-30336162458d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Text":"-If crizanlizumab is administered\r within 2 weeks after the missed dose, dosing should be continued according\r to the patient\u2019s original schedule.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;margin-right:0in;margin-bottom:\r 0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt\"><span style=\"font-size:11.0pt\">-<\/span><span style=\"font-size:11.0pt\">If crizanlizumab is administered\r more than 2 weeks after the missed dose, dosing should be continued every\r 4 weeks thereafter.<\/span><\/p>","HasBorder":false,"ID":"13ed5fe8-82b9-499f-a8f2-e1d5d87b6bf6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;margin-right:0in;margin-bottom:\r\n0in;margin-left:28.35pt;margin-bottom:.0001pt;text-align:left;text-indent:-28.35pt","Text":"-If crizanlizumab is administered\r more than 2 weeks after the missed dose, dosing should be continued every\r 4 weeks thereafter.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"57edffde-a36c-42af-bc2a-1b81b1d9da44","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/i><\/p>","HasBorder":false,"ID":"aab25962-7a97-4aa7-926b-2d8830eb0631","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Special populations","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Elderly<\/span><\/i><\/p>","HasBorder":false,"ID":"303ce01e-19f4-4558-b585-e32ec270b252","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Elderly","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Crizanlizumab\r has not been studied in elderly patients. No dose adjustment is required as the\r pharmacokinetics of crizanlizumab in adults are not affected by age.<\/span><\/p>","HasBorder":false,"ID":"87b40872-50b1-44a5-9869-caf6950352c7","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Crizanlizumab\r has not been studied in elderly patients. No dose adjustment is required as the\r pharmacokinetics of crizanlizumab in adults are not affected by age.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"9015ddb5-c34f-4ebb-ae1e-e7b255bce76a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","HasBorder":false,"ID":"0bacfedd-f4b9-4341-ad9f-a0eccfbc209f","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Renal impairment","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Based on the\r population pharmacokinetic (PK) results, no dose adjustment is required in\r patients with mild or moderate renal impairment (see section 5.2). Data\r from patients with severe renal impairment are too limited to draw conclusions\r on this population.<\/span><\/p>","HasBorder":false,"ID":"2a357219-2a21-4f8e-8ffd-935b4a7d472a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Based on the\r population pharmacokinetic (PK) results, no dose adjustment is required in\r patients with mild or moderate renal impairment (see section 5.2). Data\r from patients with severe renal impairment are too limited to draw conclusions\r on this population.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3b271fa0-c90a-48ef-af41-5d03cf71fe55","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","HasBorder":false,"ID":"063bb057-d03b-4543-a925-25055d3f20db","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Hepatic impairment","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety and\r efficacy of crizanlizumab in patients with hepatic impairment have not been\r established. Crizanlizumab is a monoclonal antibody and is cleared via\r catabolism (i.e. breakdown into peptides and amino acids), and a change in dose\r is not expected to be required for patients with hepatic impairment (see\r section<\/span><span lang=\"EN-GB\">5.2).<\/span><\/p>","HasBorder":false,"ID":"8ce9db25-eaa6-41cc-9473-55570a987d82","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The safety and\r efficacy of crizanlizumab in patients with hepatic impairment have not been\r established. Crizanlizumab is a monoclonal antibody and is cleared via\r catabolism (i.e. breakdown into peptides and amino acids), and a change in dose\r is not expected to be required for patients with hepatic impairment (see\r section5.2).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"797e30ef-e247-4086-8bd9-d1b6ea0aab1a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p>","HasBorder":false,"ID":"f605d123-3440-41e0-9460-095029486c63","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Paediatric population","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety and\r efficacy of <\/span><span lang=\"EN-GB\">crizanlizumab<\/span><span lang=\"EN-GB\"> in\r paediatric patients from 6 months to 16 years have not been\r established. No data are available.<\/span><\/p>","HasBorder":false,"ID":"98e79099-c3af-4da9-be8e-2acb1459f337","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The safety and\r efficacy of crizanlizumab in\r paediatric patients from 6 months to 16 years have not been\r established. No data are available.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"2a984bcd-60c0-4227-bada-be6975c19fe8","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\" style=\"line-height:normal\"><span lang=\"EN-GB\">There is no\r relevant use of crizanlizumab in infants aged less than 6 months for the\r indication of prevention of recurrent vaso\u2011occlusive crises.<\/span><\/p>","HasBorder":false,"ID":"0f43c7ac-8ac8-4814-9404-3f4f2894077c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"There is no\r relevant use of crizanlizumab in infants aged less than 6 months for the\r indication of prevention of recurrent vaso\u2011occlusive crises.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3f89d918-a1bb-4217-bb97-58078e96d5ee","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Method of administration<\/span><\/u><\/p>","HasBorder":false,"ID":"630148cf-1e75-44dc-ab5d-469c61ca7778","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Method of administration","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"494dedb2-bade-4ac0-9bfc-201a54c7c7ed","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo <\/span><span lang=\"EN-GB\">should be diluted with sodium chloride 9 mg\/ml (0.9%) solution\r for injection or dextrose 5% before administration.<\/span><\/p>","HasBorder":false,"ID":"6f1368d4-2815-4854-957d-4d9fe25569be","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Adakveo should be diluted with sodium chloride 9 mg\/ml (0.9%) solution\r for injection or dextrose 5% before administration.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"ed11e073-a98f-4493-9538-2f821d2cac25","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The diluted solution<\/span><span lang=\"EN-GB\"> must be administered through a sterile, non\u2011pyrogenic 0.2 micron\r in\u2011line filter by intravenous infusion over a period of 30 minutes. It\r must not be administered by intravenous push or bolus.<\/span><\/p>","HasBorder":false,"ID":"a8655149-8ca7-4eed-832f-bb525171fe5f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The diluted solution must be administered through a sterile, non\u2011pyrogenic 0.2 micron\r in\u2011line filter by intravenous infusion over a period of 30 minutes. It\r must not be administered by intravenous push or bolus.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"f6c1947e-7b72-451b-9178-1a4d0973ad7e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For instructions\r on dilution of the medicinal product before administration, see section 6.6.<\/span><\/p>","HasBorder":false,"ID":"95e9a6d9-73fe-4f81-adad-1ff61edae6c9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"For instructions\r on dilution of the medicinal product before administration, see section 6.6.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"4e64188e-5133-44e8-b3f1-e90cd75cb0d0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/b><\/p>","HasBorder":false,"ID":"2dbd13c2-4089-4e1a-ba6e-0b1836a7a579","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.3     Contraindications","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"b087f567-a70d-45ab-add8-315eba0de7dc","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","HasBorder":false,"ID":"8e8daa2f-222c-4171-bc80-0786a06b7ec5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Hypersensitivity\r to Chinese Hamster Ovary (CHO) cell products.<\/span><\/p>","HasBorder":false,"ID":"5ab9a88b-ebb6-4a7a-a58b-bd0d0d898d31","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Hypersensitivity\r to Chinese Hamster Ovary (CHO) cell products.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"a530b3e8-2062-4f77-91b8-dcfd25f4ff29","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.4     Special warnings and\r precautions for use<\/span><\/b><\/p>","HasBorder":false,"ID":"251d9480-1729-470a-a787-c2d23b006f7b","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.4     Special warnings and\r precautions for use","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"e6544374-a859-458c-9f89-0b96fa551693","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Traceability<\/span><\/u><\/p>","HasBorder":false,"ID":"99440824-f2c8-4df6-a74d-ffc3b2c0ceb3","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Traceability","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"6a8e4d57-02b5-4393-a7ba-e4e5c7c752dc","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.<\/span><\/p>","HasBorder":false,"ID":"d55402a8-120a-46ed-94fd-7745cd853c7e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","HasBorder":false,"ID":"3a50ad0c-1e8e-4206-a8f4-92ed7d2ee4b7","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Infusion\u2011related reactions<\/span><\/u><\/p>","HasBorder":false,"ID":"d4312e4a-57ec-4e00-997d-e2b7340d8d0a","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Infusion\u2011related reactions","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"d8483fea-385a-434b-9d67-54c1fda11ad0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r studies, infusion\u2011related reactions (defined as occurring within\r 24 hours) were observed in 2 patients (1.8%) treated with crizanlizumab\r 5 mg\/kg<\/span><span lang=\"EN-GB\">. Patients should be monitored for signs\r and symptoms of infusion\u2011related reactions, which may include fever,\r chills, nausea, vomiting, fatigue, dizziness, pruritus, urticaria, sweating,\r shortness of breath or wheezing. <\/span><span lang=\"EN-GB\">In the event of a\r severe reaction, crizanlizumab should be discontinued and appropriate therapy\r should be instituted.<\/span><\/p>","HasBorder":false,"ID":"e03116f1-4257-4233-a774-1a6ebc7fe1f1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"In clinical\r studies, infusion\u2011related reactions (defined as occurring within\r 24 hours) were observed in 2 patients (1.8%) treated with crizanlizumab\r 5 mg\/kg. Patients should be monitored for signs\r and symptoms of infusion\u2011related reactions, which may include fever,\r chills, nausea, vomiting, fatigue, dizziness, pruritus, urticaria, sweating,\r shortness of breath or wheezing. In the event of a\r severe reaction, crizanlizumab should be discontinued and appropriate therapy\r should be instituted.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"750ddb6c-176e-450a-8a4b-33707885a536","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Laboratory test interference: automated platelet counts<\/span><\/u><\/p>","HasBorder":false,"ID":"14df9432-13de-43ad-8a9f-7c816b173003","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Laboratory test interference: automated platelet counts","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"f4d267b3-acae-403e-9b54-56e62cfaa485","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Interference\r with automated platelet counts (platelet clumping) has been observed in\r patients treated with crizanlizumab in clinical studies, in particular when\r tubes containing EDTA (ethylenediaminetetraacetic acid) were used. This may\r lead to unevaluable or falsely decreased platelet counts. There is no evidence\r that crizanlizumab causes a reduction in circulating platelets or has a pro\u2011aggregant\r effect <i>in vivo<\/i>.<\/span><\/p>","HasBorder":false,"ID":"123ec4d3-153c-4e57-8d5a-15b0aa84b6cd","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Interference\r with automated platelet counts (platelet clumping) has been observed in\r patients treated with crizanlizumab in clinical studies, in particular when\r tubes containing EDTA (ethylenediaminetetraacetic acid) were used. This may\r lead to unevaluable or falsely decreased platelet counts. There is no evidence\r that crizanlizumab causes a reduction in circulating platelets or has a pro\u2011aggregant\r effect in vivo.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"eb335683-373f-4f46-8b6a-79206be2eadb","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">To mitigate the\r potential for laboratory test interference, it is recommended to run the test as\r soon as possible (within 4 hours of blood collection) or use citrate\r tubes. When needed, <\/span><span lang=\"EN-GB\">platelet counts can be estimated via\r a peripheral blood smear<\/span><span lang=\"EN-GB\">.<\/span><\/p>","HasBorder":false,"ID":"56c95ac4-e5ca-4584-ae69-18fdfe9fc19a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"To mitigate the\r potential for laboratory test interference, it is recommended to run the test as\r soon as possible (within 4 hours of blood collection) or use citrate\r tubes. When needed, platelet counts can be estimated via\r a peripheral blood smear.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b39e3121-ca4e-41fc-b0c2-84da4a84a523","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Excipients with known effect<\/span><\/u><\/p>","HasBorder":false,"ID":"b0a7cbf2-13ce-4855-bb3a-270029229447","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Excipients with known effect","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"cf89e468-60e1-4f78-9f0d-df7f1e68fd4f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicine\r contains less than 1 mmol sodium (23 mg) per vial, that is to say\r essentially \u201csodium\u2011free\u201d.<\/span><\/p>","HasBorder":false,"ID":"89b145c3-36c6-4ef8-9de0-afcfa5aed40d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"This medicine\r contains less than 1 mmol sodium (23 mg) per vial, that is to say\r essentially \u201csodium\u2011free\u201d.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"c85098e3-a587-4cb3-9c01-907083347b0e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.5     Interaction with\r other medicinal products and other forms of interaction<\/span><\/b><\/p>","HasBorder":false,"ID":"f0123d41-ec67-4fe0-b23b-520cda5ae8d2","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.5     Interaction with\r other medicinal products and other forms of interaction","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"940d22cb-94c6-443d-a0cb-bc910ce3ac94","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Interactions\r between crizanlizumab and other medicinal products have not been investigated\r in dedicated studies.<\/span><\/p>","HasBorder":false,"ID":"3ec4cb0a-b02d-4282-ac15-a638d8c4e794","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Interactions\r between crizanlizumab and other medicinal products have not been investigated\r in dedicated studies.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"7c2086ab-af39-48f9-bad2-bbb1455c32b6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Monoclonal\r antibodies are not metabolised by cytochrome P450 (CYP450) enzymes. Therefore,\r medicinal products that are substrates, inhibitors or inducers of CYP450 are\r not expected to affect the pharmacokinetics of crizanlizumab. In clinical\r studies, HU\/HC had no effect on crizanlizumab pharmacokinetics in patients.<\/span><\/p>","HasBorder":false,"ID":"c39d6cee-0259-473e-9db5-0a3d27160567","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Monoclonal\r antibodies are not metabolised by cytochrome P450 (CYP450) enzymes. Therefore,\r medicinal products that are substrates, inhibitors or inducers of CYP450 are\r not expected to affect the pharmacokinetics of crizanlizumab. In clinical\r studies, HU\/HC had no effect on crizanlizumab pharmacokinetics in patients.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"de3456f7-9208-4d25-868b-74138c85d5a9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">No effect on\r exposure of co\u2011administered medicinal products is expected based on the\r metabolic pathways of monoclonal antibodies.<\/span><\/p>","HasBorder":false,"ID":"6b5a801e-4220-4cc8-a86d-dd7177c151f6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"No effect on\r exposure of co\u2011administered medicinal products is expected based on the\r metabolic pathways of monoclonal antibodies.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"5173b5e8-9b42-429b-9d18-1fd418044163","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.6     <\/span><\/b><b><span lang=\"EN-GB\">Fertility, p<\/span><\/b><b><span lang=\"EN-GB\">regnancy and lactation<\/span><\/b><\/p>","HasBorder":false,"ID":"9f4a28df-7c63-4020-aea0-40560fea2999","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.6     Fertility, pregnancy and lactation","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"f29bf545-4dd9-4dea-ade1-beba10fc0e00","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","HasBorder":false,"ID":"eb1cc029-d56c-4698-b786-45d2c15931b9","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Pregnancy","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"0d67addd-6f08-4318-a5c3-3cf4ff15a7df","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\"><span lang=\"EN-GB\">There is a limited amount of data from the\r use of Adakveo in pregnant women. Based on data from animal studies, crizanlizumab\r has the potential to cause foetal losses when administered to a pregnant woman\r (see section 5.3). As a precautionary measure, it is preferable to avoid\r the use of Adakveo during pregnancy and in woman of childbearing potential not\r using contraception.<\/span><\/p>","HasBorder":false,"ID":"5d2f5b46-10f5-402c-8ebc-a2231b904bc9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"None","Text":"There is a limited amount of data from the\r use of Adakveo in pregnant women. Based on data from animal studies, crizanlizumab\r has the potential to cause foetal losses when administered to a pregnant woman\r (see section 5.3). As a precautionary measure, it is preferable to avoid\r the use of Adakveo during pregnancy and in woman of childbearing potential not\r using contraception.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"eaed6604-9800-43d4-9a6f-7e62590e8dc9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\" style=\"line-height:normal\">To help determine the effects in\r pregnant women, healthcare professionals are encouraged to report all pregnancy\r cases and complications during pregnancy (from 105 days prior to the last\r menstrual period onward) to <span lang=\"EN-GB\">the local representative of the<\/span>\r marketing authorisation holder (see package leaflet), in order to allow\r monitoring of these patients through the PRegnancy outcomes Intensive\r Monitoring programme (PRIM). In addition, all adverse pregnancy events should\r be reported <span lang=\"EN-GB\">via <span style=\"color:black;background:#D9D9D9\">the\r national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V<\/span><\/a><\/span>.<\/p>","HasBorder":false,"ID":"69b17165-e14f-4964-bd16-8780cf5f2a73","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"To help determine the effects in\r pregnant women, healthcare professionals are encouraged to report all pregnancy\r cases and complications during pregnancy (from 105 days prior to the last\r menstrual period onward) to the local representative of the\r marketing authorisation holder (see package leaflet), in order to allow\r monitoring of these patients through the PRegnancy outcomes Intensive\r Monitoring programme (PRIM). In addition, all adverse pregnancy events should\r be reported via the\r national reporting system listed in Appendix V.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"c74ef036-828a-4dc3-9f23-115b2072d83f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast\u2011feeding<\/span><\/u><\/p>","HasBorder":false,"ID":"06289019-4028-4699-99c3-1a91db142225","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Breast\u2011feeding","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"3767833a-f9e5-425b-834a-dac8d493ec99","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">It is unknown whether\r crizanlizumab is excreted in human milk after administration of Adakveo. There\r are no data on the effects of crizanlizumab on the breast\u2011fed newborn\/infant\r or on milk production.<\/span><\/p>","HasBorder":false,"ID":"dcdb6566-90c7-45b3-95f0-30817f376462","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"It is unknown whether\r crizanlizumab is excreted in human milk after administration of Adakveo. There\r are no data on the effects of crizanlizumab on the breast\u2011fed newborn\/infant\r or on milk production.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"f616af7e-ee9b-4e77-b706-dca790cefe6c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Because many\r medicinal products, including antibodies, can be excreted in human milk, a risk\r to the newborn\/infant cannot be excluded.<\/span><\/p>","HasBorder":false,"ID":"8d83dfb6-dc79-4e1a-9dae-7453d1993dd8","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Because many\r medicinal products, including antibodies, can be excreted in human milk, a risk\r to the newborn\/infant cannot be excluded.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"c550817c-a93a-4f42-974b-d12be451a73a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A decision must\r be made whether to discontinue breast\u2011feeding or to discontinue Adakveo\r therapy, taking into account the benefit of breast\u2011feeding for the child\r and the benefit of therapy for the woman.<\/span><\/p>","HasBorder":false,"ID":"1b634920-3aa3-4825-98c1-178fa5aebfb3","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"A decision must\r be made whether to discontinue breast\u2011feeding or to discontinue Adakveo\r therapy, taking into account the benefit of breast\u2011feeding for the child\r and the benefit of therapy for the woman.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"683bf2e1-b64f-4cfb-b44c-84dc0ffa14d1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","HasBorder":false,"ID":"32ee8e75-2cdd-4ab6-9e2c-3b25c6254d89","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Fertility","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"ef0ddbf1-b10d-4588-8d32-12779b37b65a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">There are no\r data on the effect of Adakveo on human fertility. Available non\u2011clinical\r data do not suggest an effect on fertility under crizanlizumab treatment (see\r section 5.3).<\/span><\/p>","HasBorder":false,"ID":"b529ae65-ae7e-4cd9-beb9-8d7af98a669a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"There are no\r data on the effect of Adakveo on human fertility. Available non\u2011clinical\r data do not suggest an effect on fertility under crizanlizumab treatment (see\r section 5.3).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","HasBorder":false,"ID":"461fbe02-5e3b-4854-a544-82a7bf5bd7ac","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":" ","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7     Effects on ability\r to drive and use machines<\/span><\/b><\/p>","HasBorder":false,"ID":"a8061de8-ee28-4dc4-a978-d5b665f4ae62","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.7     Effects on ability\r to drive and use machines","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"3207d838-f520-4d5b-84d7-3837a85808f0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo may have\r a minor influence on the ability to drive and use machines. Dizziness, fatigue\r and somnolence may occur following administration of crizanlizumab.<\/span><\/p>","HasBorder":false,"ID":"888f86c9-fbff-4cf8-9ef2-551ee0d077ae","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Adakveo may have\r a minor influence on the ability to drive and use machines. Dizziness, fatigue\r and somnolence may occur following administration of crizanlizumab.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3ffbf29b-51c7-4204-aad6-91834587cc79","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/b><\/p>","HasBorder":false,"ID":"e005dccc-3ed7-43dc-a6c1-85ef757fd71e","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"4.8     Undesirable effects","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"5b15b25b-fcf0-412e-9ddd-af2964390313","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Summary of the safety profile<\/span><\/u><a name=\"_nth_Summary_of_the_safety_6118\"><\/a><\/p>","HasBorder":false,"ID":"db23771a-41d1-4582-980f-b3f617c13a47","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Summary of the safety profile","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"e530465e-45e0-4d5c-b057-6b73b28ec7d0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The most frequently reported adverse drug reactions (\u226510% of\r patients) in the Adakveo 5 mg\/kg group were arthralgia, nausea, back pain,\r pyrexia and abdominal pain. Severe events were observed for pyrexia and\r arthralgia (each 0.9%).<\/span><\/p>","HasBorder":false,"ID":"c920cf1e-425e-4a8f-a776-91274d46dbf6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"The most frequently reported adverse drug reactions (\u226510% of\r patients) in the Adakveo 5 mg\/kg group were arthralgia, nausea, back pain,\r pyrexia and abdominal pain. Severe events were observed for pyrexia and\r arthralgia (each 0.9%).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"04a1d7cd-9cfd-47bb-9297-20ee75abd159","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Tabulated list of adverse reactions<\/span><\/u><\/p>","HasBorder":false,"ID":"0e74de6c-518a-44f0-bc86-7d5e63618e07","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Tabulated list of adverse reactions","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"35b74b8a-e5da-49ce-aefb-986e9a7866f2","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Table 1 lists adverse reactions based on pooled data from two\r studies: the pivotal study, SUSTAIN, and a single\u2011arm, open\u2011label\r pharmacokinetics\/pharmacodynamics and safety study. Use of crizanlizumab in\r combination with HU\/HC did not result in any meaningful differences in the\r safety profile.<\/span><\/p>","HasBorder":false,"ID":"b5ea5a46-d258-49b9-b9e8-57eb79f6727d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"Table 1 lists adverse reactions based on pooled data from two\r studies: the pivotal study, SUSTAIN, and a single\u2011arm, open\u2011label\r pharmacokinetics\/pharmacodynamics and safety study. Use of crizanlizumab in\r combination with HU\/HC did not result in any meaningful differences in the\r safety profile.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"e3fbe7a9-b1b3-421e-b64d-e1571ef98679","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Within each system organ class, the adverse reactions are ranked by\r frequency, with the most frequent reactions first. Within each frequency\r grouping, adverse reactions are presented in order of decreasing seriousness.\r In addition, the corresponding frequency category for each adverse reaction is\r based on the following convention: very common (\u22651\/10); common\r (\u22651\/100 to &lt;1\/10); uncommon (\u22651\/1,000 to &lt;1\/100); rare\r (\u22651\/10,000 to &lt;1\/1,000); very rare (&lt;1\/10,000).<\/span><\/p>","HasBorder":false,"ID":"b0c45c9e-1729-45b4-a0c1-1902e2eafa86","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"Within each system organ class, the adverse reactions are ranked by\r frequency, with the most frequent reactions first. Within each frequency\r grouping, adverse reactions are presented in order of decreasing seriousness.\r In addition, the corresponding frequency category for each adverse reaction is\r based on the following convention: very common (\u22651\/10); common\r (\u22651\/100 to <1\/10); uncommon (\u22651\/1,000 to <1\/100); rare\r (\u22651\/10,000 to <1\/1,000); very rare (<1\/10,000).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"d7dba98e-fbad-4fd5-adff-c9710c6a9279","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><a name=\"_Toc272145403\"><\/a><a name=\"_Toc272145564\"><\/a><a name=\"_Toc266768477\"><\/a><a name=\"_Toc260903679\"><\/a><a name=\"_Toc266264818\"><\/a><a name=\"_Toc499550967\"><\/a><a name=\"_Toc517716325\"><b><span lang=\"EN-GB\">Table 1       Adverse\r reactions in clinical studies<\/span><\/b><\/a><a name=\"_hd6_Table_7_1_Percentage_o7395\"><\/a><\/p>","HasBorder":false,"ID":"208d2321-ab96-4a52-891d-901bcf8a9393","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Table 1       Adverse\r reactions in clinical studies","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"3769ec54-9248-426f-b319-3177f7d15364","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormalTable']","Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:459.0pt;border-collapse:collapse;border:none\" width=\"612\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">System organ class<\/span><\/b><\/p> <\/td> <td style=\"width:81.0pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Frequency<\/span><\/b><\/p> <\/td> <td style=\"width:202.5pt;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><b><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Adverse reaction<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Respiratory, thoracic and\r   mediastinal disorders<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Oropharyngeal pain<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Gastrointestinal disorders<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Very common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Nausea, abdominal pain*<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:13.45pt\"> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:13.45pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">D<\/span><span lang=\"EN-GB\" style=\"font-size:11.0pt\">iarrhoea, vomiting<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Skin and subcutaneous tissue\r   disorders<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pruritus*<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Musculoskeletal and\r   connective tissue disorders<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Very common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Arthralgia, back pain<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Myalgia, musculoskeletal\r   chest pain<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">General disorders and\r   administration site conditions<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Very common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Pyrexia<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Infusion site reaction*<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:175.5pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"234\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Injury, poisoning and\r   procedural complications<\/span><\/p> <\/td> <td style=\"width:81.0pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"108\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Common<\/span><\/p> <\/td> <td style=\"width:202.5pt;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"270\"> <p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r   avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Infusion\u2011related\r   reaction<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"3\" style=\"width:459.0pt;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"612\"> <p class=\"Table\" style=\"margin:0in\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>*The\r   following groupings contain the following MedDRA preferred terms:<\/span><\/p> <p class=\"Table\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r   margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-family:\r   \"Times New Roman\",serif'>-<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Abdominal\r   pain: abdominal pain, abdominal pain upper, abdominal pain lower, abdominal\r   discomfort, and abdominal tenderness<\/span><\/p> <p class=\"Table\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r   margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"FR-CH\" style='font-family:\r   \"Times New Roman\",serif'>-<\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman\",serif'>Pruritus:\r   pruritus and vulvovaginal pruritus<\/span><\/p> <p class=\"Table\" style=\"margin-top:0in;margin-right:0in;margin-bottom:0in;\r   margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\" style='font-size:\r   11.0pt;font-family:\"Times New Roman\",serif'>-<\/span><span lang=\"FR-CH\" style='font-family:\"Times New Roman\",serif'>Infusion\r   site reaction: infusion site extravasation, infusion site pain, and infusion\r   site swelling<\/span><\/p> <\/td> <\/tr> <\/table>","HasBorder":false,"ID":"cb8d2a53-93ef-424c-8fd9-993e5f3e3820","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"width:459.0pt;border-collapse:collapse;border:none","Text":"   System organ class   Frequency   Adverse reaction     Respiratory, thoracic and\r   mediastinal disorders   Common   Oropharyngeal pain     Gastrointestinal disorders   Very common   Nausea, abdominal pain*     Common   Diarrhoea, vomiting     Skin and subcutaneous tissue\r   disorders   Common   Pruritus*     Musculoskeletal and\r   connective tissue disorders   Very common   Arthralgia, back pain     Common   Myalgia, musculoskeletal\r   chest pain     General disorders and\r   administration site conditions   Very common   Pyrexia     Common   Infusion site reaction*     Injury, poisoning and\r   procedural complications   Common   Infusion\u2011related\r   reaction     *The\r   following groupings contain the following MedDRA preferred terms: -Abdominal\r   pain: abdominal pain, abdominal pain upper, abdominal pain lower, abdominal\r   discomfort, and abdominal tenderness -Pruritus:\r   pruritus and vulvovaginal pruritus -Infusion\r   site reaction: infusion site extravasation, infusion site pain, and infusion\r   site swelling   ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","HasBorder":false,"ID":"30064b95-5d72-4d39-92f9-a95247eb96b6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p>","HasBorder":false,"ID":"892af4a9-36f7-4864-99a5-4c9766074d64","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Description of selected adverse reactions","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r avoid\"><\/p>","HasBorder":false,"ID":"f133e75c-1184-40e9-ba21-a81396ba8ad0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left;page-break-after:\r\navoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left;page-break-after:\r avoid\"><i><u><span style=\"font-size:11.0pt\">Immunogenicity<\/span><\/u><\/i><\/p>","HasBorder":false,"ID":"e5cb75ad-ce10-4a31-b273-53fe8a040cfe","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left;page-break-after:\r\navoid","Text":"Immunogenicity","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">In clinical studies, treatment\u2011induced anti\u2011crizanlizumab\r antibodies were transiently detected in 1 patient (0.9%) among the 111 patients\r who received Adakveo 5 mg\/kg.<\/span><\/p>","HasBorder":false,"ID":"432e50f2-ef76-469b-a428-50299dc00194","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"In clinical studies, treatment\u2011induced anti\u2011crizanlizumab\r antibodies were transiently detected in 1 patient (0.9%) among the 111 patients\r who received Adakveo 5 mg\/kg.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","HasBorder":false,"ID":"94faf8af-99fd-415d-a20a-7ba08045b47b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">There was no evidence of altered pharmacokinetics or of\r an altered safety profile with anti\u2011crizanlizumab antibody development.<\/span><\/p>","HasBorder":false,"ID":"374fb216-4abc-4065-b167-67a2ad415c8b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"There was no evidence of altered pharmacokinetics or of\r an altered safety profile with anti\u2011crizanlizumab antibody development.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","HasBorder":false,"ID":"67fb0a09-f5c3-43fe-a93b-7f8f99adbfbe","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","HasBorder":false,"ID":"8a8bed60-bd29-4a3e-af50-2e779b6024c9","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Paediatric population","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['Standard']","Element":"<p class=\"Standard\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"9daabf19-41b5-4056-b163-ecc71e4c4242","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Frequency, type and severity of adverse reactions in\r patients aged 16 and 17 years are expected to be the same as in adults.\r The safety of crizanlizumab was evaluated in 3 patients aged &lt;18 years.<\/span><\/p>","HasBorder":false,"ID":"f7a257de-dd90-4996-ac31-118aad74c9ee","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"Frequency, type and severity of adverse reactions in\r patients aged 16 and 17 years are expected to be the same as in adults.\r The safety of crizanlizumab was evaluated in 3 patients aged <18 years.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><\/p>","HasBorder":false,"ID":"1a2d30cd-9fe8-45aa-90d5-b84fc6a970e1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p>","HasBorder":false,"ID":"30022a58-5cce-441e-a040-9f75bde8a9c8","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Reporting of suspected adverse reactions","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"19b01f59-6042-4ada-9ef0-67f71532906c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via <span style=\"color:black;\r background:#D9D9D9\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"background:#D9D9D9\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p>","HasBorder":false,"ID":"44e1a2f9-9968-4238-beed-ffde9ec6265d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"1b18e677-b819-46d4-92e7-25e1b80e691c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.9     Overdose<\/span><\/b><\/p>","HasBorder":false,"ID":"c31d84c2-94e1-4345-9b74-268968f4a52c","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.9     Overdose","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"03f29f7c-0948-480b-91af-3a1d6fd6dc97","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">No cases of overdose have been reported in clinical studies.<\/span><\/p>","HasBorder":false,"ID":"96631149-bcaa-4e90-b0bc-97ca5ec3ad3a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Text":"No cases of overdose have been reported in clinical studies.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p>","HasBorder":false,"ID":"7dc89382-5902-4bee-a56d-ff3153e54972","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">General supportive\r measures and symptomatic treatment should be initiated in cases of suspected\r overdose.<\/span><\/p>","HasBorder":false,"ID":"fa700ec0-f981-494b-8d28-15c455b1b770","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"General supportive\r measures and symptomatic treatment should be initiated in cases of suspected\r overdose.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"86e35820-f22d-48e8-aa1a-5ca90e2eaca5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"9b961575-50a6-4c1b-8b47-1eb043af0f82","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.       PHARMACOLOGICAL\r PROPERTIES<\/span><\/b><\/p>","HasBorder":false,"ID":"659d48b6-f2a4-4bbb-b17a-f5d84307f09e","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"5.       PHARMACOLOGICAL\r PROPERTIES","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"235f303a-9c30-439c-bd27-7d24ccbba2bd","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.1     Pharmacodynamic\r properties<\/span><\/b><\/p>","HasBorder":false,"ID":"7c556791-fa60-424d-bfc0-d2395f86c321","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"5.1     Pharmacodynamic\r properties","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"06248fba-a5ce-4f9d-8b39-ae605b594653","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic group: Other haematological agents, ATC code: B06AX01<\/span><\/p>","HasBorder":false,"ID":"31e420b4-78b0-4451-beb4-6158f7b90fa6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Pharmacotherapeutic group: Other haematological agents, ATC code: B06AX01","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"5f1ad3ee-781e-4633-a55c-f8fecfb9f8d6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","HasBorder":false,"ID":"ad440526-7822-4026-a055-1ff039ae737c","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Mechanism of action","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"f51dc5a1-48fd-46bf-9bf6-ee5b48e42d31","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Crizanlizumab is a selective IgG2 kappa humanised monoclonal\r antibody (mAb) that binds to P\u2011selectin with high affinity and blocks the\r interaction with its ligands, including P\u2011selectin glycoprotein ligand 1.\r <\/span><span lang=\"EN-GB\">Crizanlizumab can also dissociate preformed P\u2011selectin\/PSGL\u20111\r complex. <\/span><span lang=\"EN-GB\">P\u2011selectin is an adhesion molecule\r expressed on activated endothelial cells and platelets. It plays an essential\r role in the initial recruitment of leukocytes and the aggregation of platelets\r to the site of vascular injury during inflammation. In the chronic pro\u2011inflammatory\r state associated with sickle cell disease, P\u2011selectin is over\u2011expressed\r and circulating blood cells and the endothelium are activated and become\r hyperadhesive. P\u2011selectin\u2011mediated multi\u2011cellular adhesion is\r a key factor in the pathogenesis of vaso\u2011occlusion and vaso\u2011occlusive\r crises (VOC). Elevated levels of P\u2011selectin are found in patients with\r sickle cell disease.<\/span><\/p>","HasBorder":false,"ID":"b9946a70-666b-40d2-b3fd-59313b28340b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"Crizanlizumab is a selective IgG2 kappa humanised monoclonal\r antibody (mAb) that binds to P\u2011selectin with high affinity and blocks the\r interaction with its ligands, including P\u2011selectin glycoprotein ligand 1.\r Crizanlizumab can also dissociate preformed P\u2011selectin\/PSGL\u20111\r complex. P\u2011selectin is an adhesion molecule\r expressed on activated endothelial cells and platelets. It plays an essential\r role in the initial recruitment of leukocytes and the aggregation of platelets\r to the site of vascular injury during inflammation. In the chronic pro\u2011inflammatory\r state associated with sickle cell disease, P\u2011selectin is over\u2011expressed\r and circulating blood cells and the endothelium are activated and become\r hyperadhesive. P\u2011selectin\u2011mediated multi\u2011cellular adhesion is\r a key factor in the pathogenesis of vaso\u2011occlusion and vaso\u2011occlusive\r crises (VOC). Elevated levels of P\u2011selectin are found in patients with\r sickle cell disease.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"bfce3c04-9f9b-45ed-8291-c86fdc12c5c7","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Binding P\u2011selectin on the surface of the activated endothelium\r and platelets has been shown to effectively block interactions between\r endothelial cells, platelets, red blood cells and leukocytes, thereby\r preventing vaso\u2011occlusion.<\/span><\/p>","HasBorder":false,"ID":"ff6f88fa-28e0-4ca6-8803-7961f8ed28f1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"Binding P\u2011selectin on the surface of the activated endothelium\r and platelets has been shown to effectively block interactions between\r endothelial cells, platelets, red blood cells and leukocytes, thereby\r preventing vaso\u2011occlusion.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"2ad22533-f1d2-4d6a-b6fe-434980a854ff","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Pharmacodynamic effects<\/span><\/u><\/p>","HasBorder":false,"ID":"543c0984-89bf-4597-9471-50691a2aca7d","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Pharmacodynamic effects","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"6f93006f-4494-4a86-8feb-edb752b64686","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Throughout\r clinical studies, treatment with crizanlizumab 5 mg\/kg resulted in dose\u2011dependent,\r immediate and sustained P\u2011selectin inhibition <\/span><span lang=\"EN-GB\">(as\r measured <i>ex vivo<\/i>) <\/span><span lang=\"EN-GB\">in patients with sickle cell disease.<\/span><\/p>","HasBorder":false,"ID":"cfa3580e-7ad3-428d-b00b-2ff5aa008ef6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Throughout\r clinical studies, treatment with crizanlizumab 5 mg\/kg resulted in dose\u2011dependent,\r immediate and sustained P\u2011selectin inhibition (as\r measured ex vivo) in patients with sickle cell disease.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"8e0f52b6-2f72-4808-a96b-b2324c319eab","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Clinical efficacy and safety<\/span><\/u><\/p>","HasBorder":false,"ID":"97fcee75-5b40-424b-9d8d-bded1dfaa86c","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Clinical efficacy and safety","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"> <\/p>","HasBorder":false,"ID":"6b3606bf-3666-47cb-95f0-34262c2cbe65","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":" ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The efficacy of crizanlizumab, with or without HU\/HC, was evaluated\r in the pivotal study SUSTAIN, a 52\u2011week, randomised, placebo\u2011controlled,\r double\u2011blind, multicentre clinical study in sickle cell disease patients\r with a history of vaso\u2011occlusive crises (VOCs).<\/span><\/p>","HasBorder":false,"ID":"19f32350-8bfb-4f8b-97a3-055f31c67b91","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"The efficacy of crizanlizumab, with or without HU\/HC, was evaluated\r in the pivotal study SUSTAIN, a 52\u2011week, randomised, placebo\u2011controlled,\r double\u2011blind, multicentre clinical study in sickle cell disease patients\r with a history of vaso\u2011occlusive crises (VOCs).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"fddec904-a5b1-475f-abf9-d5371a8cc923","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In this study, VOCs were defined as those leading to a healthcare\r visit, which captured all acute episodes of pain with no other cause than a\r vaso\u2011occlusive event that required a healthcare visit and treatment with\r oral or parenteral opioids or parenteral non\u2011steroidal anti\u2011inflammatory\r drugs (NSAIDs). Acute chest syndrome, hepatic sequestration, splenic\r sequestration and priapism (requiring a healthcare visit), by definition, were\r also considered VOCs.<\/span><\/p>","HasBorder":false,"ID":"f13677ab-d747-41db-83b7-ac3de9dae158","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"In this study, VOCs were defined as those leading to a healthcare\r visit, which captured all acute episodes of pain with no other cause than a\r vaso\u2011occlusive event that required a healthcare visit and treatment with\r oral or parenteral opioids or parenteral non\u2011steroidal anti\u2011inflammatory\r drugs (NSAIDs). Acute chest syndrome, hepatic sequestration, splenic\r sequestration and priapism (requiring a healthcare visit), by definition, were\r also considered VOCs.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"23bcab79-0440-4385-83a0-9972b15e3b21","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A total of 198 sickle cell disease patients aged 16 to 63 years\r (inclusive; mean age 30.1\u00b110.3 years), with any sickle cell disease genotype\r (including HbSS [71.2%], HbSC [16.2%], HbSbeta0\u2011thalassaemia [6.1%],\r HbSbeta+\u2011thalassaemia [5.1%], and others [1.5%]) and a history of between\r 2 and 10 VOCs in the previous 12 months (62.6% and 37.4% of the\r patients had 2\u20114 or 5\u201110 VOCs, respectively), were randomised\r 1:1:1 to Adakveo 5 mg\/kg, Adakveo 2.5 mg\/kg or placebo. The majority\r of patients were Black or African American (91.9%). Patients received Adakveo with\r (62.1%) or without (37.9%) HU\/HC. Randomisation was stratified by patients\r already receiving HU\/HC (Y\/N) and by number of VOCs in the previous 12 months\r (2 to 4, 5 to 10). Patients were allowed to take medicinal products to\r relieve pain (i.e. paracetamol, NSAIDs and opioids) and to receive occasional\r transfusions on an \u201cas needed\u201d basis. Patients participating in a chronic\r transfusion programme (pre-planned series of transfusions for prophylactic\r purposes) were excluded from the study.<\/span><\/p>","HasBorder":false,"ID":"2cb6e373-7d6c-48c2-bbaf-39a795d697f8","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"A total of 198 sickle cell disease patients aged 16 to 63 years\r (inclusive; mean age 30.1\u00b110.3 years), with any sickle cell disease genotype\r (including HbSS [71.2%], HbSC [16.2%], HbSbeta0\u2011thalassaemia [6.1%],\r HbSbeta+\u2011thalassaemia [5.1%], and others [1.5%]) and a history of between\r 2 and 10 VOCs in the previous 12 months (62.6% and 37.4% of the\r patients had 2\u20114 or 5\u201110 VOCs, respectively), were randomised\r 1:1:1 to Adakveo 5 mg\/kg, Adakveo 2.5 mg\/kg or placebo. The majority\r of patients were Black or African American (91.9%). Patients received Adakveo with\r (62.1%) or without (37.9%) HU\/HC. Randomisation was stratified by patients\r already receiving HU\/HC (Y\/N) and by number of VOCs in the previous 12 months\r (2 to 4, 5 to 10). Patients were allowed to take medicinal products to\r relieve pain (i.e. paracetamol, NSAIDs and opioids) and to receive occasional\r transfusions on an \u201cas needed\u201d basis. Patients participating in a chronic\r transfusion programme (pre-planned series of transfusions for prophylactic\r purposes) were excluded from the study.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"b16dccec-298e-4b9c-a586-64f6f30fb2a5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Treatment with Adakveo 5 mg\/kg resulted in a 45.3% lower median\r annual rate of VOCs compared to placebo (Hodges\u2011Lehmann, median absolute\r difference of \u20111.01 compared with placebo, 95% CI [\u20112.00, 0.00]),\r which was statistically significant (p=0.010). The median annual rates of uncomplicated\r VOCs (any VOCs as defined above, excluding acute chest syndrome, hepatic\r sequestration, splenic sequestration or priapism) and days hospitalised were\r 62.9% and 41.8% lower in the Adakveo 5 mg\/kg than in the placebo group,\r respectively. The VOCs occurring during the study were assessed by an\r independent review committee.<\/span><\/p>","HasBorder":false,"ID":"bf5ed49a-84d6-40da-bc15-313ee8514232","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"Treatment with Adakveo 5 mg\/kg resulted in a 45.3% lower median\r annual rate of VOCs compared to placebo (Hodges\u2011Lehmann, median absolute\r difference of \u20111.01 compared with placebo, 95% CI [\u20112.00, 0.00]),\r which was statistically significant (p=0.010). The median annual rates of uncomplicated\r VOCs (any VOCs as defined above, excluding acute chest syndrome, hepatic\r sequestration, splenic sequestration or priapism) and days hospitalised were\r 62.9% and 41.8% lower in the Adakveo 5 mg\/kg than in the placebo group,\r respectively. The VOCs occurring during the study were assessed by an\r independent review committee.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"0ac7d828-8d76-47c4-85e5-03e4ff476cdb","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Main efficacy outcomes of the pivotal SUSTAIN study are summarised\r in Tables 2 and 3.<\/span><\/p>","HasBorder":false,"ID":"d8ad9b77-0e30-4fac-a6a7-c83ff03da2a5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"Main efficacy outcomes of the pivotal SUSTAIN study are summarised\r in Tables 2 and 3.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"6e837024-4eeb-4e13-9fee-0a266216d209","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><a name=\"_Toc499550968\"><\/a><a name=\"_Toc517716326\"><b><span lang=\"EN-GB\">Table <\/span><\/b><\/a><b><span lang=\"EN-GB\">2       Results from SUSTAIN clinical study in <\/span><\/b><a name=\"_hd6_Table_12_1_Results_fro16811\"><\/a><b><span lang=\"EN-GB\">sickle cell\r disease<\/span><\/b><\/p>","HasBorder":false,"ID":"c906fb92-8505-48a6-bd50-5201419c78d8","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Table 2       Results from SUSTAIN clinical study in sickle cell\r disease","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"79d94e3f-a125-45c2-ba2e-44b49f351f50","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormalTable']","Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"width:98.84%;border-collapse:collapse;border:none\" width=\"98%\"> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td style=\"width:20.16%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Event<\/span><\/b><\/p> <\/td> <td style=\"width:23.82%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Adakveo 5 mg\/kg<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">(N=67)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(standard median)<\/span><\/p> <\/td> <td style=\"width:11.54%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Placebo<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">(N=65)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(standard median)<\/span><\/p> <\/td> <td style=\"width:10.46%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Change vs placebo<\/span><\/b><\/p> <\/td> <td style=\"width:21.1%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Hodges\u2011Lehmann median\r   difference<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(95% CI)<\/span><\/p> <\/td> <td style=\"width:12.9%;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">p-value<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(Wilcoxon rank sum)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td style=\"width:20.18%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Primary endpoint<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Annual rate of VOCs<\/span><\/p> <\/td> <td style=\"width:23.82%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.63<\/span><\/p> <\/td> <td style=\"width:11.54%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.98<\/span><\/p> <\/td> <td style=\"width:10.46%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201145.3%<\/span><\/p> <\/td> <td style=\"width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.00, 0.00)<\/span><\/p> <\/td> <td style=\"width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">0.010<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"5\" style=\"width:87.1%;border:none;\r   border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Secondary endpoints<\/span><\/b><\/p> <\/td> <td style=\"width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td style=\"width:20.18%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Annual rate of days hospitalised<\/span><\/p> <\/td> <td style=\"width:23.82%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">4.00<\/span><\/p> <\/td> <td style=\"width:11.54%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">6.87<\/span><\/p> <\/td> <td style=\"width:10.46%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201141.8%<\/span><\/p> <\/td> <td style=\"width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">0.00<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20114.36, 0.00)<\/span><\/p> <\/td> <td style=\"width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">0.450<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td style=\"width:20.18%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"20%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Annual rate of uncomplicated VOCs<\/span><\/p> <\/td> <td style=\"width:23.82%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.08<\/span><\/p> <\/td> <td style=\"width:11.54%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.91<\/span><\/p> <\/td> <td style=\"width:10.46%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201162.9%<\/span><\/p> <\/td> <td style=\"width:21.1%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"21%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.00<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20111.98, 0.00)<\/span><\/p> <\/td> <td style=\"width:12.9%;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">-<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:1.0pt\"> <td colspan=\"6\" style=\"width:.02%;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;height:1.0pt\" valign=\"top\" width=\"0%\"> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-size:10.0pt\">The primary (annual rate of VOC leading\r   to healthcare visit) and key secondary (annual rate of days hospitalised)\r   endpoints were the only ones formally tested for statistical significance\r   according to protocol.<\/span><\/p> <\/td> <\/tr> <\/table>","HasBorder":false,"ID":"e446f18a-07a8-4fd0-9b81-07e1a708c0c9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"width:98.84%;border-collapse:collapse;border:none","Text":"   Event   Adakveo 5 mg\/kg (N=67) (standard median)   Placebo (N=65) (standard median)   Change vs placebo   Hodges\u2011Lehmann median\r   difference (95% CI)   p-value (Wilcoxon rank sum)     Primary endpoint Annual rate of VOCs   1.63   2.98   \u201145.3%   \u20111.01 (\u20112.00, 0.00)   0.010     Secondary endpoints        Annual rate of days hospitalised   4.00   6.87   \u201141.8%   0.00 (\u20114.36, 0.00)   0.450     Annual rate of uncomplicated VOCs   1.08   2.91   \u201162.9%   \u20111.00 (\u20111.98, 0.00)   -     The primary (annual rate of VOC leading\r   to healthcare visit) and key secondary (annual rate of days hospitalised)\r   endpoints were the only ones formally tested for statistical significance\r   according to protocol.   ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"db1854e1-af7e-4771-95ad-debec684d91d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">The clinical effect demonstrated in the\r primary efficacy analysis was supported by multiple supplementary analyses\r including a negative binomial regression on investigator assessments with a\r conservative method to handle missing data due to early discontinuation of\r treatment based on outcomes in the placebo group (RR=0.74, 95% CI=0.52, 1.06).<\/span><\/p>","HasBorder":false,"ID":"484fd169-1a59-49e1-9c29-a50f6624036b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"None","Text":"The clinical effect demonstrated in the\r primary efficacy analysis was supported by multiple supplementary analyses\r including a negative binomial regression on investigator assessments with a\r conservative method to handle missing data due to early discontinuation of\r treatment based on outcomes in the placebo group (RR=0.74, 95% CI=0.52, 1.06).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"> <\/p>","HasBorder":false,"ID":"1ab29ed1-ed81-4fe9-a257-0115286990fd","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":" ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In the Adakveo 5 mg\/kg group, clinically significant reductions\r in the annual rate of VOCs were observed across important subgroups (<\/span><span lang=\"EN-GB\">HU\/HC use, 2\u20114 or 5\u201110 VOCs in the previous 12 months,\r and HbSS or non\u2011HbSS genotypes; <\/span><span lang=\"EN-GB\">see Table 3).<\/span><\/p>","HasBorder":false,"ID":"2bdb4029-8647-4e4e-9eb1-7f44bf2245a2","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"In the Adakveo 5 mg\/kg group, clinically significant reductions\r in the annual rate of VOCs were observed across important subgroups (HU\/HC use, 2\u20114 or 5\u201110 VOCs in the previous 12 months,\r and HbSS or non\u2011HbSS genotypes; see Table 3).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"ad9902d2-9c5f-4a62-9a93-37e5f1744327","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><b><span lang=\"EN-GB\">Table 3       Annual rate of VOCs in patients \u2011\r subgroup analyses<\/span><\/b><\/p>","HasBorder":false,"ID":"d1891d3d-4aaf-4ef1-9679-26cc4e553296","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"Table 3       Annual rate of VOCs in patients \u2011\r subgroup analyses","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"63ef2698-6188-4a2f-a488-a4d8121145e6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormalTable']","Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"border-collapse:collapse;border:none\" width=\"612\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:90.45pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"121\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Subgroup <\/span><\/b><\/p> <\/td> <td style=\"width:63.8pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><\/p> <\/td> <td style=\"width:70.85pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Adakveo 5 mg\/kg (N=67)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(standard median)<\/span><\/p> <\/td> <td style=\"width:63.8pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Placebo (N=65)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(standard median)<\/span><\/p> <\/td> <td style=\"width:63.8pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Change vs placebo<\/span><\/b><\/p> <\/td> <td style=\"width:106.3pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">Hodges\u2011Lehmann median\r   difference<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"EN-GB\">(95% CI)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"121\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">HU\/HC use<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Yes<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=42<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.43<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n= 40<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">3.58<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201132.1%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.44, 0.00)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">No<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=25<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.00<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=25<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.00<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201150.0%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.02<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.00, 0.00)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid;height:20.2pt\"> <td rowspan=\"2\" style=\"width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:20.2pt\" width=\"121\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Number of VOCs in previous\r   12 months<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2\u20114 VOCs<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=42<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.14<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=41<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.00<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201143.0%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt;\r   height:20.2pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20110.05<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20111.56, 0.01)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">5\u201110 VOCs<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=25<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.97<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=24<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">5.32<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201163.0%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20112.74<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20115.00, \u20110.83)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td rowspan=\"2\" style=\"width:90.45pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"121\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Sickle cell disease genotypes,\r   including HbSC<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">HbSS<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=47<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">1.97<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=47<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">3.01<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201134.6%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.18, 0.00)<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Non\u2011HbSS<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"94\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=20<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">0.99<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">n=18<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">2.00<\/span><\/p> <\/td> <td style=\"width:63.8pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"85\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u201150.5%<\/span><\/p> <\/td> <td style=\"width:106.3pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"142\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">\u20111.01<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">(\u20112.01, 0.00)<\/span><\/p> <\/td> <\/tr> <\/table>","HasBorder":false,"ID":"c175d089-52ef-425d-b055-ea9089400aea","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"border-collapse:collapse;border:none","Text":"   Subgroup       Adakveo 5 mg\/kg (N=67) (standard median)   Placebo (N=65) (standard median)   Change vs placebo   Hodges\u2011Lehmann median\r   difference (95% CI)     HU\/HC use   Yes   n=42 2.43   n= 40 3.58   \u201132.1%   \u20111.01 (\u20112.44, 0.00)     No   n=25 1.00   n=25 2.00   \u201150.0%   \u20111.02 (\u20112.00, 0.00)     Number of VOCs in previous\r   12 months   2\u20114 VOCs   n=42 1.14   n=41 2.00   \u201143.0%   \u20110.05 (\u20111.56, 0.01)     5\u201110 VOCs   n=25 1.97   n=24 5.32   \u201163.0%   \u20112.74 (\u20115.00, \u20110.83)     Sickle cell disease genotypes,\r   including HbSC   HbSS   n=47 1.97   n=47 3.01   \u201134.6%   \u20111.01 (\u20112.18, 0.00)     Non\u2011HbSS   n=20 0.99   n=18 2.00   \u201150.5%   \u20111.01 (\u20112.01, 0.00)   ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"9f718494-a284-4115-9250-7bda4f0399c4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A greater than two\u2011fold increase in the proportion of patients\r with no VOC and who completed the study was observed in the Adakveo 5 mg\/kg\r group compared to placebo (22% vs 8%; odds ratio [95% CI]: 3.57 [1.20, 10.63]).\r A similar difference was also observed across important subgroups (HU\/HC use,\r genotype).<\/span><\/p>","HasBorder":false,"ID":"5f1ddddc-7c2d-4fc4-8950-891f4efeb563","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"A greater than two\u2011fold increase in the proportion of patients\r with no VOC and who completed the study was observed in the Adakveo 5 mg\/kg\r group compared to placebo (22% vs 8%; odds ratio [95% CI]: 3.57 [1.20, 10.63]).\r A similar difference was also observed across important subgroups (HU\/HC use,\r genotype).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"c977d047-f80d-4fc3-acc0-20a31fb32264","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Treatment with Adakveo 5 mg\/kg was also associated with a three\u2011fold\r longer Kaplan\u2011Meier estimated median time to first VOC compared with\r placebo (4.07 vs 1.38 months; HR=0.495, 95% CI: 0.331, 0.741) (Figure 1)\r and a two\u2011fold longer median time from randomisation to second VOC\r compared to placebo (10.32 vs 5.09 months; HR=0.534, 95% CI: 0.329, 0.866).<\/span><\/p>","HasBorder":false,"ID":"c6cf158c-6975-461c-938d-004924bee757","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"Treatment with Adakveo 5 mg\/kg was also associated with a three\u2011fold\r longer Kaplan\u2011Meier estimated median time to first VOC compared with\r placebo (4.07 vs 1.38 months; HR=0.495, 95% CI: 0.331, 0.741) (Figure 1)\r and a two\u2011fold longer median time from randomisation to second VOC\r compared to placebo (10.32 vs 5.09 months; HR=0.534, 95% CI: 0.329, 0.866).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"197af3f7-cdd3-4de6-9de5-0f6b7ce7a670","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 1      Kaplan\u2011Meier curve of time to first VOC<\/span><\/b><\/p>","HasBorder":false,"ID":"12c80b1c-a3b8-468f-97ae-923206c745e4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Figure 1      Kaplan\u2011Meier curve of time to first VOC","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"f3fa6a76-30d0-4a4a-a2a7-dd0a70029b23","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><span style=\"position:absolute;z-index:251748352;left:0px;margin-left:61px;\r margin-top:211px;width:13px;height:9px\"><img alt=\"0\" height=\"9\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA0AAAAJCAYAAADpeqZqAAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAABRSURBVCjPY2hsbGQgFTPQRFN9noehiYnJTGNjj+7Y+npJojRFGxvXgxSDNBu75aWQpqk+VtLNLS+MdjbVR3rYGRtH13sYG3d75NUb0i70sGEAGHyta9OJwycAAAAASUVORK5CYII=\" width=\"13\"\/><\/span><span style=\"position:absolute;z-index:251746304;left:0px;margin-left:63px;\r margin-top:190px;width:10px;height:10px\"><img alt=\"10\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACHSURBVCjPY2hsbGQgBsMZ0aYehbH19ZIdHWk80R6mhbKyJtsj8+pV4QpBEu7GcrNAEiCFeW7GKcbRDT4gcTdjt9q0jg4euEIQJ9rYuB6kMMpYttcjr94QbAtUDNVqqCCyJF6FIKtBJoJs8jA27sapsD4vUtVE1mQFyN3GbnkpGL4mOniophAA2LuQewVJW9oAAAAASUVORK5CYII=\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251744256;left:0px;margin-left:64px;\r margin-top:169px;width:10px;height:10px\"><img alt=\"20\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACsSURBVCjPrZCxDYNADEUZgAUoTJcB0HfalOaKLEAQHaKKTopSI4fuJMQAYQIyQdaLjMQp6ShSuLDvPev7kmEYkj2VhNClJfKZmBdX6cn62h1vRPyuvB4ieBW6O6\/FKuSYRdCjfpytF0jfhZCu4GaoNhnycrbtJtqsBrRRzSJotiN6GfD9+APaJiZetjxe0G5RHDBG8AKa7BBmfgJu9L4qTLQIEN\/GY3Z\/z9\/BDzIIjqpQaDPwAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251742208;left:0px;margin-left:64px;\r margin-top:149px;width:10px;height:10px\"><img alt=\"30\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACoSURBVCjPrZDBCcMwDEUzQBbIwbllgPDdFWxRuoBrcgs5CjpAUX0zhA7QTJANul5RwYbecuhBgi89fb7dpJSaI9XkvLQErD38FlgG1ZFON2PsW3UF2WEmllFk6tD7TSHEx0UPHNx9ybn9gtqKCxzPV5inHuo8AjKJdBXUYg4jQKvGKMsfkCOdi1A3a+1LHUv2CgrTaI3dPfrNUBThMBStUepjDn\/P38EPZ1mO4Ar4bTAAAAAASUVORK5CYII=\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251740160;left:0px;margin-left:65px;\r margin-top:130px;width:10px;height:10px\"><img alt=\"40\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACjSURBVCjPY2hsbGQgBsMZOW6yxcbRDT4dHWk80R6mhbKyJtsj8+pVURTW53kYmsjKbgcpzHMzToFpcDN2q03r6OABK4QJ5EWbRoAURBnL9nrk1RuCJKONjetj6+slwQpBJoAkGqKNfUAKkSVRFILcY2JiMhNktaysx0oQH6QRZJOHsXE3XCHMsTAT6\/MiVU1kTVa4G8vNMnbLS8HwNdHBQzWFAHAmjuhoo9TWAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251738112;left:0px;margin-left:64px;\r margin-top:110px;width:10px;height:10px\"><img alt=\"50\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACrSURBVCjPrZCxDcJADEVvgAwAhekyQGRnhcNFakSw6KKUljIActKdhBgAJmCDrIeMOBS6FBRX3P3n568L0zSFNSek1BeMeCWie80y6Kgb4XoAoLlVK7+gKVcYtcsPGrFDGRsXRIyXPqXiDY6CjU8TwFyLHk8IN1arPBREO5ttP8a2zFMeeIUc\/oAa4yF3cZuDbszdF0aufPUedw9gMd9AQE+\/L7uH1d\/zd\/AF4j2OYb789v4AAAAASUVORK5CYII=\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251736064;left:0px;margin-left:64px;\r margin-top:90px;width:10px;height:10px\"><img alt=\"60\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACkSURBVCjPY2hsbGQgBoOJaA\/TQllZk+0ekfV2HR1pPDB+ZF69KlxhnptxinF0gw9IgZubWz5IEZxv7Fab1tHBA1YYbWxc7+ZmXAs2Ma\/eMMpYthdEg20CysXW10uCFUYZMyyEmeAuZzzLxMRkJkwSTSGqCSDTQXyQRg9j4264wvo8D0MTWZMVIEFZ46je+rxIVRDf3VhulrFbXgqKr4kOHqoqBABGdo3GbfQMNwAAAABJRU5ErkJggg==\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251734016;left:0px;margin-left:64px;\r margin-top:70px;width:10px;height:10px\"><img alt=\"70\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACdSURBVCjPY2hsbGQgBjPkuRmnmJiYzARhY2OP7si8PMNoD9NCWVmT7ZF59apwhTBGfZ6HobFxdD1Io3F0g09HRxqPm7FbbVpHBw9cIUjQw9i4O7a+XjLKWLbXI6\/eECQebWxcDxKDK2yINvYxdstLQZfEUIhsCshqEBvZFrBCkIC7nPEsmEB9XqSqiazJCndjuVkwW1A8QzB4qK4QAMhsj66qiUfoAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251731968;left:0px;margin-left:63px;\r margin-top:48px;width:10px;height:10px\"><img alt=\"80\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACmSURBVCjPY2hsbGQgBjN0dKTxRBnL9sqamKzwyKs3BPGjPUwLZWVNtkfm1avCFea4yRYbRzf4gBS4GbvVghQh89M6OnjACuvzPAyNjT26wQrc8lJApoNMBklGGxvXx9bXS4IV5rkZp4AU5OVFgjV4GBt3wyRRFCJzQKaZmJjMhLkVWRPYahNZkxVubsa1ssZRvfV5kaogvrux3CyQTXDPEB08VFcIAGfxjehIKaxZAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251729920;left:0px;margin-left:65px;\r margin-top:28px;width:10px;height:10px\"><img alt=\"90\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACjSURBVCjPY2hsbGQgBjN0dKTxuBvLzZIzdp8VmVevCuJHe5gWysqabAfx4Qpz3GSLPfLqDUEK3IzdakGKjKMbfGD8tI4OHrDCKGPZXpBCECfa2LjexER2BTI\/tr5eEqywPs\/DEGSNiYnJTBgNk0RR2JCXJwEyHmSVh7Fxt5ubcS3MKSA+ionGxh7dIA8Zu+Wl1OdFqprImqyA8eGeITp4qK4QAJ5TjiisGzNqAAAAAElFTkSuQmCC\" width=\"10\"\/><\/span><span style=\"position:absolute;z-index:251727872;left:0px;margin-left:60px;\r margin-top:9px;width:15px;height:10px\"><img alt=\"100\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA8AAAAKCAYAAABrGwT5AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAClSURBVCjPY2hsbGQgF8MZ0aYehbH19ZIgdkdHGk+0h2mhrKzJ9si8elV0PlwzSMLdWG4WSAKmOc\/NOMU4usEHJOdm7FYL0ojMT+vo4IFrBnGijY3rYZqjjGV7PfLqDcEuAoqbmMiuQObD1CGcjSSIzjYxMZmJTQ6rZpCzQTaBXOVhbNzt5mZci8zHq7k+L1LVRNZkBSgsjN3yUtD5GKFNUVTRXTMA8B3XufAXr20AAAAASUVORK5CYII=\" width=\"15\"\/><\/span><span style=\"position:absolute;z-index:251781120;left:0px;margin-left:459px;\r margin-top:8px;width:125px;height:38px\"><img height=\"38\" src=\"data:image\/png;base64,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\" width=\"125\"\/><\/span><span style=\"position:\r absolute;z-index:251779072;left:0px;margin-left:494px;margin-top:7px;\r width:92px;height:26px\"><img height=\"26\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFwAAAAaCAMAAAANMMsbAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJUExURf\/\/\/\/\/\/\/\/\/\/\/45K5f4AAAACdFJOU9vzMOtySgAAAAlwSFlzAAAOwwAADsMBx2+oZAAAADVJREFUSEvtzCECADAIw0Dg\/4\/eBDKSusS06qomVtL++m4kcUwcE8fEMXFMHBPHsnjvuW\/6ASpfEqvzA8MRAAAAAElFTkSuQmCC\" width=\"92\"\/><\/span><span style=\"position:\r absolute;z-index:251666432;left:0px;margin-left:22px;margin-top:28px;\r width:32px;height:178px\"><img alt=\"Probability of being free from first VOC (%)\" height=\"178\" src=\"data:image\/png;base64,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\" width=\"32\"\/><\/span><span style=\"position:absolute;z-index:251725824;left:0px;margin-left:320px;\r margin-top:242px;width:56px;height:10px\"><img alt=\"Time (months)\u00ac\u00ac\u00ac\u00ac\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAADgAAAAKCAYAAADhNJ24AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAFqSURBVEjH3VVBasNADPQD8oAEvDk1Dwiyj+mprLcl59JE7M3kYILA5BzWvhlKPuAXNC\/oC\/qvVimCrRu3pnZzyEGskbQzmpW8G5RlGVyzBQlM6zAM38QUrA+kITXk5n2A3crcrsjNhiiyqjYjomLcpS7m9XM+nc5OYJrUm6oanduUZdkNrwXR2M8R4m8kjAfo+mBI\/mkPwhKwWIpAPyaYgsF4GvReOM4KFKCtVrspJDWaOFcqetXWPkYqerHOTZiUY9ZC2hQjBfF3VwxemV\/ymz6ltzs0yjVjXCtYm65BHUBT6tf\/q0BZ\/Y6IjwFjgzki3huljv5Y+AQ\/YSCAY6HsYzyf0+9Es4N+jH0s1iA9SP3+Af9ZIBd3R7TgcSFrF\/7YXVLgaTyLD8P4ie+PwQQ6MnMeNa1hL8DnRrQLBl90gtEmUClzNADPbR1kjNYRHdqaP\/oljblNjPmXW\/Q\/zNFqNtQz0Yf3qh95tnfD5idClibkYQAAAABJRU5ErkJggg==\" width=\"56\"\/><\/span><sub><span style=\"font-size:11.0pt\">                                <img border=\"0\" height=\"223\" id=\"Picture 1243\" src=\"data:image\/jpg;base64,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\" width=\"518\"\/><\/span><\/sub><\/p>","HasBorder":false,"ID":"34750f88-f018-43dc-bb5d-40ab16836b8b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;page-break-after:avoid","Text":"                                ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"> <table align=\"left\" cellpadding=\"0\" cellspacing=\"0\"> <tr> <td height=\"1\" width=\"3\"><\/td> <td width=\"36\"><\/td> <td width=\"33\"><\/td> <td width=\"2\"><\/td> <td width=\"2\"><\/td> <td width=\"5\"><\/td> <td width=\"10\"><\/td> <td width=\"3\"><\/td> <td width=\"23\"><\/td> <td width=\"10\"><\/td> <td width=\"27\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"3\"><\/td> <td width=\"7\"><\/td> <td width=\"28\"><\/td> <td width=\"10\"><\/td> <td width=\"28\"><\/td> <td width=\"10\"><\/td> <td width=\"25\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"13\"><\/td> <td width=\"26\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"10\"><\/td> <td width=\"30\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"10\"><\/td> <td width=\"26\"><\/td> <td width=\"10\"><\/td> <td width=\"27\"><\/td> <td width=\"10\"><\/td> <td width=\"18\"><\/td> <\/tr> <tr> <td height=\"10\"><\/td> <td colspan=\"5\"><\/td> <td align=\"left\" valign=\"top\"><img alt=\"0\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB0SURBVCjPY2hsbGQgBsMZHR1pPNEepoWysibbI\/PqVXEqzHMzTjGObvABaXAzdqtN6+jgwaowyli21yOv3hDEjjY2ro+tr5fEqhBZEq9CkNUgE0FWexgbd+NUWJ8XqWoia7LC3VhulrFbXgpOzxAdPFRTCAAolJLNIdXXkAAAAABJRU5ErkJggg==\" width=\"10\"\/><\/td> <td colspan=\"2\"><\/td> <td align=\"left\" valign=\"top\"><img alt=\"1\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAA9SURBVCjPY2hsbGQgBmMIRJt6FMbW10viVNjRkcbjbiw3S1bWZDtBhWkdHTzRxsb1eBXCrR44hUQHD8UKAQJJlNuO03ePAAAAAElFTkSuQmCC\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"2\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB0SURBVCjPY2hsbGQgBsMZHR1pPO7GcrNkTUxWeETW2+FUmOMmW+yRV28I1iBnPCu2vl4Sq0IYrq+PlTSWc5+V1tHBg1MhyDQPWdmVIJNxWg0yyUTWZEVkXr0qXs9EGcv2gjxiYmIy09jYoxuv1UQFD9UUAgBwNJMS8y8R2wAAAABJRU5ErkJggg==\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" colspan=\"2\" valign=\"top\"><img alt=\"3\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB7SURBVCjPY2hsbGQgBsMZHR1pPB7Gxt1yxu6zIvPqVXEqzHMzTvHIqzesr4+VNJZzn5XW0cGDVSHM1GgP00Jjt7wUnCbCTc6LNDQ29ujGaWJetIdXbH29JIgdZSzbC3IGVoX1eR6GJrImK9yN5WbJekTXE7SaYPBQTSEAnxOTQJNoygYAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"4\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAABgSURBVCjPY2hsbGQgBmMI5LjJFhtHN\/jgVVif52FoIiu7Ha\/Cjo40Hjdjt9q8aNMIvArz3IxTPPLqDRuijX1wKgSZFu1hWmhiYjITZLWsrMfKtI4OHryewWsiWcFDsUIApiiTSLHBUzIAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"5\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB6SURBVCjPY2hsbGQgBsMZHR1pPB7Gxt0mJiYzTT2iC9M6OniwKqzP8zA0dstLIWhiQ7Sxj6ysyXYTWdntptF5ETgV1udFqsKsizY2ro+tr5fEqjDPzS0sMq9eFcSOMpbt9cirN8TpRpDV7sZys2Q9outxWk108FBNIQAlxZLDHicfXQAAAABJRU5ErkJggg==\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"6\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB2SURBVCjPY2hsbGQgBqNwoj1MC2VlTbZ7RNbb4VSY52acYhzd4NPRkcbj5uaWn9bRwYNVYbSxcb2bm3Et2MS8ekOcJkYZMyyEmeguZzwrtr5eEodC2V6YSSDTcSqsz\/MwNJE1WeFhbNwtaxzVi9fXRAcPVRQCAINekiNWacDGAAAAAElFTkSuQmCC\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"7\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAA0AAAAKCAYAAABv7tTEAAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB7SURBVCjPY2hsbGQgFaNwysvLBYKDg2NBODw8PDgrK0uHoKb6+npRBweHeicnp0oFBYW9fn5+iQQ1IdnIC9TcwMDAwEi0Jltb29b4+HhnovwEtUXIwMBg4apVq5iI1hQbG+tuamo6hejQA+G8vDy5tLQ0LZI0kRxPxGIAnwu\/7JsP81AAAAAASUVORK5CYII=\" width=\"13\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"8\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB7SURBVCjPY2hsbGQgBsMZHR1pPFHGsr2yJiYrPPLqDXEqzHGTLTaObvABaXAzdqtN6+jgwaqwPs\/D0NjYozvaw7TQ2C0vBaeJeW7GKSAFeXmRYA04TYw2Nq6Pra+XBLFBbkV3J4rVJrImK9zcjGtljaN6cVpNdPBQTSEAp2uSSOWzepoAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"9\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAAB6SURBVCjPY2hsbGQgBsMZHR1pPO7GcrPkjN1nRebVq+JUmOMmW+yRV28I0uBm7Fab1tHBg1VhlLFsL0ghiB1tbFwfW18viVVhfZ6HoaysyXYTE5OZIBqnwoa8PAmQdSCrPYyNu\/GaaGzs0Q3ykLFbXgpOzxAdPFRTCADTGpKAXsOmnQAAAABJRU5ErkJggg==\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"10\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACHSURBVCjPY2hsbGQgBsMZ0aYehbH19ZIdHWk80R6mhbKyJtsj8+pV4QpBEu7GcrNAEiCFeW7GKcbRDT4gcTdjt9q0jg4euEIQJ9rYuB6kMMpYttcjr94QbAtUDNVqqCCyJF6FIKtBJoJs8jA27sapsD4vUtVE1mQFyN3GbnkpGL4mOniophAA2LuQewVJW9oAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"11\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAABFSURBVCjPY2hsbGQgBsMZ0aYehbH19ZK4+AwdHWk87sZys2RlTbaDJND5KArTOjp4oo2N62EKkfmYVqNJ0FEh0cFDNYUAogCSidVvHywAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"12\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACNSURBVCjPY2hsbGQgBsMZ0aYehbH19ZIdHWk87sZys2RNTFZ4RNbbwRXCJWRNtoMU5rjJFnvk1RuCxeWMZ4HE4ArTOjp4oo2N62GCIFxfHytpLOc+CySHajWSQpBmD1nZlSCTMd0IVQgyyUTWZEVkXr0qds9AFUYZy\/aCPGJiYjLT2NijG8NqooOHagoBHkKQwNKEDRYAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"13\" height=\"10\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAKCAYAAACNMs+9AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAACWSURBVCjPY2hsbGQgBsMZ0aYehbH19ZIdHWk8HsbG3XLG7rMi8+pV4QpBEu7GcrNkZU22gxTmuRmneOTVG9bXx0oay7nPSuvo4IErBHGijY3rQQpBgiCxaA\/TQmO3vBRMq5EUgnBeXqShsbFHN9xEdIV50R5eMA1RxrK9IGdgVVif52FoImuyAuxuj+h6DKuJDh6qKQQAS7GQ7lbNrkIAAAAASUVORK5CYII=\" width=\"10\"\/><\/td> <\/tr> <tr> <td height=\"14\"><\/td> <\/tr> <tr> <td height=\"9\"><\/td> <td colspan=\"7\"><\/td> <td align=\"left\" colspan=\"6\" valign=\"top\"><img alt=\"Number of patients at risk\" height=\"9\" src=\"data:image\/png;base64,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\" width=\"99\"\/><\/td> <\/tr> <tr> <td height=\"7\"><\/td> <\/tr> <tr> <td height=\"7\"><\/td> <td colspan=\"4\"><\/td> <td align=\"left\" colspan=\"31\" rowspan=\"5\" valign=\"top\"><img alt=\"67,49,41,35,30,26,24,20,18,17,16,15,7,65,37,23,21,17,13,12,9,8,6,5,4,1,0,0\" height=\"43\" src=\"data:image\/png;base64,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\" width=\"513\"\/><\/td> <\/tr> <tr> <td height=\"10\"><\/td> <td align=\"left\" colspan=\"3\" valign=\"top\"><img alt=\"Adakveo 5 mg\/kg \" height=\"10\" src=\"data:image\/png;base64,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\" width=\"71\"\/><\/td> <\/tr> <tr> <td height=\"14\"><\/td> <\/tr> <tr> <td height=\"10\"><\/td> <td><\/td> <td align=\"left\" valign=\"top\"><img alt=\"Placebo\" height=\"10\" src=\"data:image\/png;base64,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\" width=\"33\"\/><\/td> <\/tr> <tr> <td height=\"2\"><\/td> <\/tr> <\/table> <\/p>","HasBorder":false,"ID":"6a055c4f-011e-49fd-ac74-0947d81f9494","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"                                                                                                       ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"8e7cbd5f-22db-4cb2-8276-745058629d77","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p class=\"Text\" style=\"margin-top:0in;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"39aae6df-7640-4e4a-8e28-799e1632492d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","HasBorder":false,"ID":"31978105-ae84-4699-8524-ca7ebdc461d9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"a2b59bb3-efab-4709-973d-033e508ea70a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","HasBorder":false,"ID":"028c81f2-51e8-4446-9a17-bb82102f4166","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;text-autospace:none","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"None","Element":"<br clear=\"ALL\"\/>","HasBorder":false,"ID":"0aad3b0a-1595-4286-b02d-a4dba11a6b1c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"None","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><a name=\"_hd6_Table_2_1_Patients_wit18544\"><\/a><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","HasBorder":false,"ID":"c039cc90-61a8-44bf-8af5-d88f78374b14","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Paediatric population","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"29a1784f-d13a-4cbf-83a3-b92b56468a1d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The efficacy of\r crizanlizumab in patients aged 16 and 17 years is expected to be the same\r as in adults. Three patients (2.7%) aged less than 18 years were treated\r with crizanlizumab 5 mg\/kg in clinical studies.<\/span><\/p>","HasBorder":false,"ID":"c5f20359-af59-4b16-9f5e-66df0a35ef27","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The efficacy of\r crizanlizumab in patients aged 16 and 17 years is expected to be the same\r as in adults. Three patients (2.7%) aged less than 18 years were treated\r with crizanlizumab 5 mg\/kg in clinical studies.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"52fe82fd-438e-4a70-8603-badddd09becd","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European\r Medicines Agency has deferred the obligation to submit the results of studies\r with Adakveo in one or more subsets of the paediatric population in the\r treatment of sickle cell disease (see section 4.2 for information on\r paediatric use).<\/span><\/p>","HasBorder":false,"ID":"2604f5d0-94a0-4eb0-a65c-8d09a8ed1c1f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The European\r Medicines Agency has deferred the obligation to submit the results of studies\r with Adakveo in one or more subsets of the paediatric population in the\r treatment of sickle cell disease (see section 4.2 for information on\r paediatric use).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"127ee624-2ee5-4aa4-b72c-5319b412fb47","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Conditional approval<\/span><\/u><\/p>","HasBorder":false,"ID":"56e5e177-0a71-444a-b90b-cfd385d165fe","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Conditional approval","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"cb94bb52-0f96-48f3-b0fd-314b0a32d1f1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicinal\r product has been authorised under a so\u2011called \u201cconditional approval\u201d\r scheme. This means that further evidence on this medicinal product is awaited.<\/span><\/p>","HasBorder":false,"ID":"ee620abf-d27e-4d36-a99b-4e40c3f017b1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"This medicinal\r product has been authorised under a so\u2011called \u201cconditional approval\u201d\r scheme. This means that further evidence on this medicinal product is awaited.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"4c87875f-fceb-4892-9fa0-2d0b30e10ba6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The European\r Medicines Agency will review new information on this medicinal product at least\r every year and this SmPC will be updated as necessary.<\/span><\/p>","HasBorder":false,"ID":"29ac003f-cace-499f-9fe0-3ddb022cd170","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The European\r Medicines Agency will review new information on this medicinal product at least\r every year and this SmPC will be updated as necessary.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","HasBorder":false,"ID":"4cf474d6-d315-41f7-be46-a6e6ad1bc866","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":" ","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic\r properties<\/span><\/b><\/p>","HasBorder":false,"ID":"64371946-4750-4e65-9000-470bd05dbf97","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"5.2     Pharmacokinetic\r properties","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"7895d6e0-aaf9-4769-970b-8daf54a64012","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","HasBorder":false,"ID":"f178d069-fd02-4562-88bd-7d3e145fcb09","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Absorption","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"b1c241e7-7ab4-4e44-a6b4-2a5c4e95098b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The median time\r to reach maximum serum concentration of crizanlizumab (T<sub>max<\/sub>) was 1.92 hours\r at steady state following intravenous administration of 5 mg\/kg over a\r period of 30 minutes in sickle cell disease patients.<\/span><\/p>","HasBorder":false,"ID":"eda00441-4776-4ffb-bc02-0a9763526745","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The median time\r to reach maximum serum concentration of crizanlizumab (Tmax) was 1.92 hours\r at steady state following intravenous administration of 5 mg\/kg over a\r period of 30 minutes in sickle cell disease patients.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"d9916254-4972-4b50-8ed3-0e7b2442e043","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","HasBorder":false,"ID":"e5017607-c72e-4a6f-9181-6e1819e9fd0b","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Distribution","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"e6d01662-5e51-4c6a-98f3-b416cf00d19b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Crizanlizumab\r distribution is typical of endogenous human antibodies within the vascular and\r extracellular spaces. The volume of distribution (V<sub>z<\/sub>) was 4.26 litres\r after a single 5 mg\/kg intravenous infusion of crizanlizumab in healthy\r volunteers.<\/span><\/p>","HasBorder":false,"ID":"74886205-b897-4609-99a0-b1e4ee3b458c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Crizanlizumab\r distribution is typical of endogenous human antibodies within the vascular and\r extracellular spaces. The volume of distribution (Vz) was 4.26 litres\r after a single 5 mg\/kg intravenous infusion of crizanlizumab in healthy\r volunteers.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"cfba73cd-3f2d-4a6d-acb6-c6a7cc34c93e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","HasBorder":false,"ID":"9782b031-f302-42ce-8994-f341f5d5a3cf","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Biotransformation","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"1b84e6bf-7bc1-4606-9615-a06e4a2a7fd7","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Antibodies are\r primarily eliminated via proteolysis by lysosomal enzymes in the liver to small\r peptides and amino acids.<\/span><\/p>","HasBorder":false,"ID":"a2b2321b-2c5d-45dd-9632-e9429a5a8524","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Antibodies are\r primarily eliminated via proteolysis by lysosomal enzymes in the liver to small\r peptides and amino acids.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3080f966-3604-4032-a4ca-777a2612de24","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","HasBorder":false,"ID":"438e07aa-0802-4eed-b93e-eeb481c32bd6","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Elimination","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"2a8933b5-5a18-49e4-9a2f-e9effd726be8","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In healthy\r volunteers, the mean terminal elimination half\u2011life (T<sub>\u00bd<\/sub>) was\r 10.6 days and the mean clearance was 11.7 ml\/h at crizanlizumab dose\r level 5 mg\/kg. In patients with sickle cell disease, the mean elimination T<sub>\u00bd<\/sub>\r during the dosing interval was 7.5 days.<\/span><\/p>","HasBorder":false,"ID":"cdd92091-1701-434c-96eb-2c756762f7a3","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"In healthy\r volunteers, the mean terminal elimination half\u2011life (T\u00bd) was\r 10.6 days and the mean clearance was 11.7 ml\/h at crizanlizumab dose\r level 5 mg\/kg. In patients with sickle cell disease, the mean elimination T\u00bd\r during the dosing interval was 7.5 days.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"071a759f-6141-40ad-8a94-969dafdcfab6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Linearity\/non\u2011linearity<\/span><\/u><\/p>","HasBorder":false,"ID":"7e9a86b9-66cc-409b-93ca-3932dc72234d","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Linearity\/non\u2011linearity","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"52645866-5128-4f0d-b445-78a6316342cf","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The exposure to\r crizanlizumab (mean C<sub>max<\/sub>, AUC<sub>last<\/sub>, or AUC<sub>inf<\/sub>)\r increased in non\u2011linear manner over the dose range of 0.2 to 8 mg\/kg\r in healthy volunteers.<\/span><\/p>","HasBorder":false,"ID":"74d7f53c-8999-443d-a50f-e5f5e6a338a4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The exposure to\r crizanlizumab (mean Cmax, AUClast, or AUCinf)\r increased in non\u2011linear manner over the dose range of 0.2 to 8 mg\/kg\r in healthy volunteers.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"5f280fcc-8161-41aa-a3fb-39e89ae24b57","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/p>","HasBorder":false,"ID":"353e6646-db41-42a8-bd17-d417ef06c480","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Special populations","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"c9b57900-24ac-4625-b10b-979877e72fed","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/i><\/p>","HasBorder":false,"ID":"6933d9e7-4511-458a-a9f6-6c8a42862f34","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Renal impairment","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a population\r PK analysis in patients with eGFR ranging from 35 to 202 ml\/min\/1.73 m<sup>2<\/sup>,\r no clinically important differences in the pharmacokinetics of crizanlizumab\r were found between patients with mild or moderate renal impairment and patients\r with normal renal function. Data from patients with severe renal impairment are\r too limited to draw conclusions on this population (see section<\/span><span lang=\"EN-GB\">4.2).<\/span><\/p>","HasBorder":false,"ID":"9bf9e5a6-9b95-42b4-a53d-9ce56cc4866a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"In a population\r PK analysis in patients with eGFR ranging from 35 to 202 ml\/min\/1.73 m2,\r no clinically important differences in the pharmacokinetics of crizanlizumab\r were found between patients with mild or moderate renal impairment and patients\r with normal renal function. Data from patients with severe renal impairment are\r too limited to draw conclusions on this population (see section4.2).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"6d510c9f-96a8-4b76-a7b6-0ad17a608b8f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/i><\/p>","HasBorder":false,"ID":"245257c4-ac3a-412f-b2b8-5ebbe91c1692","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Hepatic impairment","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The safety and\r efficacy of crizanlizumab in patients with hepatic impairment have not been\r established. Crizanlizumab is a monoclonal antibody and is cleared via\r catabolism (i.e. breakdown into peptides and amino acids), and a change in dose\r is not expected to be required for patients with hepatic impairment.<\/span><\/p>","HasBorder":false,"ID":"09ad5910-c73d-4ece-b2a0-9e3e34787493","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The safety and\r efficacy of crizanlizumab in patients with hepatic impairment have not been\r established. Crizanlizumab is a monoclonal antibody and is cleared via\r catabolism (i.e. breakdown into peptides and amino acids), and a change in dose\r is not expected to be required for patients with hepatic impairment.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"ba2348b9-49ab-4e99-be29-21341de61438","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><i><u><span lang=\"EN-GB\">Paediatric <a name=\"_nth_Pediatric_patients__be14752\"><\/a>population<\/span><\/u><\/i><\/p>","HasBorder":false,"ID":"4165f1c4-d534-4d9d-9681-bc230cc7a383","Indexed":false,"IsHeadingType":"L4","IsListItem":false,"IsPossibleHeading":true,"Italics":true,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Paediatric population","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharmacokinetics\r in paediatric patients below the age of 16 years have not been\r investigated.<\/span><\/p>","HasBorder":false,"ID":"0546cc1e-4f19-49a7-a911-cd0b8a5ac1e2","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Pharmacokinetics\r in paediatric patients below the age of 16 years have not been\r investigated.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"814c8221-9e02-4363-9624-a1fe931e7687","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.3     Preclinical safety\r data<\/span><\/b><\/p>","HasBorder":false,"ID":"fa64df00-9b3b-4b31-9a5d-f2b19ba139db","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"5.3     Preclinical safety\r data","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"8603c28b-861b-46ea-8efe-a7f83f7bd26c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">N<\/span><span lang=\"EN-GB\">on\u2011clinical data revealed no special hazard for humans based\r on conventional studies of safety pharmacology, tissue cross\u2011reactivity\r and repeated dose toxicity.<\/span><\/p>","HasBorder":false,"ID":"ee6b5303-8ac6-4a3b-94f0-ab1017ef631d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Non\u2011clinical data revealed no special hazard for humans based\r on conventional studies of safety pharmacology, tissue cross\u2011reactivity\r and repeated dose toxicity.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"23aef8a1-ba99-4124-b0bf-784ef6bf7e47","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In the 26\u2011week\r repeated dose toxicity study, administration of crizanlizumab in cynomolgus\r monkeys at dose levels up to 50 mg\/kg\/dose once every 4 weeks (at\r least 13.5 times the human clinical exposure based on AUC in patients with\r sickle cell disease at 5 mg\/kg once every four weeks) was generally well tolerated.\r There were no primary crizanlizumab\u2011related findings on any endpoint\r evaluated. At 50 mg\/kg, minimal to moderate inflammation of the vessels in\r multiple tissues considered to be an antigen\u2011antibody complex reaction\r (primate antihuman antibody) was observed in 2 of 10 animals. There was one\r death attributed to aspiration of gastric contents following a peri\u2011infusional\r reaction mediated by anti\u2011drug\u2011antibody\u2011dependent\r hypersensitivity.<\/span><\/p>","HasBorder":false,"ID":"2b45658d-4fc1-4163-abd0-900683c1a1fe","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"In the 26\u2011week\r repeated dose toxicity study, administration of crizanlizumab in cynomolgus\r monkeys at dose levels up to 50 mg\/kg\/dose once every 4 weeks (at\r least 13.5 times the human clinical exposure based on AUC in patients with\r sickle cell disease at 5 mg\/kg once every four weeks) was generally well tolerated.\r There were no primary crizanlizumab\u2011related findings on any endpoint\r evaluated. At 50 mg\/kg, minimal to moderate inflammation of the vessels in\r multiple tissues considered to be an antigen\u2011antibody complex reaction\r (primate antihuman antibody) was observed in 2 of 10 animals. There was one\r death attributed to aspiration of gastric contents following a peri\u2011infusional\r reaction mediated by anti\u2011drug\u2011antibody\u2011dependent\r hypersensitivity.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"51ce8336-56c8-46ea-a1f6-39f65ca8f5ba","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\">Pharmacological effects of\r crizanlizumab on haemodynamic and electrocardiographic parameters in the\r cynomolgus monkey were evaluated in the 26\u2011week repeated dose toxicology\r study. Respiratory rate and neurological parameters were also assessed. There\r were no crizanlizumab\u2011related effects on arterial blood pressure or on\r heart rate, PR, RR, QRS, QT, and heart rate corrected QT (QTc) intervals on the\r electrocardiograms (ECG). No rhythm abnormalities or qualitative changes were\r observed during the qualitative ECG assessment. There were no crizanlizumab\u2011related\r effects on respiration rate or any neurological parameter evaluated.<\/p>","HasBorder":false,"ID":"85f7f5ed-355d-4906-a3f6-9a48bddcbc82","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Pharmacological effects of\r crizanlizumab on haemodynamic and electrocardiographic parameters in the\r cynomolgus monkey were evaluated in the 26\u2011week repeated dose toxicology\r study. Respiratory rate and neurological parameters were also assessed. There\r were no crizanlizumab\u2011related effects on arterial blood pressure or on\r heart rate, PR, RR, QRS, QT, and heart rate corrected QT (QTc) intervals on the\r electrocardiograms (ECG). No rhythm abnormalities or qualitative changes were\r observed during the qualitative ECG assessment. There were no crizanlizumab\u2011related\r effects on respiration rate or any neurological parameter evaluated.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","HasBorder":false,"ID":"45dad596-ec0b-476f-a8ca-a446eeea7631","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":" ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Formal\r carcinogenicity, genotoxicity and juvenile toxicity studies have not been\r conducted with crizanlizumab.<\/span><\/p>","HasBorder":false,"ID":"aaa79cd7-6520-46c6-8e8f-cb7c321085a4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Formal\r carcinogenicity, genotoxicity and juvenile toxicity studies have not been\r conducted with crizanlizumab.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"2658a286-4f47-4637-8e0b-713e204cad3a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a 26\u2011week\r repeated dose toxicity study, cynomolgus monkeys were administered\r crizanlizumab once every 4 weeks at doses up to 50 mg\/kg (at least\r 13.5 times the human clinical exposure based on AUC in patients with\r sickle cell disease at 5 mg\/kg once every four weeks). <\/span><span lang=\"EN-GB\">There were no adverse effects of crizanlizumab on male and female\r reproductive organs<\/span>.<\/p>","HasBorder":false,"ID":"469349f9-1d38-4acf-954c-29ade69e0731","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"In a 26\u2011week\r repeated dose toxicity study, cynomolgus monkeys were administered\r crizanlizumab once every 4 weeks at doses up to 50 mg\/kg (at least\r 13.5 times the human clinical exposure based on AUC in patients with\r sickle cell disease at 5 mg\/kg once every four weeks). There were no adverse effects of crizanlizumab on male and female\r reproductive organs.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"9fbd64d0-a74d-4117-94e8-94ef9b88f599","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In an enhanced\r pre\u2011 and postnatal development study in cynomolgus monkeys, pregnant\r animals received intravenous crizanlizumab once every two weeks during the\r period of organogenesis, at doses of 10 and 50 mg\/kg (approximately 2.8\r and 16 times <\/span><span lang=\"EN-GB\">the human clinical exposure based on\r AUC in patients with sickle cell disease at 5 mg\/kg\/dose once every four\r weeks, respectively)<\/span><span lang=\"EN-GB\">. No maternal toxicity was\r observed. <\/span><span lang=\"EN-GB\">There was an increase in foetal loss\r (abortions or stillbirths) at both doses and this was higher in the third\r trimester. The cause of the foetal losses in monkeys is unknown but may be due\r to the development of anti\u2011drug antibodies against crizanlizumab<\/span><span lang=\"EN-GB\">. There were no effects on infant growth and development during the 6 months\r postpartum that were attributable to crizanlizumab.<\/span><\/p>","HasBorder":false,"ID":"cffbe662-42f9-4248-8b44-c791599ded97","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"In an enhanced\r pre\u2011 and postnatal development study in cynomolgus monkeys, pregnant\r animals received intravenous crizanlizumab once every two weeks during the\r period of organogenesis, at doses of 10 and 50 mg\/kg (approximately 2.8\r and 16 times the human clinical exposure based on\r AUC in patients with sickle cell disease at 5 mg\/kg\/dose once every four\r weeks, respectively). No maternal toxicity was\r observed. There was an increase in foetal loss\r (abortions or stillbirths) at both doses and this was higher in the third\r trimester. The cause of the foetal losses in monkeys is unknown but may be due\r to the development of anti\u2011drug antibodies against crizanlizumab. There were no effects on infant growth and development during the 6 months\r postpartum that were attributable to crizanlizumab.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"83944569-34b2-401e-8175-0118a70cb64e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Measurable\r crizanlizumab serum concentrations were observed in the infant monkeys at\r postnatal day 28, confirming that crizanlizumab, like other IgG\r antibodies, crosses the placental barrier.<\/span><\/p>","HasBorder":false,"ID":"92b1aad2-2ca1-43a3-a24d-3b107f8ebdbe","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Measurable\r crizanlizumab serum concentrations were observed in the infant monkeys at\r postnatal day 28, confirming that crizanlizumab, like other IgG\r antibodies, crosses the placental barrier.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"648268b4-90d4-46c9-8ef3-33b34a8bfa3f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"af8149d0-dfa8-4020-99f8-1916de6c1001","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.       PHARMACEUTICAL\r PARTICULARS<\/span><\/b><\/p>","HasBorder":false,"ID":"d906139e-f5dd-446c-82ad-ebd232445fd7","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"6.       PHARMACEUTICAL\r PARTICULARS","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"e4f85a21-9a6b-41ea-bf3c-7972b49cd985","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p>","HasBorder":false,"ID":"03e264f9-0100-4a8a-94ec-7b87aaafacc0","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"6.1     List of excipients","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"f59dc604-2b36-4d12-828f-8e026e5b079c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Sucrose<\/span><\/p>","HasBorder":false,"ID":"7e9bc4ce-4539-404f-89dd-f936e5b34c71","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Sucrose","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Sodium citrate (E331)<\/span><\/p>","HasBorder":false,"ID":"37ac4ccb-012e-4248-bae0-37a4b1b53032","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Sodium citrate (E331)","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Citric acid (E330)<\/span><\/p>","HasBorder":false,"ID":"a2358c9d-148b-43b9-a681-9234951d98e5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Citric acid (E330)","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Polysorbate 80 (E433)<\/span><\/p>","HasBorder":false,"ID":"1bb0c6a7-6fd7-4941-8104-0a7fcfbff4ee","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Polysorbate 80 (E433)","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Water for\r injections<\/span><\/p>","HasBorder":false,"ID":"de2fd15d-98b4-442e-8b54-8ec44e519a39","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Water for\r injections","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"902699cd-1656-4abb-9b13-464dba22feb7","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p>","HasBorder":false,"ID":"59dc8808-b21b-421a-9720-4c5ab4d81c9b","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"6.2     Incompatibilities","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"0c835d75-b077-4c21-8e36-d1abcfcaf830","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">This medicinal\r product<\/span><span lang=\"EN-GB\"> must not be mixed with other medicinal products\r except those mentioned in section 6.6.<\/span><\/p>","HasBorder":false,"ID":"90b938fa-f730-4dcc-9d4b-4ca39e720047","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"This medicinal\r product must not be mixed with other medicinal products\r except those mentioned in section 6.6.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"af74a1f0-6a7e-43a3-8d8f-f27be9586a4e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p>","HasBorder":false,"ID":"45a582e4-8d9c-4a48-a19e-baf09322e2f9","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"6.3     Shelf life","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"0da4c938-67c8-4ade-a1d9-746899b6bb38","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Unopened vial<\/span><\/u><\/p>","HasBorder":false,"ID":"9e076bbb-1cef-410d-bce4-c6a7bf65c69d","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Unopened vial","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"0e3fd59e-71c0-4366-bde9-8d66aeb623c1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">18 months<\/span><\/p>","HasBorder":false,"ID":"4959cd34-feba-4083-a66e-2854f51838f5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Text":"18 months","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"a3edcb68-bf84-44b4-89e2-2bbf29f2762f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Diluted solution<\/span><\/u><\/p>","HasBorder":false,"ID":"263822d6-0d5b-40d6-b8e9-c8438eb6c7de","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Diluted solution","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"85c7ebb3-3de8-4633-b5b8-9d6399366336","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Chemical and\r physical in\u2011use stability, from the start of preparation of the diluted\r solution for infusion until end of infusion, has been demonstrated for up to 8 hours\r at room temperature (up to 25\u00b0C) and at 2\u00b0C to 8\u00b0C for up to 24 hours\r overall.<\/span><\/p>","HasBorder":false,"ID":"4409ae64-3f6b-4984-b852-731321fc1c50","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Chemical and\r physical in\u2011use stability, from the start of preparation of the diluted\r solution for infusion until end of infusion, has been demonstrated for up to 8 hours\r at room temperature (up to 25\u00b0C) and at 2\u00b0C to 8\u00b0C for up to 24 hours\r overall.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"efac3a93-3435-4a2f-86a1-1b561d39593b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">From a microbiological point of view, the diluted\r solution for infusion should be used immediately. If not used immediately, in\u2011use\r storage times and conditions prior to use are the responsibility of the user\r and would normally not be longer than 24 hours at 2\u00b0C to 8\u00b0C, including\r 4.5 hours at room temperature (up to 25\u00b0C) from the start of preparation\r to completion of the infusion, unless dilution has taken place in controlled\r and validated aseptic conditions.<\/span><\/p>","HasBorder":false,"ID":"0901414c-b79f-44de-9112-e03ce37a7e44","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"From a microbiological point of view, the diluted\r solution for infusion should be used immediately. If not used immediately, in\u2011use\r storage times and conditions prior to use are the responsibility of the user\r and would normally not be longer than 24 hours at 2\u00b0C to 8\u00b0C, including\r 4.5 hours at room temperature (up to 25\u00b0C) from the start of preparation\r to completion of the infusion, unless dilution has taken place in controlled\r and validated aseptic conditions.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","HasBorder":false,"ID":"629ab2f8-a8da-48fd-b245-e67f31b2ddff","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":" ","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.4     Special precautions\r for storage<\/span><\/b><\/p>","HasBorder":false,"ID":"9ad0f69a-703c-4cac-a2b1-245fafcb8211","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"6.4     Special precautions\r for storage","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"8b748f51-6dd2-400a-8698-a44bf0c6f29a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Store in a refrigerator\r (2\u00b0C \u2013 8\u00b0C).<\/span><\/p>","HasBorder":false,"ID":"b5fa149c-79d7-4316-bc5e-d6b4b4168b5a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Store in a refrigerator\r (2\u00b0C \u2013 8\u00b0C).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Do not freeze.<\/span><\/p>","HasBorder":false,"ID":"db269ec4-2f21-4946-affb-5d2aff340fc5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Do not freeze.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep the vial in\r the outer carton in order to protect from light.<\/span><\/p>","HasBorder":false,"ID":"fbeaec5d-4224-4a89-be96-ad57c9b98528","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Keep the vial in\r the outer carton in order to protect from light.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"2a702b87-e8b7-4570-8cc6-ed6b7c275388","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">For storage conditions\r after dilution of the medicinal product, see section 6.3.<\/span><\/p>","HasBorder":false,"ID":"0bd246aa-1a5a-4e3e-b392-c5bbb2511820","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"For storage conditions\r after dilution of the medicinal product, see section 6.3.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"5181d95d-338c-4ca3-899a-3ae051ed042f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">6.5     Nature and contents\r of container<\/span><\/b><\/p>","HasBorder":false,"ID":"3b3b4dc6-40d5-4688-8645-737529fc8b07","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"6.5     Nature and contents\r of container","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"cd0eedb3-ddc9-4c02-bf41-0fb34f8fd08f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">10 ml concentrate\r for solution for infusion in a type I glass vial with a coated chlorobutyl\r rubber stopper sealed with an aluminium cap with a plastic flip\u2011off disk containing\r 100 mg crizanlizumab.<\/span><\/p>","HasBorder":false,"ID":"7894049b-e862-4bfe-a70a-f5223aa4c278","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"10 ml concentrate\r for solution for infusion in a type I glass vial with a coated chlorobutyl\r rubber stopper sealed with an aluminium cap with a plastic flip\u2011off disk containing\r 100 mg crizanlizumab.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"1ad9153c-5169-4508-9d02-82c1973d484b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pack of 1 vial.<\/span><\/p>","HasBorder":false,"ID":"f0f8f8fc-6a54-47a8-b539-2fb48732f5b0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Pack of 1 vial.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"522636e9-cc28-488c-af98-3f517f1877eb","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><a name=\"OLE_LINK1\"><b><span lang=\"EN-GB\">6.6     Special\r precautions for disposal and other handling<\/span><\/b><\/a><\/p>","HasBorder":false,"ID":"854643ec-9838-4014-87ab-6c50fcf58759","Indexed":true,"IsHeadingType":"L2","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"6.6     Special\r precautions for disposal and other handling","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"6cc47cda-b3a7-488d-90f8-28551da90ecf","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Adakveo vials\r are for single use only.<\/span><\/p>","HasBorder":false,"ID":"0f237f7e-29f1-4f07-ba19-c5f7022e6bfb","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Adakveo vials\r are for single use only.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"a67374ec-e77d-4d74-ae6d-54031d27d5db","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Preparing the infusion<\/span><\/u><\/p>","HasBorder":false,"ID":"ceead268-c784-4fc3-b286-a8b597d78f32","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Preparing the infusion","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"7d593e91-d1c1-4901-9f05-ab3d0a8191e1","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The diluted\r solution for infusion should be prepared by a healthcare professional using\r aseptic techniques.<\/span><\/p>","HasBorder":false,"ID":"9f52cd4e-b8c6-432b-905f-233b758b60c5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The diluted\r solution for infusion should be prepared by a healthcare professional using\r aseptic techniques.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"a667a78a-6a33-4cd7-95da-85c60f3ecbee","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The total dose\r and required volume of Adakveo depend on the patient\u2019s body weight; 5 mg\r of crizanlizumab is administered per kg body weight.<\/span><\/p>","HasBorder":false,"ID":"52b74ca0-7322-426e-af26-ae15656b4b43","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"The total dose\r and required volume of Adakveo depend on the patient\u2019s body weight; 5 mg\r of crizanlizumab is administered per kg body weight.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"0f7161a2-ac50-4e90-8ab6-46ff638d770c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">The volume to be used for the preparation of the infusion is\r calculated according to the following equation:<\/span><\/p>","HasBorder":false,"ID":"70bd08cc-ffa8-46ef-b99a-7b3339ddd0be","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"The volume to be used for the preparation of the infusion is\r calculated according to the following equation:","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"8e64aa37-3661-4215-9922-7722e5874d63","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormalTable']","Element":"<table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:12.5pt;border-collapse:collapse\" width=\"567\"> <tr> <td rowspan=\"2\" style=\"width:85.05pt;padding:0in 5.4pt 0in 5.4pt\" width=\"113\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r   line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Volume (ml) =<\/span><\/p> <\/td> <td style=\"width:269.35pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"359\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r   text-indent:-28.35pt;line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Patient\u2019s body weight (kg) x prescribed dose<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" width=\"94\"> <p align=\"center\" class=\"MsoNormal\" style=\"margin-left:28.35pt;text-align:center;\r   text-indent:-28.35pt;line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">[5 mg\/kg]<\/span><\/p> <\/td> <\/tr> <tr> <td style=\"width:269.35pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"359\"> <p align=\"center\" class=\"Text\" style=\"margin-top:0in;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Concentration\r   of Adakveo<\/span><\/p> <\/td> <td style=\"width:70.85pt;border:none;padding:0in 5.4pt 0in 5.4pt\" width=\"94\"> <p align=\"center\" class=\"Text\" style=\"margin-top:0in;text-align:center;\r   page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">[10 mg\/ml]<\/span><\/p> <\/td> <\/tr> <\/table>","HasBorder":false,"ID":"3fc1608e-7c60-463c-be06-6066557437b4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:12.5pt;border-collapse:collapse","Text":"   Volume (ml) =   Patient\u2019s body weight (kg) x prescribed dose   [5 mg\/kg]     Concentration\r   of Adakveo   [10 mg\/ml]   ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"_hd6_Table_3_1_Example_of_d12477\"><\/a><\/p>","HasBorder":false,"ID":"b202557d-bbd8-4e59-ab5a-ba86b4f8b4b6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">1.       Obtain the number of\r vials required to deliver the prescribed dose and bring them to room\r temperature (for a maximum of 4 hours). One vial is needed for every\r 10 ml of Adakveo (see below table).<\/span><\/p>","HasBorder":false,"ID":"32452a43-4a00-4baf-bb67-8c5d13532ff7","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"1.       Obtain the number of\r vials required to deliver the prescribed dose and bring them to room\r temperature (for a maximum of 4 hours). One vial is needed for every\r 10 ml of Adakveo (see below table).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"9cb9f37b-244a-4a74-ae79-9907a0e707f0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormalTable']","Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:28.35pt;border-collapse:collapse;border:none\" width=\"568\"> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Body weight (kg)<\/span><\/b><\/p> <\/td> <td style=\"width:92.15pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Dose (mg)<\/span><\/b><\/p> <\/td> <td style=\"width:114.75pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Volume (ml)<\/span><\/b><\/p> <\/td> <td style=\"width:114.75pt;border-top:solid windowtext 1.0pt;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><b><span lang=\"EN-GB\">Vials (n)<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">200<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">20<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">2<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">60<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">300<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">30<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">3<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">80<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">400<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">40<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">4<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">100<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">500<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">50<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;page-break-after:\r   avoid;text-autospace:none\"><span lang=\"EN-GB\">5<\/span><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"width:104.65pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"140\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">120<\/span><\/p> <\/td> <td style=\"width:92.15pt;border:none;border-bottom:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"123\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">600<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">60<\/span><\/p> <\/td> <td style=\"width:114.75pt;border:none;border-bottom:\r   solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"153\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;line-height:normal;text-autospace:\r   none\"><span lang=\"EN-GB\">6<\/span><\/p> <\/td> <\/tr> <\/table>","HasBorder":false,"ID":"e2396b43-3623-4121-a94c-9ee463d4e9da","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;border-collapse:collapse;border:none","Text":"   Body weight (kg)   Dose (mg)   Volume (ml)   Vials (n)     40   200   20   2     60   300   30   3     80   400   40   4     100   500   50   5     120   600   60   6   ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"a32e85bc-e9c5-4a92-a9b8-b9fe3cdf1715","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">2.       Visually inspect the vials.<\/span><\/p>","HasBorder":false,"ID":"b16bf905-c884-4145-9a50-08fc49c0220f","Indexed":true,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"2.       Visually inspect the vials.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The solution in the vials should be clear to\r opalescent. Do not use if particles are present in the solution.<\/span><\/p>","HasBorder":false,"ID":"d1bec757-87f2-4507-b356-99331fdac48c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:56.7pt;text-indent:-28.35pt;line-height:\r\nnormal","Text":"-The solution in the vials should be clear to\r opalescent. Do not use if particles are present in the solution.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The solution should be colourless or may have a\r slight brownish\u2011yellow tint.<\/span><\/p>","HasBorder":false,"ID":"e3de4897-5721-4703-8b69-0c088ef8cfd3","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:56.7pt;text-indent:-28.35pt;line-height:\r\nnormal","Text":"-The solution should be colourless or may have a\r slight brownish\u2011yellow tint.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"7ba89851-8900-4150-9810-97f340762ee6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">3.       Withdraw a volume\r equal to the required volume of Adakveo from a 100 ml infusion bag containing\r either sodium chloride 9 mg\/ml (0.9%) solution for injection or dextrose\r 5% and discard.<\/span><\/p>","HasBorder":false,"ID":"1fda43dd-e0f2-4072-961b-8da41c107467","Indexed":true,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"3.       Withdraw a volume\r equal to the required volume of Adakveo from a 100 ml infusion bag containing\r either sodium chloride 9 mg\/ml (0.9%) solution for injection or dextrose\r 5% and discard.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">No incompatibilities between the diluted Adakveo\r solution and infusion bags composed of polyvinylchloride (PVC), polyethylene\r (PE) and polypropylene (PP) have been observed.<\/span><\/p>","HasBorder":false,"ID":"2f252e88-a628-45b0-b74f-c52bb9d6194d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:56.7pt;text-indent:-28.35pt","Text":"-No incompatibilities between the diluted Adakveo\r solution and infusion bags composed of polyvinylchloride (PVC), polyethylene\r (PE) and polypropylene (PP) have been observed.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\"><\/p>","HasBorder":false,"ID":"3b362b4b-0f4f-4cfd-b953-a509a52dee4f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"None","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><span lang=\"EN-GB\">4.       Withdraw the necessary\r volume of Adakveo from the vials and inject slowly into the previously prepared\r infusion bag.<\/span><\/p>","HasBorder":false,"ID":"991b1a79-8a3e-4153-9752-aab95313185e","Indexed":true,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"4.       Withdraw the necessary\r volume of Adakveo from the vials and inject slowly into the previously prepared\r infusion bag.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">The <\/span><span lang=\"EN-GB\">solution<\/span><span lang=\"EN-GB\"> must not be mixed or co\u2011administered with other medicinal\r products through the same intravenous line.<\/span><\/p>","HasBorder":false,"ID":"fd50fd77-5e48-4554-97eb-a74825574aa3","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:56.7pt;text-indent:-28.35pt","Text":"-The solution must not be mixed or co\u2011administered with other medicinal\r products through the same intravenous line.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:56.7pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep the volume of Adakveo added to the infusion\r bag in the range of 10 ml to 96 ml to obtain a final\r concentration in the infusion bag within 1 mg\/ml to 9.6 mg\/ml.<\/span><\/p>","HasBorder":false,"ID":"69e21d30-e7b6-4b6c-bb09-9791c1eb84a5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:56.7pt;text-indent:-28.35pt","Text":"-Keep the volume of Adakveo added to the infusion\r bag in the range of 10 ml to 96 ml to obtain a final\r concentration in the infusion bag within 1 mg\/ml to 9.6 mg\/ml.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"f60def0a-ef1b-434d-8db3-91e895a7b739","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">5.       Mix the\r diluted solution by gently inverting the infusion bag. DO NOT SHAKE.<\/span><\/p>","HasBorder":false,"ID":"f556b56a-a0b0-4f30-a0b9-83f6231668ce","Indexed":true,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"5.       Mix the\r diluted solution by gently inverting the infusion bag. DO NOT SHAKE.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"f7dec427-0037-4dc2-b280-f0ec09b3a838","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Administration<\/span><\/u><a name=\"_nth_Administration25012\"><\/a><\/p>","HasBorder":false,"ID":"d506f779-4651-4122-bc28-d58532b1c34f","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Administration","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"38bf0022-6b9f-411f-9afb-05a258a12c24","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Text']","Element":"<p align=\"left\" class=\"Text\" style=\"margin-top:0in;text-align:left\"><span style=\"font-size:11.0pt\">Adakveo diluted solution must be administered through\r a sterile, non\u2011pyrogenic 0.2 micron in\u2011line filter by\r intravenous infusion over a period of 30 minutes.<\/span><span style=\"font-size:11.0pt\"> <span lang=\"EN-GB\">No incompatibilities have been\r observed between Adakveo and infusion sets composed of PVC, PE\u2011lined PVC,\r polyurethane, and in\u2011line filter membranes composed of polyethersulfone\r (PES), polyamide (PA) or polysulphone (PSU).<\/span><\/span><\/p>","HasBorder":false,"ID":"3dfa811d-6a83-4c3b-8951-826bfe37f082","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-top:0in;text-align:left","Text":"Adakveo diluted solution must be administered through\r a sterile, non\u2011pyrogenic 0.2 micron in\u2011line filter by\r intravenous infusion over a period of 30 minutes. No incompatibilities have been\r observed between Adakveo and infusion sets composed of PVC, PE\u2011lined PVC,\r polyurethane, and in\u2011line filter membranes composed of polyethersulfone\r (PES), polyamide (PA) or polysulphone (PSU).","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"35ecb7a7-c5db-4448-b7c6-2bf9efac0d6d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">After\r administration of Adakveo, flush the line with at least 25 ml sodium\r chloride 9 mg\/ml (0.9%) solution for injection or dextrose 5%.<\/span><\/p>","HasBorder":false,"ID":"a1b8fd77-f4fc-46fe-b44d-e1cead692624","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"After\r administration of Adakveo, flush the line with at least 25 ml sodium\r chloride 9 mg\/ml (0.9%) solution for injection or dextrose 5%.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"c4e64fa8-ab17-417a-8ff0-4e383c40c492","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><u><span lang=\"EN-GB\">Disposal<\/span><\/u><\/p>","HasBorder":false,"ID":"35e7b4d4-df5d-44d8-86a2-5251b4dd05e0","Indexed":false,"IsHeadingType":"L3","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Disposal","Underlined":true,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"bc8bc6e4-6a3c-41a4-868f-f030b96a81c6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Any unused medicinal\r product or waste material should be disposed of in accordance with local\r requirements.<\/span><\/p>","HasBorder":false,"ID":"de39ba9a-5ac2-41e7-afc5-30eecc63bf77","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Any unused medicinal\r product or waste material should be disposed of in accordance with local\r requirements.","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"e191c1de-540a-4a56-b9cd-ccd68b4607ac","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"d3d9b4d9-58e8-4b5c-bb97-36acde82d1be","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/p>","HasBorder":false,"ID":"23dc4029-d975-4466-9fa2-12958fc7025b","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"7.       MARKETING\r AUTHORISATION HOLDER","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"b22ce3eb-98be-4654-b0a0-ec501883b2fd","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['Default']","Element":"<p class=\"Default\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-size:11.0pt;color:windowtext\">Novartis Europharm Limited<\/span><\/p>","HasBorder":false,"ID":"b4eff755-e32b-4c48-9765-20561f29a7cf","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"page-break-after:avoid","Text":"Novartis Europharm Limited","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Vista Building<\/span><\/p>","HasBorder":false,"ID":"58d7491b-92d7-47c6-ac82-af61b2791a61","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Vista Building","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Elm Park, Merrion Road<\/span><\/p>","HasBorder":false,"ID":"cd88c355-1654-4c8b-8d51-e70b16896ba6","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Elm Park, Merrion Road","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\" style=\"color:black\">Dublin 4<\/span><\/p>","HasBorder":false,"ID":"e379b300-0d76-436e-86fc-91e2928d8696","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"Dublin 4","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">Ireland<\/span><\/p>","HasBorder":false,"ID":"f77f13ae-38b7-4996-930c-fe44cc2dcfce","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Ireland","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"a3e46618-163c-453e-bca6-cea15e31a288","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b8725011-bdca-48a2-9e21-50cda1970943","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">8.       MARKETING\r AUTHORISATION NUMBER(S)<\/span><\/b><\/p>","HasBorder":false,"ID":"ad8c9b97-2d93-40de-b2eb-92a756c9dea6","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Text":"8.       MARKETING\r AUTHORISATION NUMBER(S)","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","HasBorder":false,"ID":"150dce11-2595-4127-b415-e5d0013a2025","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal;page-break-after:avoid","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"color:black\">EU\/1\/20\/1476\/001<\/span><\/p>","HasBorder":false,"ID":"dde404d0-4209-4f9d-8d03-778ff73f4437","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"EU\/1\/20\/1476\/001","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"60447dbb-78a4-45fd-a5f3-e7e5734669e5","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"7b50b62e-9929-4357-9e77-31b0a4ae9798","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE\r AUTHORISATION<\/span><\/b><\/p>","HasBorder":false,"ID":"63bd6123-2866-4aa5-9eab-64dbb0b2ed41","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Text":"9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE\r AUTHORISATION","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b3e4c954-9cf7-4963-b089-2cf5dd37b77f","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"48e2d6f2-7758-467c-ab03-775aaded774b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":true,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/b><\/p>","HasBorder":false,"ID":"283a65b5-4976-46c1-978a-88efda30f4e7","Indexed":true,"IsHeadingType":"L1","IsListItem":false,"IsPossibleHeading":true,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Text":"10.     DATE OF REVISION OF THE TEXT","Underlined":false,"Uppercased":true},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"7d9ba827-d973-4bac-8293-1c1a0c8ecb96","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"829dca6e-6cd7-4e80-8705-3d40568b8b53","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed\r information on this medicinal product is available on the website of the\r European Medicines <\/span><span lang=\"EN-GB\">Agency <a href=\"http:\/\/www.ema.europa.eu\">http:\/\/www.ema.europa.eu<\/a><\/span><span lang=\"EN-GB\">.<br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/p>","HasBorder":false,"ID":"0a7013e9-dc4c-437f-88d5-7f242f5db21a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"Detailed\r information on this medicinal product is available on the website of the\r European Medicines Agency http:\/\/www.ema.europa.eu. ","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","HasBorder":false,"ID":"adb67faa-c886-400b-9802-96b6e195d77e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"margin-right:-.1pt;line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b7ea1645-949b-4f72-99ad-281bbe6287fe","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"2585f062-88e1-4999-a767-4f043b379106","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"f96b65d9-a2db-4d2c-8e8e-cf8b48775237","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"7149a04d-4391-4f0f-87b3-091ea4fb00a9","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"54d620e9-08e9-4a1d-8293-ed00d127488d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"06dfd007-5b59-4ba2-b475-1526740122c4","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"996812d0-b59a-40bd-a31e-819fe30b2b74","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"8a9f433d-156e-4661-8030-f1ba53576fea","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"bba4d7e4-0c52-47fb-8daf-664346f4826c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"bf24bbc6-3700-41fd-acfb-ce3260923157","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3805e0f1-f059-4ab0-9b56-9055e5421b8a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"ee032976-c5da-431e-abce-efb4d3e86ad0","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"5d0725f1-bc56-4012-aa61-b6370745d41b","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"45ec7e31-732f-40b2-b7d5-d01062ea998c","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"d4b87324-7b1e-453f-9a41-35d561347f5a","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"9720334d-0c9f-4cec-b612-22b4c026769e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"0a2d91de-13a8-4598-b72d-eca621a4ba94","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"798eee4d-da15-4523-b811-b51803ee8c6e","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"3394621d-3f9c-4805-89b9-b2d033707523","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"1216f2b4-d4f7-476a-a52d-662746e2b579","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b73c20c0-d71b-4cf5-a76d-d52f9395b867","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false},{"Bold":false,"Classes":"['MsoNormal']","Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","HasBorder":false,"ID":"b442dcaa-c350-4fc2-bb23-510a67a3ba8d","Indexed":false,"IsHeadingType":null,"IsListItem":false,"IsPossibleHeading":false,"Italics":false,"ParentId":"c4aa3582-b12f-4af8-9392-0d721a01d452","Styles":"line-height:normal","Text":"","Underlined":false,"Uppercased":false}]